(dp0
(S'ZEB1'
p1
S'FOXA1'
p2
S'increases'
p3
tp4
(lp5
s(S'FOXJ1'
p6
S'GATA6'
p7
S'increases'
p8
tp9
(lp10
s(S'TFAP4'
p11
S'FOXD3'
p12
S'increases'
p13
tp14
(lp15
s(S'TBP'
p16
S'MEIS1'
p17
S'increases'
p18
tp19
(lp20
s(S'GCM1'
p21
S'GATA6'
p22
S'increases'
p23
tp24
(lp25
s(S'T-DHT'
p26
S'SRC'
p27
S'adds_modification'
p28
tp29
(lp30
s(S'MAZ'
p31
S'GABPB2'
p32
S'increases'
p33
tp34
(lp35
s(S'HMGA1'
p36
S'EN1'
p37
S'increases'
p38
tp39
(lp40
s(S'CYP26A1'
p41
S'NRAS'
p42
S'increases'
p43
tp44
(lp45
s(S'CUX1'
p46
S'MEIS1'
p47
S'increases'
p48
tp49
(lp50
s(S'REPIN1'
p51
S'BACH1'
p52
S'increases'
p53
tp54
(lp55
s(S'TFDP1'
p56
S'HOXA9'
p57
S'increases'
p58
tp59
(lp60
S'Expression constructs for HOXA9, HOXA10, ID2 and TFDP1 (in pCMV-XL5/4 vectors) were obtained from Origene (Wiesbaden, Germany).'
p61
as(S'NFE2L1'
p62
S'CYP26A1'
p63
S'increases'
p64
tp65
(lp66
s(S'MAZ'
p67
S'GATA1'
p68
S'increases'
p69
tp70
(lp71
s(S'TCF12'
p72
S'GABPB2'
p73
S'increases'
p74
tp75
(lp76
s(S'ETS2'
p77
S'FOXO3'
p78
S'increases'
p79
tp80
(lp81
s(S'hsa-let-7c-5p'
p82
S'NRAS'
p83
S'decreases'
p84
tp85
(lp86
s(S'SPI1'
p87
S'CYP26A1'
p88
S'increases'
p89
tp90
(lp91
s(S'RAC1/GTP'
p92
S'MKK4'
p93
S'adds_modification'
p94
tp95
(lp96
s(S'Quercetin'
p97
S'KRAS MRNA'
p98
S'decreases'
p99
tp100
(lp101
s(S'INSULIN RECEPTOR/INSULIN/SHC'
p102
S'GRB2'
p103
S'binds'
p104
tp105
(lp106
s(S'TAp63a (tetramer)'
p107
S'PKC DELTA'
p108
S'increases'
p109
tp110
(lp111
s(S'FOXO1'
p112
S'POU2F1'
p113
S'increases'
p114
tp115
(lp116
s(S'FOXL1'
p117
S'EN1'
p118
S'increases'
p119
tp120
(lp121
s(S'TBP'
p122
S'CYP26A1'
p123
S'increases'
p124
tp125
(lp126
s(S'Heptachlor'
p127
S'HRAS MRNA'
p128
S'decreases'
p129
tp130
(lp131
s(S'PCBP1'
p132
S'CYP26A1'
p133
S'increases'
p134
tp135
(lp136
s(S'ZBTB18'
p137
S'CYP26A1'
p138
S'increases'
p139
tp140
(lp141
s(S'GATA2'
p142
S'CYP26A1'
p143
S'increases'
p144
tp145
(lp146
s(S'Cadmium'
p147
S'KRAS MRNA'
p148
S'increases'
p149
tp150
(lp151
s(S'HNF1A'
p152
S'POU2F1'
p153
S'increases'
p154
tp155
(lp156
s(S'ABT-100'
p157
S'HRAS PROTEIN'
p158
S'inhibits_modification'
p159
tp160
(lp161
s(S'ELF1'
p162
S'CYP26A1'
p163
S'increases'
p164
tp165
(lp166
s(S'LEF1'
p167
S'KRAS'
p168
S'increases'
p169
tp170
(lp171
s(S'NKX2-1'
p172
S'FOXD3'
p173
S'increases'
p174
tp175
(lp176
s(S'PI-3-4-5-P3'
p177
S'BTK-ITK'
p178
S'translocates'
p179
tp180
(lp181
s(S'POU6F1'
p182
S'HOXA9'
p183
S'increases'
p184
tp185
(lp186
s(S'Myb'
p187
S'MYB'
p188
S'increases'
p189
tp190
(lp191
S'To examine whether it is the c-Myb protein that is responsible for increased migration and Matrigel invasiveness of MDA-MB-231MYBup cells, we specifically silenced c-'
p192
aS'To elucidate the mechanism by which c-Myb regulates MMP9, MMP1, and cathepsin D in MYBup cells, we first examined whether c-Myb can activate transcription of '
p193
aS'To confirm the role of cathepsin D in c-Myb-induced cell migration/invasion, we performed RNAi-mediated silencing of cathepsin D in MDA-MB-231MYBup cells, resulting in effective reduction of the endogenous cathepsin D protein (Figure '
p194
aS'Constructs encoding human (pcDNA3-hcMYB) and mouse c-Myb proteins (pcDNA3-mcMYB) were kindly provided by J. Bies ['
p195
as(S'PAX5'
p196
S'CYP26A1'
p197
S'increases'
p198
tp199
(lp200
s(S'FOXO4'
p201
S'FOXD3'
p202
S'increases'
p203
tp204
(lp205
s(S'CYP26A1'
p206
S'FOXO4'
p207
S'increases'
p208
tp209
(lp210
s(S'cell adhesion'
p211
S'HRAS/GDP'
p212
S'increases_activity'
p213
tp214
(lp215
s(S'IRF7'
p216
S'CYP26A1'
p217
S'increases'
p218
tp219
(lp220
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p221
S'KRAS PROTEIN'
p222
S'increases'
p223
tp224
(lp225
s(S'PITX2'
p226
S'POU2F1'
p227
S'increases'
p228
tp229
(lp230
s(S'E2F1'
p231
S'CYP26A1'
p232
S'increases'
p233
tp234
(lp235
s(S'ATF1'
p236
S'CYP26A1'
p237
S'increases'
p238
tp239
(lp240
s(S'PI3K'
p241
S'PKC DELTA'
p242
S'adds_modification'
p243
tp244
(lp245
s(S'SOX5'
p246
S'HOXA9'
p247
S'increases'
p248
tp249
(lp250
s(S'FOXO4'
p251
S'POU2F1'
p252
S'increases'
p253
tp254
(lp255
s(S'FOXO4'
p256
S'GATA6'
p257
S'increases'
p258
tp259
(lp260
s(S'LEF1'
p261
S'FOXF2'
p262
S'increases'
p263
tp264
(lp265
s(S'Insulin Receptor/Insuli/IRS1/GRB2/SHC/Sos'
p266
S'HRAS/GDP'
p267
S'increases_activity'
p268
tp269
(lp270
s(S'TLX2'
p271
S'RUNX1'
p272
S'increases'
p273
tp274
(lp275
s(S'ALX4'
p276
S'JUN'
p277
S'increases'
p278
tp279
(lp280
s(S'RHOA/GTP'
p281
S'RHOGDI'
p282
S'binds'
p283
tp284
(lp285
s(S'GCM1'
p286
S'CYP26A1'
p287
S'increases'
p288
tp289
(lp290
s(S'RB1'
p291
S'ONECUT1'
p292
S'increases'
p293
tp294
(lp295
s(S'NHLH1'
p296
S'CYP26A1'
p297
S'increases'
p298
tp299
(lp300
s(S'NR3C1'
p301
S'BACH1'
p302
S'increases'
p303
tp304
(lp305
s(S'HNF4A'
p306
S'CYP26A1'
p307
S'increases'
p308
tp309
(lp310
s(S'YY1'
p311
S'FOXO3'
p312
S'increases'
p313
tp314
(lp315
s(S'GRB2:SOS1'
p316
S'P-EGFR MUTANTS DIMER'
p317
S'binds'
p318
tp319
(lp320
s(S'P-Y349,350-SHC1:P-ERBB4'
p321
S'GRB2:SOS1'
p322
S'binds'
p323
tp324
(lp325
s(S'FOXN1'
p326
S'ONECUT1'
p327
S'increases'
p328
tp329
(lp330
s(S'TFAP4'
p331
S'MYC'
p332
S'increases'
p333
tp334
(lp335
s(S'MYC'
p336
S'EN1'
p337
S'increases'
p338
tp339
(lp340
S'Lal et al showed that miR-24 suppresses several key genes that regulate cell-cycle progression like MYC and E2F2 and several genes downstream of E2F2 and MYC i.e., AURKB, CCNA2, CDK4, CDC2 and FEN1 ['
p341
aS'For example, miR-24 regulates expression of E2F2, MYC, AURKB, CCNA2, CDC2, CDK4, and FEN1 by recognizing seedless but highly complementary sequences ('
p342
as(S'Antigen/IgE/Fc epsilon R1/LYN/SYK'
p343
S'SHC/GRB2/SOS1'
p344
S'increases_activity'
p345
tp346
(lp347
s(S'14-3-3 BETA, ZETA'
p348
S'GARNL4'
p349
S'binds'
p350
tp351
(lp352
s(S'SMAD1'
p353
S'EN1'
p354
S'increases'
p355
tp356
(lp357
s(S'Raf-1'
p358
S'MEK1-2'
p359
S'adds_modification'
p360
tp361
(lp362
s(S'POU2F1'
p363
S'FOXO3'
p364
S'increases'
p365
tp366
(lp367
s(S'NGF (dimer)/TRKA'
p368
S'RASGRF1'
p369
S'adds_modification'
p370
tp371
(lp372
s(S'TCF4'
p373
S'CYP26A1'
p374
S'increases'
p375
tp376
(lp377
s(S'STAT5B'
p378
S'TLX2'
p379
S'increases'
p380
tp381
(lp382
s(S'CYP26A1'
p383
S'SRF'
p384
S'increases'
p385
tp386
(lp387
s(S'STAT1'
p388
S'NRAS'
p389
S'increases'
p390
tp391
(lp392
s(S'TFDP1'
p393
S'GATA1'
p394
S'increases'
p395
tp396
(lp397
s(S'PI3K'
p398
S'ALPHA6/BETA4 INTEGRIN/LAMININ'
p399
S'binds'
p400
tp401
(lp402
s(S'FOXF2'
p403
S'NRAS'
p404
S'increases'
p405
tp406
(lp407
s(S'CUX1'
p408
S'POU2F1'
p409
S'increases'
p410
tp411
(lp412
s(S'ETS2'
p413
S'STAT4'
p414
S'increases'
p415
tp416
(lp417
s(S'EN1'
p418
S'CYP26A1'
p419
S'increases'
p420
tp421
(lp422
s(S'COMPLEX (RAS/GTP)'
p423
S'RAF'
p424
S'binds'
p425
tp426
(lp427
s(S'LEF1'
p428
S'EN1'
p429
S'increases'
p430
tp431
(lp432
s(S'FOXL1'
p433
S'NRAS'
p434
S'increases'
p435
tp436
(lp437
s(S'ELF2'
p438
S'CYP26A1'
p439
S'increases'
p440
tp441
(lp442
s(S'Src Family Kinases-active'
p443
S'EGF/EGFR'
p444
S'adds_modification'
p445
tp446
(lp447
s(S'RUNX1'
p448
S'POU2F1'
p449
S'increases'
p450
tp451
(lp452
s(S'RHOA/GTP'
p453
S'CITRON-N'
p454
S'increases_activity'
p455
tp456
(lp457
s(S'PAX4'
p458
S'SRF'
p459
S'increases'
p460
tp461
(lp462
s(S'Vitamin E'
p463
S'HRAS MRNA'
p464
S'increases'
p465
tp466
(lp467
s(S'CDX2'
p468
S'FOXD3'
p469
S'increases'
p470
tp471
(lp472
s(S'Plant Extracts'
p473
S'KEAP1 PROTEIN'
p474
S'decreases'
p475
tp476
(lp477
s(S'PAX4'
p478
S'CBFA2T3'
p479
S'increases'
p480
tp481
(lp482
s(S'FOXD1'
p483
S'CYP26A1'
p484
S'increases'
p485
tp486
(lp487
s(S'Antigen/IgE/Fc epsilon R1/LYN/SYK'
p488
S'VAV1'
p489
S'adds_modification'
p490
tp491
(lp492
s(S'PCBP1'
p493
S'MEIS1'
p494
S'increases'
p495
tp496
(lp497
s(S'FOXI1'
p498
S'FOXD3'
p499
S'increases'
p500
tp501
(lp502
s(S'GATA4'
p503
S'MEIS1'
p504
S'increases'
p505
tp506
(lp507
s(S'STAT5B'
p508
S'CEBPG'
p509
S'increases'
p510
tp511
(lp512
s(S'TFDP2'
p513
S'MAZ'
p514
S'increases'
p515
tp516
(lp517
s(S'PI3K'
p518
S'SHP2'
p519
S'binds'
p520
tp521
(lp522
S'Association of Grb2, PI3K, or SHP2 with GAB1 in response to EGF, insulin, or their combination.'
p523
as(S'SPI1'
p524
S'ONECUT1'
p525
S'increases'
p526
tp527
(lp528
s(S'STAT6'
p529
S'EN1'
p530
S'increases'
p531
tp532
(lp533
s(S'TLX2'
p534
S'CYP26A1'
p535
S'increases'
p536
tp537
(lp538
s(S'RAF1'
p539
S'MEK1-2'
p540
S'increases_activity'
p541
tp542
(lp543
s(S'STAT5A'
p544
S'IRF1'
p545
S'increases'
p546
tp547
(lp548
s(S'2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine'
p549
S'HRAS MRNA'
p550
S'increases'
p551
tp552
(lp553
s(S'MAZ'
p554
S'POU2F1'
p555
S'increases'
p556
tp557
(lp558
s(S'MAZ'
p559
S'SRF'
p560
S'increases'
p561
tp562
(lp563
s(S'GATA1'
p564
S'JUN'
p565
S'increases'
p566
tp567
(lp568
s(S'FOXA1'
p569
S'NRAS'
p570
S'increases'
p571
tp572
(lp573
s(S'STAT1'
p574
S'EN1'
p575
S'increases'
p576
tp577
(lp578
s(S'GTF2A2'
p579
S'MAX'
p580
S'increases'
p581
tp582
(lp583
s(S'LMO2'
p584
S'EN1'
p585
S'increases'
p586
tp587
(lp588
s(S'MYOD1'
p589
S'LEF1'
p590
S'increases'
p591
tp592
(lp593
s(S'ATF3'
p594
S'JUN'
p595
S'increases'
p596
tp597
(lp598
S'Transcriptional activation of ATF3, FOSL2, JUN, and KLF7.'
p599
as(S'GRB2:SOS1'
p600
S'ACTIVATED FGFR:P-SHC1'
p601
S'binds'
p602
tp603
(lp604
s(S'MAFG'
p605
S'BACH1'
p606
S'increases'
p607
tp608
(lp609
s(S'POU3F2'
p610
S'POU2F1'
p611
S'increases'
p612
tp613
(lp614
s(S'K 7174'
p615
S'KRAS MRNA'
p616
S'increases'
p617
tp618
(lp619
s(S'POU1F1'
p620
S'RUNX1'
p621
S'increases'
p622
tp623
(lp624
s(S'HRAS protein'
p625
S'CCND1 MRNA'
p626
S'increases'
p627
tp628
(lp629
s(S'YY1'
p630
S'EN1'
p631
S'increases'
p632
tp633
(lp634
s(S'resveratrol'
p635
S'HRAS MRNA'
p636
S'increases'
p637
tp638
(lp639
s(S'NKX2-1'
p640
S'HOXA9'
p641
S'increases'
p642
tp643
(lp644
s(S'HSF1'
p645
S'CYP26A1'
p646
S'increases'
p647
tp648
(lp649
s(S'MYC'
p650
S'HOXA9'
p651
S'increases'
p652
tp653
(lp654
s(S'Raf'
p655
S'MEK'
p656
S'adds_modification'
p657
tp658
(lp659
S'The Raf/MEK/ERK and PI3K/Akt pathways are prominent effectors of oncogenic Ras.'
p660
aS'The Raf/MEK/ERK pathway is among the most thoroughly studied downstream effectors of activated Ras ('
p661
aS'In this context, MEK reportedly binds to paxillin, and growth factor treatment induces the recruitment of Raf and ERK to this complex.'
p662
aS'Growth factors bind to RTKs and stimulate both the Ras/Raf/MEK/ERK and PI3K pathways.'
p663
aS'It has been shown that stress induced by the isolation procedure and plating of the cells can activate signaling pathways including the PI3K/Akt and the Raf/MEK/ERK pathway (Fausto '
p664
aS'We set the total protein abundances for MKKK (Raf), MKK (MEK) and ERK for our model on the basis of previous estimates ('
p665
aS'We obtained five small molecule antagonists of the kinases Phosphatidylinositol 3-kinase (PI3K), Raf, Akt, Phospholipase C (PLC), and MEK1.'
p666
aS'We also noted that changes in the phosphorylation status of several kinases and regulators acting upstream of ERK1/2, such as Pak1, Raf1, Map3k1, MEK1, MEK2, Ksr1, Rras2 and Ywhae (14-3-3 epsilon), were detected in cells treated with PD184352 ('
p667
aS'In the current model, reaction compartments were used to encode cytosolic and membrane-bound Ras and to represent protein phosphatase 2A (PP2A), an enzyme that dephosphorylates Raf, MEK and Akt in IERMv1.0 ('
p668
aS'Although some signaling cascades such as Ras/PI3K/PTEN/Akt/mTOR, Ras/Raf/MEK/ERK and p53 have been implicated in regulation of tumor radioresistance, the detail mechanism is still largely unknown.'
p669
aS'EGFR-mediated Ras-Raf-MEK-ERK and PI3K-PTEN-AKT pathways plays an important role in transmission of signals from membrane receptors to downstream targets that regulate apoptosis, cell growth and angiogenesis.'
p670
aS'There is a high level of ERK1/2 phosphorylation in WM9 cells, indicating an activated Ras-Raf-MEK-ERK1/2 MAPK pathway.'
p671
aS'Little is known about the hypoxic induction of members of the Ras/Raf/MEK/ERK signalling pathway.'
p672
aS'Activation of the Raf/MEK/ERK pathway has been often associated with the promotion of cell proliferation but also represents, in addition to the PI3K/Akt pathway, an important survival signaling pathway in many tumor cells\n['
p673
aS'Also contributory to the control of G1 is the Ras effector pathway Raf/MEK/ERK MAP kinase.'
p674
aS'Two of the better-understood EGFR signal transduction pathways involved in cell proliferation are the Ras-Raf-MEK-p44/p42 MAP kinase pathway and the PI3K/Akt pathway ['
p675
aS'Regulation c-Raf phosphorylation at Ser259 has a role in the anti-apoptotic pathways mediated by Akt or Raf/MEK/ERK proteins.'
p676
aS'Raf and MEK have been shown to be the upstream regulators of Erk1/2 ['
p677
aS'Androgen-independent advanced prostate cancer cell lines such as DU145 and PC3 typically express low levels of activated Raf, MEK, and ERK ['
p678
aS'The EGFR-Ras-Raf-MEK-ERK signaling pathway has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment (24).'
p679
aS'Several genetic alterations of cancer cause induction of cellular proliferation through the epidermal growth factor receptor (EGFR)-Ras-Raf-mitogen activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK; MEK)-ERK-MAPK pathway, including EGFR amplifications (colorectal, pancreatic and lung cancers) and mutations (lung adenocarcinomas and glioblastoma), and activating mutations of Ras (pancreatic, papillary thyroid, colon and lung cancers) and Raf (melanoma, papillary thyroid and colon cancers) ['
p680
aS'Although a great body of evidence shows the importance of Ras and its downstream signaling mediators (Raf-MEK-ERK) on colorectal tumor development, the precise role of MEK remains undefined.'
p681
aS'In addition, we have found that prosaptide TX14A stimulates prostate cancer cell proliferation, migration, and invasion, activates the Raf-MEK-ERK-Elk-1 signaling cascade of the mitogen-activated protein kinase (MAPK) pathway, and inhibits the growth-inhibitory effects of sodium selenite administered at apoptogenic concentrations ['
p682
aS'A common feature of many human epithelial cancers is a constitutive activation of the Ras/Raf/MEK/Erk signal transduction pathway ['
p683
aS'Phosphatidylethanolamine-binding protein (PEBP) has been reported to act as a negative regulator of the ERK cascade (Raf-MEK-ERK) by binding to Raf-1 kinase.'
p684
aS'Finally, ODN administration also leads to increased levels of phospho-ERK and activation of the Raf/MEK/ERK signaling pathway ['
p685
aS'SHIP2 is able to activate Ras through Grb2 and SOS, leading to the phosphorylation and activation of Raf-1/MEK-1/MAP kinases ['
p686
aS'The upstream MAPK kinase-kinases Raf phosphorylate MAPK/ERK-kinases (MEKs).'
p687
aS'In many different cell types, IR activation turns on downstream signaling pathways involving Ras and PI3K, which subsequently activate the Akt kinase and/or the Raf-MEK-ERK cascade.'
p688
aS'It has been shown that one role of Shc in cells is to promote the formation of a Shc-Grb2-SOS complex, which can activate the Ras-Raf-MEK-ERK kinase cascade ['
p689
aS'Raf can then phosphorylate MEK, which activates ERK through phosphorylation in two different residues.'
p690
aS'The p16INK4A cyclin-dependent kinase inhibitor has been implicated in replicative senescence, the state of permanent growth arrest induced by cumulative cell divisions or constitutive Ras-Raf-MEK signaling in somatic cells.'
p691
aS'This, in turn, induces Raf-1 kinase translocation to the plasma membrane and Raf-1-mediated phosphorylation of MEK proteins (MEK1 and 2).'
p692
aS'In many cell types in culture, sustained\nexpression of activated Ras or its downstream effector \ncan elicit cell cycle arrest and differentiation, and some\nreseachers revealed that the biological effects of the\nRas/Raf/MEK/ERK pathway were activated via LIF/JAK/STAT\npathway ['
p693
aS'   MEK is the key regulatory protein kinase activation in the Ras/Raf/MEK/ERK pathway ('
p694
aS'   Compelling evidence arising from malignant transformation studies in which MEK SMIs were employed in vitro has also implicated Raf/MEK/ERK ['
p695
aS'The discovery of promising specific targets for intervention in the inflammatory arthritis process have included, S1P, IL-7R, Syk, Raf/MEK/ERK 1/2, MK5/PRAK, miRNA, PI3K/PTEN/Akt, NF-'
p696
aS'The phosphorylation (i.e., activation) of A-Raf, B-Raf or c-RAF, by MAPKKK (i.e., MAP3K) results in MAP2K-mediated phosphorylation of MEK 1/2 and downstream activation of ERK 1/2 (reviewed in ['
p697
aS'Finally, we have found that automated imaging of fluorescent protein reporters provides a powerful means of interrogating GnRHR signalling to the Raf/MEK/ERK and Ca'
p698
aS'The best-characterized member of this family is KSR1, which promotes activation of the Raf/MEK/ERK kinase cascade ('
p699
aS'On growth factor stimulation, many receptor-type or non-receptor-type tyrosine kinases are activated, followed by the activation of the Ras/Raf/MEK/ERK signaling cascades, which regulate various aspects of cellular function, including the proliferation, differentiation, and oncogenic transformation of high eukaryotes ('
p700
aS'The following antibodies were also used in this study: anti-Raf1, anti-MEK1, and anti-pan ERK antibody were purchased from BD Transduction Laboratories (San Jose, CA); anti-Pan Ras (AB-3) antibody was from Calbiochem; anti-FLAG M5 antibody was purchased from Sigma; anti-Myc (9E10) antibody was from Santa Cruz Biotechnology (Santa Cruz, CA); antibodies against phospho-Raf1 (Ser'
p701
aS"(D) The activity of Ras as measured by Bos' pulldown analysis and the activities of MEK, Raf1, and ERK as measured by phospho-specific antibodies in C were normalized to the maximum values during the time course and are shown by line plots."
p702
aS'In agreement with the suppression of Raf1 activation by Shoc2 knockdown, the activation of both MEK and ERK was also suppressed by Shoc2 knockdown in cells stimulated with EGF or 007 plus ionomycin ('
p703
aS'(B) The activity of Raf1 and MEK as measured with the phospho-specific antibodies was normalized to the maximum values of scramble siRNA-transfected EGF-stimulated cells.'
p704
aS'We further provide evidence that inhibition of PKD blocks mitotic Raf-1 and mitogen-activated protein kinase kinase (MEK) activation, and, as a consequence, mitotic Golgi fragmentation, which could be rescued by expression of active MEK1.'
p705
aS'The best-characterized kinase cascade involved in mitotic Golgi fragmentation is the Raf-MEK-Erk pathway, playing a role before prophase in late G2.'
p706
aS'Our previous results indicate that PKD is upstream of the Raf-1/MEK pathway in mitotic Golgi fragmentation.'
p707
aS'In intact cells we further show that PKD is critical for Golgi fragmentation in the late G2 phase of the cell cycle and mitotic entry by activating the Raf-1/MEK1 pathway.'
p708
aS'The importance of the Raf-1/MEK1 pathway in Golgi mitotic checkpoint control is underscored by the fact that expression of active MEK1 in PKD1/2-depleted cells rescued the block in Golgi membrane fragmentation and mitotic entry.'
p709
aS'Raf-1 is immediately upstream of MEK1 ('
p710
aS'Immunoblot of pERK1/2 serves as a control for Raf-MEK-ERK activation after the addition of 4-OHT.'
p711
aS'Since the etiology of pilocytic astrocytoma (PA) is associated to several major cellular signaling pathways we investigated whether some of the annotated genes belong to pathways specific to PA. We found genes that are involved in Ras-Raf-MEK-ERK signaling, p53 signaling, RB signaling, Wnt signaling.'
p712
aS'The Raf kinase, MAP kinase kinase (MEK) and MAPK combine to form a pathway that links extracellular signals to the phosphorylation of cellular proteins to regulate cell proliferation and differentiation ['
p713
aS'Here we first demonstrate that asperolide A, a very recently reported marine-derived tetranorditerpenoid, leads to the inhibition of NCI-H460 lung carcinoma cell proliferation by G2/M arrest with the activation of the Ras/Raf/MEK/ERK signaling and p53-dependent p21 pathway.'
p714
aS'The Ras family, containing H-(or Ha-) Ras, K-(or Ki-) Ras, and N-Ras, which transmits extracellular signals to the interior of the cells via switching the inactive GDP-bound state to the active GTP-bound state, are commonly thought of as oncogenes; the Ras/Raf/MEK/MAPK pathway is thought to be functional downstream of EGFR (Epidermal growth-factor receptor), which has been associated with a more aggressive disease or poor prognosis in variety of cancer systems including lung cancer ['
p715
aS'And c-Raf (Raf-1), the main effector recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway, was also enhanced activity by phosphorylation at Ser338 ('
p716
aS'Above all, these results suggest that the Ras/Raf/MEK/ERK signaling pathway may be involved in asperolide A-induced p53-p21-mediated G2/M-phase arrest and growth inhibition in NCI-H460 cells.'
p717
aS'In order to further explore whether the Ras/Raf/MEK/ERK pathway is required by G2/M phase cell cycle arrest induced by asperolide A in NCI-H460 cells, cells were transfected with a dominant negative Ras (RasN17) and then treated with asperolide A for 48 h. The percentage of G2/M phase cells came to normal level and asperolide A-induced increase of p-ERK, p-p53, p21 and decrease of CDC2, cyclin B1 were completely reversed by transfection with RasN17.'
p718
aS'All above strongly suggest it is the Ras/Raf/MEK/ERK signaling pathway that is participating in p53-p21 stabilization in order to induce G2/M arrest in human NCI-H460 lung carcinoma cells.'
p719
aS'We characterize the probable effect of asperolide A on Ras/Raf/MEK/ERK signaling pathway in '
p720
aS'In summary, our data indicate that: (a) asperolide A inhibit cell-cycle progression at the G2/M phase by decreasing the levels of CDC2, cdc25c and cyclinB; (b) asperolide A-induced G2/M arrest is mediated by p53-dependent p21 induction which is regulated by Ras/Raf/MEK/ERK signaling pathway; and (c) '
p721
aS'Binding of SOS to GRB2 in the plasma membrane sequentially activates Ras, Raf, MEK1/2, and ERK1/2 ['
p722
aS'Raf/MEK/ERK pathway is the best proven MAPK signaling pathway ['
p723
aS'A recent study suggests that Raf/MEK/ERK signaling is activated by proper accumulation of HA/lipid-raft association within the cellular membrane ['
p724
aS'The protein kinase C (PKC) is an upstream molecule of Raf, which transmits signals to the downstream molecules for the activation of the Raf/MEK/ERK pathway ['
p725
as(S'TFDP1'
p726
S'MAZ'
p727
S'increases'
p728
tp729
(lp730
s(S'SPRED1'
p731
S'HRAS'
p732
S'binds'
p733
tp734
(lp735
s(S'MYCN'
p736
S'CYP26A1'
p737
S'increases'
p738
tp739
(lp740
s(S'AHR'
p741
S'FOXD3'
p742
S'increases'
p743
tp744
(lp745
s(S'SF1'
p746
S'CYP26A1'
p747
S'increases'
p748
tp749
(lp750
s(S'MEIS1'
p751
S'ETS1'
p752
S'increases'
p753
tp754
(lp755
s(S'Copper Sulfate'
p756
S'HRAS MRNA'
p757
S'decreases'
p758
tp759
(lp760
s(S'MAZ'
p761
S'MYC'
p762
S'increases'
p763
tp764
(lp765
s(S'E4F1'
p766
S'HOXA9'
p767
S'increases'
p768
tp769
(lp770
s(S'GATA1'
p771
S'GATA6'
p772
S'increases'
p773
tp774
(lp775
s(S'RUNX2'
p776
S'POU2F1'
p777
S'increases'
p778
tp779
(lp780
s(S'CYP26A1'
p781
S'GATA6'
p782
S'increases'
p783
tp784
(lp785
s(S'PAX4'
p786
S'GATA1'
p787
S'increases'
p788
tp789
(lp790
s(S'ELF2'
p791
S'STAT5A'
p792
S'increases'
p793
tp794
(lp795
s(S'CART1'
p796
S'NRAS'
p797
S'increases'
p798
tp799
(lp800
s(S'IGF-1R heterotetramer/IGF1/GRB2/Sos/Shc'
p801
S'HRAS/GDP'
p802
S'increases_activity'
p803
tp804
(lp805
s(S'RB1'
p806
S'CYP26A1'
p807
S'increases'
p808
tp809
(lp810
s(S'CEBPG'
p811
S'HOXA9'
p812
S'increases'
p813
tp814
(lp815
s(S'GRB2/SOS1/SHC'
p816
S'IGF-1R HETEROTETRAMER/IGF1'
p817
S'binds'
p818
tp819
(lp820
s(S'PRRX2'
p821
S'CYP26A1'
p822
S'increases'
p823
tp824
(lp825
s(S'TEAD1'
p826
S'CYP26A1'
p827
S'increases'
p828
tp829
(lp830
s(S'STAT5A'
p831
S'FOXA1'
p832
S'increases'
p833
tp834
(lp835
s(S'ATF2'
p836
S'FOXD3'
p837
S'increases'
p838
tp839
(lp840
s(S'REPIN1'
p841
S'FOXO4'
p842
S'increases'
p843
tp844
(lp845
s(S'FOXF2'
p846
S'ETS1'
p847
S'increases'
p848
tp849
(lp850
s(S'ETV7'
p851
S'MEIS1'
p852
S'increases'
p853
tp854
(lp855
s(S'RUNX2'
p856
S'RUNX1'
p857
S'increases'
p858
tp859
(lp860
s(S'OR5I1'
p861
S'GATA1'
p862
S'increases'
p863
tp864
(lp865
s(S'MSX1'
p866
S'EN1'
p867
S'increases'
p868
tp869
(lp870
s(S'GTF3A'
p871
S'IRF1'
p872
S'increases'
p873
tp874
(lp875
s(S'POU2F1'
p876
S'SRF'
p877
S'increases'
p878
tp879
(lp880
s(S'PLC-GAMMA'
p881
S'COMPLEX (GADS/SLP-76)'
p882
S'binds'
p883
tp884
(lp885
s(S'STAT4'
p886
S'STAT5A'
p887
S'increases'
p888
tp889
(lp890
s(S'JUN'
p891
S'BACH1'
p892
S'increases'
p893
tp894
(lp895
s(S'POU1F1'
p896
S'HOXA9'
p897
S'increases'
p898
tp899
(lp900
s(S'docetaxel'
p901
S'HRAS PROTEIN'
p902
S'increases'
p903
tp904
(lp905
s(S'MAX'
p906
S'LEF1'
p907
S'increases'
p908
tp909
(lp910
s(S'FOXA1'
p911
S'CYP26A1'
p912
S'increases'
p913
tp914
(lp915
s(S'GATA4'
p916
S'FOXD3'
p917
S'increases'
p918
tp919
(lp920
s(S'ZBTB18'
p921
S'RUNX1'
p922
S'increases'
p923
tp924
(lp925
s(S'ATF3'
p926
S'RUNX1'
p927
S'increases'
p928
tp929
(lp930
s(S'NKX2-1'
p931
S'CYP26A1'
p932
S'increases'
p933
tp934
(lp935
s(S'NR3C1'
p936
S'FOXA1'
p937
S'increases'
p938
tp939
(lp940
s(S'RAS family/GTP'
p941
S'RIN1'
p942
S'increases_activity'
p943
tp944
(lp945
s(S'COMPLEX (RAS/GTP/ RAF)'
p946
S'MEK'
p947
S'binds'
p948
tp949
(lp950
s(S'CDC5L'
p951
S'NRAS'
p952
S'increases'
p953
tp954
(lp955
s(S'Vitamin E'
p956
S'NRAS MRNA'
p957
S'decreases'
p958
tp959
(lp960
s(S'NF1'
p961
S'LEF1'
p962
S'increases'
p963
tp964
(lp965
s(S'ETS1'
p966
S'EN1'
p967
S'increases'
p968
tp969
(lp970
s(S'CRAF'
p971
S'YWHAB'
p972
S'binds'
p973
tp974
(lp975
s(S'CEBPD'
p976
S'JUN'
p977
S'increases'
p978
tp979
(lp980
s(S'MAX'
p981
S'RUNX2'
p982
S'increases'
p983
tp984
(lp985
s(S'CEBPA'
p986
S'MECOM'
p987
S'increases'
p988
tp989
(lp990
s(S'PAX2'
p991
S'GATA1'
p992
S'increases'
p993
tp994
(lp995
s(S'CYP26A1'
p996
S'TLX2'
p997
S'increases'
p998
tp999
(lp1000
s(S'GFI1'
p1001
S'ETS1'
p1002
S'increases'
p1003
tp1004
(lp1005
s(S'14-3-3:P-S259,Y340,Y341,S621-RAF1:RAS:GTP'
p1006
S'MEK'
p1007
S'binds'
p1008
tp1009
(lp1010
s(S'P-S,T-MEK2'
p1011
S'ERK2'
p1012
S'binds'
p1013
tp1014
(lp1015
s(S'HRAS/GTP'
p1016
S'RIN2'
p1017
S'increases_activity'
p1018
tp1019
(lp1020
s(S'Ras-GTP'
p1021
S'P42/P44MAPKS'
p1022
S'adds_modification'
p1023
tp1024
(lp1025
s(S'SRF'
p1026
S'CYP26A1'
p1027
S'increases'
p1028
tp1029
(lp1030
s(S'FOXL1'
p1031
S'RUNX2'
p1032
S'increases'
p1033
tp1034
(lp1035
s(S'EGR4'
p1036
S'LEF1'
p1037
S'increases'
p1038
tp1039
(lp1040
s(S'P-IRS1,2'
p1041
S'GRB2:SOS1'
p1042
S'binds'
p1043
tp1044
(lp1045
s(S'VEGFR2 (dimer)/VEGFA (dimer)/alphav/beta3 Integrin/Vitronectin'
p1046
S'SRC'
p1047
S'adds_modification'
p1048
tp1049
(lp1050
s(S'BACH2'
p1051
S'BACH1'
p1052
S'increases'
p1053
tp1054
(lp1055
s(S'ONECUT1'
p1056
S'RUNX1'
p1057
S'increases'
p1058
tp1059
(lp1060
s(S'FOXJ2'
p1061
S'RUNX2'
p1062
S'increases'
p1063
tp1064
(lp1065
s(S'PI-3-4-5-P3'
p1066
S'AKT1'
p1067
S'translocates'
p1068
tp1069
(lp1070
s(S'TFAP4'
p1071
S'BACH1'
p1072
S'increases'
p1073
tp1074
(lp1075
s(S'MEKK1/4'
p1076
S'MKK3/6'
p1077
S'adds_modification'
p1078
tp1079
(lp1080
s(S'VSX1'
p1081
S'MECOM'
p1082
S'increases'
p1083
tp1084
(lp1085
s(S'IRF1'
p1086
S'GATA6'
p1087
S'increases'
p1088
tp1089
(lp1090
s(S'MAX'
p1091
S'HOXA9'
p1092
S'increases'
p1093
tp1094
(lp1095
s(S'RB1'
p1096
S'MAZ'
p1097
S'increases'
p1098
tp1099
(lp1100
s(S'GATA1'
p1101
S'EN1'
p1102
S'increases'
p1103
tp1104
(lp1105
s(S'HIF1A'
p1106
S'SRF'
p1107
S'increases'
p1108
tp1109
(lp1110
s(S'IRF8'
p1111
S'CYP26A1'
p1112
S'increases'
p1113
tp1114
(lp1115
s(S'MTF1'
p1116
S'CYP26A1'
p1117
S'increases'
p1118
tp1119
(lp1120
s(S'PI-3-4-5-P3'
p1121
S'GAB1'
p1122
S'translocates'
p1123
tp1124
(lp1125
s(S'PI-3-4-5-P3'
p1126
S'AKT1'
p1127
S'adds_modification'
p1128
tp1129
(lp1130
s(S'RXRA'
p1131
S'HOXA9'
p1132
S'increases'
p1133
tp1134
(lp1135
s(S'AKT1'
p1136
S'RAF1'
p1137
S'binds'
p1138
tp1139
(lp1140
s(S'HSF2'
p1141
S'JUN'
p1142
S'increases'
p1143
tp1144
(lp1145
s(S'PAX2'
p1146
S'CYP26A1'
p1147
S'increases'
p1148
tp1149
(lp1150
s(S'ETV7'
p1151
S'CYP26A1'
p1152
S'increases'
p1153
tp1154
(lp1155
s(S'FOXO3'
p1156
S'NRAS'
p1157
S'increases'
p1158
tp1159
(lp1160
s(S'TP53'
p1161
S'REPIN1'
p1162
S'increases'
p1163
tp1164
(lp1165
s(S'STAT6'
p1166
S'CYP26A1'
p1167
S'increases'
p1168
tp1169
(lp1170
s(S'JUN'
p1171
S'NRAS'
p1172
S'increases'
p1173
tp1174
(lp1175
s(S'MYCN'
p1176
S'NRAS'
p1177
S'increases'
p1178
tp1179
(lp1180
s(S'STAT3'
p1181
S'YY1'
p1182
S'increases'
p1183
tp1184
(lp1185
s(S'Methyl Methanesulfonate'
p1186
S'HRAS MRNA'
p1187
S'increases'
p1188
tp1189
(lp1190
s(S'RHOA/GTP'
p1191
S'PKN'
p1192
S'increases_activity'
p1193
tp1194
(lp1195
s(S'NHLH1'
p1196
S'FOXJ2'
p1197
S'increases'
p1198
tp1199
(lp1200
s(S'RAS family/GTP'
p1201
S'BRAF'
p1202
S'adds_modification'
p1203
tp1204
(lp1205
s(S'RELA'
p1206
S'FOXJ2'
p1207
S'increases'
p1208
tp1209
(lp1210
s(S'TCF3'
p1211
S'RUNX1'
p1212
S'increases'
p1213
tp1214
(lp1215
S'TCF3: transcription factor 3; PBX1: pre B-cell leukemia transcription factor 1; BCR: breakpoint cluster region; ABL1: Abelson murine leukemia viral oncogene homolog 1; MLL: myeloid/lymphoid or mixed lineage leukemia gene; ETV6: ets variant gene 6; RUNX1: runt-related transcription factor 1; RUNX1T1: runt-related transcription factor 1 translocated to, 1; MYC: v-myc avian myelocytomatosis viral oncogene homolog; IGH: IgG heavy chain locus; BCL6: B-cell lymphoma 6; SCL: stem cell leukemia hematopoietic transcription factor; TCRA: T-cell antigen receptor, alpha subunit; LMO2: lim domain only 2, t: therapy related.'
p1216
aS'The Myc network and the mRNA export machinery are perturbed in ETV6-RUNX1 and TCF3-PBX1 subtypes of leukemia.'
p1217
aS'To determine whether the structure of the network is modified after ETV6-RUNX1 or TCF3-PBX1 fusions, we analyzed network topology perturbations using three metrics: characteristic path length (cpl), edge betweenness centrality (ebc), and edge-clustering coefficient (ecc).'
p1218
aS'Comparison of local metrics between perturbed edges and the rest of the network for (A) ETV6-RUNX1 and (B) TCF3-PBX1 fusion.'
p1219
aS'Taken together, our network topology analysis suggests that ETV6-RUNX1 chromosomal translocation may lead to disruption of molecular interactions important for B-cell communication circuits, whereas TCF3-PBX1 fusion only slightly modifies the structure of the network.'
p1220
aS'We ranked nodes based on the proportion of their perturbed interactions in HBCI, and highlighted the 10 most deregulated nodes in ETV6-RUNX1 and TCF3-PBX1 fusion subtypes of ALL.'
p1221
aS'The 10 top perturbed pathways after (A) ETV6-RUNX1 and (B) TCF3-PBX1 gene fusion.'
p1222
aS"TCF3-PBX1 (gift of David P. LeBrun, Queen's University, Kingston, Canada) and ETV6-RUNX1 (gift of Guy Leclerc, University of Miami, Miami, FL) cDNA clones were also subcloned by Gateway technology into pDEST1899 Flag N-ter vector."
p1223
as(S'FOXF2'
p1224
S'FOXO4'
p1225
S'increases'
p1226
tp1227
(lp1228
s(S'ATF4'
p1229
S'FOXD3'
p1230
S'increases'
p1231
tp1232
(lp1233
s(S'HAND1'
p1234
S'MECOM'
p1235
S'increases'
p1236
tp1237
(lp1238
s(S'RHOA/GTP'
p1239
S'P27KIP1'
p1240
S'adds_modification'
p1241
tp1242
(lp1243
s(S'SRF'
p1244
S'NRAS'
p1245
S'increases'
p1246
tp1247
(lp1248
s(S'ESRRA'
p1249
S'POU3F2'
p1250
S'increases'
p1251
tp1252
(lp1253
s(S'BRAF'
p1254
S'MEK1'
p1255
S'adds_modification'
p1256
tp1257
(lp1258
S'Our data indicate that serpinE2 is up-regulated by oncogenic activation of Ras, BRAF and MEK1 and contributes to pro-neoplastic actions of ERK signaling in intestinal epithelial cells.'
p1259
aS'Small-molecule inhibitors targeting BRAF reduced MEK1/2-ERK1/2 pathway activation and cell survival; yet, viable cell subpopulations persisted.'
p1260
as(S'Cadmium Chloride'
p1261
S'KRAS PROTEIN'
p1262
S'increases'
p1263
tp1264
(lp1265
s(S'PRRX2'
p1266
S'MEIS1'
p1267
S'increases'
p1268
tp1269
(lp1270
s(S'MYC'
p1271
S'NRAS'
p1272
S'increases'
p1273
tp1274
(lp1275
s(S'MAZ'
p1276
S'KRAS'
p1277
S'increases'
p1278
tp1279
(lp1280
s(S'Rho Family GTPase-active'
p1281
S'PI3K'
p1282
S'increases_activity'
p1283
tp1284
(lp1285
s(S'STAT2'
p1286
S'CYP26A1'
p1287
S'increases'
p1288
tp1289
(lp1290
s(S'hsa-let-7a-5p'
p1291
S'KRAS'
p1292
S'decreases'
p1293
tp1294
(lp1295
s(S'POU3F2'
p1296
S'NRAS'
p1297
S'increases'
p1298
tp1299
(lp1300
s(S'SRF'
p1301
S'FOXO4'
p1302
S'increases'
p1303
tp1304
(lp1305
s(S'S1P1/Sphingosine-1-phosphate/PDGF-BB/PDGFRB (dimer)'
p1306
S'SRC FAMILY KINASES'
p1307
S'increases_activity'
p1308
tp1309
(lp1310
s(S'MYC/Max'
p1311
S'ERBB2'
p1312
S'decreases'
p1313
tp1314
(lp1315
s(S'SREBF1'
p1316
S'CBFA2T3'
p1317
S'increases'
p1318
tp1319
(lp1320
s(S'PI3K'
p1321
S'GELSOLIN/PI-3-4-5-P3'
p1322
S'binds'
p1323
tp1324
(lp1325
s(S'NHLH1'
p1326
S'EN1'
p1327
S'increases'
p1328
tp1329
(lp1330
s(S'LMO2'
p1331
S'GATA6'
p1332
S'increases'
p1333
tp1334
(lp1335
s(S'POU1F1'
p1336
S'FOXD3'
p1337
S'increases'
p1338
tp1339
(lp1340
s(S'hsa-miR-148b-3p'
p1341
S'NRAS'
p1342
S'decreases'
p1343
tp1344
(lp1345
s(S'Quercetin'
p1346
S'KRAS PROTEIN'
p1347
S'decreases'
p1348
tp1349
(lp1350
s(S'PAK2'
p1351
S'MEKK1'
p1352
S'adds_modification'
p1353
tp1354
(lp1355
s(S'LMO2'
p1356
S'MAZ'
p1357
S'increases'
p1358
tp1359
(lp1360
s(S'FOXO1'
p1361
S'POU3F2'
p1362
S'increases'
p1363
tp1364
(lp1365
s(S'NKX2-1'
p1366
S'MAZ'
p1367
S'increases'
p1368
tp1369
(lp1370
s(S'GRB2/SOS1'
p1371
S'PDGF-BB/PDGFRB (DIMER)/P52 SHC'
p1372
S'binds'
p1373
tp1374
(lp1375
s(S'PI3K'
p1376
S'CRK/P130 CAS/PAXILLIN'
p1377
S'increases_activity'
p1378
tp1379
(lp1380
s(S'ATF1'
p1381
S'FOXD3'
p1382
S'increases'
p1383
tp1384
(lp1385
s(S'GATA1'
p1386
S'SRF'
p1387
S'increases'
p1388
tp1389
(lp1390
s(S'TFAP2C'
p1391
S'CYP26A1'
p1392
S'increases'
p1393
tp1394
(lp1395
s(S'AHR'
p1396
S'MEIS1'
p1397
S'increases'
p1398
tp1399
(lp1400
s(S'ETS2'
p1401
S'CYP26A1'
p1402
S'increases'
p1403
tp1404
(lp1405
s(S'Estradiol'
p1406
S'NRAS MRNA'
p1407
S'increases'
p1408
tp1409
(lp1410
s(S'E2F1'
p1411
S'HOXA9'
p1412
S'increases'
p1413
tp1414
(lp1415
s(S'PDGF-BB/PDGFRB (DIMER)'
p1416
S'RASGAP'
p1417
S'binds'
p1418
tp1419
(lp1420
s(S'E2F1'
p1421
S'GABPB2'
p1422
S'increases'
p1423
tp1424
(lp1425
s(S'FOXJ1'
p1426
S'POU3F2'
p1427
S'increases'
p1428
tp1429
(lp1430
s(S'VSX1'
p1431
S'CYP26A1'
p1432
S'increases'
p1433
tp1434
(lp1435
s(S'SPI1'
p1436
S'CDC5L'
p1437
S'increases'
p1438
tp1439
(lp1440
s(S'Gi family'
p1441
S'HRAS/GDP'
p1442
S'increases_activity'
p1443
tp1444
(lp1445
s(S'TCF3'
p1446
S'CYP26A1'
p1447
S'increases'
p1448
tp1449
(lp1450
s(S'IGF-1R HETEROTETRAMER/IGF1/IRS1'
p1451
S'GRB2/SOS1'
p1452
S'binds'
p1453
tp1454
(lp1455
s(S'RAS family/GTP'
p1456
S'RALGDS'
p1457
S'translocates'
p1458
tp1459
(lp1460
s(S'PI3K'
p1461
S'RAC1/GDP'
p1462
S'increases_activity'
p1463
tp1464
(lp1465
s(S'Ca2+'
p1466
S'PKC'
p1467
S'increases_activity'
p1468
tp1469
(lp1470
s(S'ZIC1'
p1471
S'CYP26A1'
p1472
S'increases'
p1473
tp1474
(lp1475
s(S'IRF7'
p1476
S'TLX2'
p1477
S'increases'
p1478
tp1479
(lp1480
s(S'SHC/SHIP'
p1481
S'HRAS/GDP'
p1482
S'decreases_activity'
p1483
tp1484
(lp1485
s(S'hsa-let-7a-5p'
p1486
S'HRAS'
p1487
S'decreases'
p1488
tp1489
(lp1490
s(S'GATA4'
p1491
S'MAZ'
p1492
S'increases'
p1493
tp1494
(lp1495
s(S'EN1'
p1496
S'NRAS'
p1497
S'increases'
p1498
tp1499
(lp1500
s(S'PI3K'
p1501
S'BAM32'
p1502
S'adds_modification'
p1503
tp1504
(lp1505
s(S'GABPB1'
p1506
S'CYP26A1'
p1507
S'increases'
p1508
tp1509
(lp1510
s(S'Trifluoroethanol'
p1511
S'HRAS'
p1512
S'increases_activity'
p1513
tp1514
(lp1515
s(S'SOX5'
p1516
S'CYP26A1'
p1517
S'increases'
p1518
tp1519
(lp1520
s(S'GRB2/SOS1'
p1521
S'HGF(DIMER)/MET(DIMER)/P52 SHC'
p1522
S'binds'
p1523
tp1524
(lp1525
s(S'TCF12'
p1526
S'EN1'
p1527
S'increases'
p1528
tp1529
(lp1530
s(S'SOX9'
p1531
S'MEIS1'
p1532
S'increases'
p1533
tp1534
(lp1535
s(S'RB1'
p1536
S'MYC'
p1537
S'increases'
p1538
tp1539
(lp1540
S'Interestingly "transcription from Pol II promoter" was, indeed, one of the biological process identified by EASE analysis as significantly enriched in the list of U87-MG down-regulated genes, where we found the repression of many transcription factors mRNAs such as AHR; CHD1; CNOT2; DEK; ELL2; EPAS1; ETV1; FOXC2; FOXM1; GLI3; GTF2F2; HIPK2; HIRA; ID1; MNAT1; MYC; NCOA6; NCOR1; NR2F2; PBX3; RB1; RBBP8; SMARCA5; TCF4; TFDP1 and TRIP13.'
p1541
as(S'RXRA'
p1542
S'FOXA1'
p1543
S'increases'
p1544
tp1545
(lp1546
s(S'decitabine'
p1547
S'HRAS MRNA'
p1548
S'decreases'
p1549
tp1550
(lp1551
s(S'VSX1'
p1552
S'EN1'
p1553
S'increases'
p1554
tp1555
(lp1556
s(S'FOXL1'
p1557
S'CYP26A1'
p1558
S'increases'
p1559
tp1560
(lp1561
s(S'PAX2'
p1562
S'RUNX1'
p1563
S'increases'
p1564
tp1565
(lp1566
s(S'MEKK1/4'
p1567
S'MKK4/7'
p1568
S'adds_modification'
p1569
tp1570
(lp1571
s(S'HOXA9'
p1572
S'CYP26A1'
p1573
S'increases'
p1574
tp1575
(lp1576
s(S'TRKC'
p1577
S'NT3 (DIMER)'
p1578
S'binds'
p1579
tp1580
(lp1581
s(S'PTF1A'
p1582
S'REPIN1'
p1583
S'increases'
p1584
tp1585
(lp1586
s(S'TGIF'
p1587
S'CYP26A1'
p1588
S'increases'
p1589
tp1590
(lp1591
s(S'MYOD1'
p1592
S'MYC'
p1593
S'increases'
p1594
tp1595
(lp1596
s(S'PKCT'
p1597
S'KRAS ISO2'
p1598
S'adds_modification'
p1599
tp1600
(lp1601
s(S'RAS family/GTP'
p1602
S'BRAF'
p1603
S'increases_activity'
p1604
tp1605
(lp1606
s(S'SPZ1'
p1607
S'CYP26A1'
p1608
S'increases'
p1609
tp1610
(lp1611
s(S'HRAS/GTP'
p1612
S'GALECTIN-1'
p1613
S'binds'
p1614
tp1615
(lp1616
s(S'DBP'
p1617
S'FOXD3'
p1618
S'increases'
p1619
tp1620
(lp1621
s(S'E2F1'
p1622
S'POU2F1'
p1623
S'increases'
p1624
tp1625
(lp1626
s(S'MEIS1'
p1627
S'CYP26A1'
p1628
S'increases'
p1629
tp1630
(lp1631
s(S'YY1'
p1632
S'NRAS'
p1633
S'increases'
p1634
tp1635
(lp1636
s(S'RAS:RAF'
p1637
S'YWHAB'
p1638
S'binds'
p1639
tp1640
(lp1641
s(S'NFE2L2'
p1642
S'CYP26A1'
p1643
S'increases'
p1644
tp1645
(lp1646
s(S'FARNESYL'
p1647
S'KRAS'
p1648
S'increases_activity'
p1649
tp1650
(lp1651
s(S'MTF1'
p1652
S'MECOM'
p1653
S'increases'
p1654
tp1655
(lp1656
s(S'TLX2'
p1657
S'FOXD3'
p1658
S'increases'
p1659
tp1660
(lp1661
s(S'Insulin Receptor/Insulin/SHC/GRB2/Sos1'
p1662
S'HRAS/GDP'
p1663
S'increases_activity'
p1664
tp1665
(lp1666
s(S'MYC'
p1667
S'ELK1'
p1668
S'increases'
p1669
tp1670
(lp1671
s(S'ONECUT1'
p1672
S'POU2F1'
p1673
S'increases'
p1674
tp1675
(lp1676
s(S'Paraquat'
p1677
S'HRAS MRNA'
p1678
S'translocates'
p1679
tp1680
(lp1681
s(S'GRB2/SOS1'
p1682
S'PDGF-BB/PDGFRB (DIMER)/SHP2'
p1683
S'binds'
p1684
tp1685
(lp1686
s(S'ONECUT1'
p1687
S'CYP26A1'
p1688
S'increases'
p1689
tp1690
(lp1691
s(S'MYC'
p1692
S'FOXO3'
p1693
S'increases'
p1694
tp1695
(lp1696
S'FOXO3-induced MYC-mediated gene repression possibly entails an important mechanism by which FOXO indirectly represses gene expression.'
p1697
aS'We observe an increase in MXI1 expression, a previously reported FOXO3-induced negative regulator of MYC function ('
p1698
as(S'PAX3'
p1699
S'ELK1'
p1700
S'increases'
p1701
tp1702
(lp1703
s(S'DOK-R'
p1704
S'RASGAP'
p1705
S'binds'
p1706
tp1707
(lp1708
s(S'HOXA4'
p1709
S'HOXA9'
p1710
S'increases'
p1711
tp1712
(lp1713
s(S'MAX'
p1714
S'POU3F2'
p1715
S'increases'
p1716
tp1717
(lp1718
s(S'Estradiol'
p1719
S'KRAS MRNA'
p1720
S'decreases'
p1721
tp1722
(lp1723
s(S'KRAS ISOFORM 4B/GTP'
p1724
S'CAM/CA2+'
p1725
S'binds'
p1726
tp1727
(lp1728
s(S'MAZ'
p1729
S'FOXO4'
p1730
S'increases'
p1731
tp1732
(lp1733
s(S'hsa-miR-181a-5p'
p1734
S'KRAS'
p1735
S'decreases'
p1736
tp1737
(lp1738
s(S'GATA1'
p1739
S'CYP26A1'
p1740
S'increases'
p1741
tp1742
(lp1743
s(S'PGR'
p1744
S'ETS1'
p1745
S'increases'
p1746
tp1747
(lp1748
s(S'GATA1'
p1749
S'POU2F1'
p1750
S'increases'
p1751
tp1752
(lp1753
s(S'BRAF'
p1754
S'MEK1-2'
p1755
S'increases_activity'
p1756
tp1757
(lp1758
s(S'LEF1'
p1759
S'GABPB2'
p1760
S'increases'
p1761
tp1762
(lp1763
s(S'CYP26A1'
p1764
S'MYC'
p1765
S'increases'
p1766
tp1767
(lp1768
s(S'STAT1'
p1769
S'IRF1'
p1770
S'increases'
p1771
tp1772
(lp1773
S'The results obtained by qRT-PCR confirmed the upregulation of BIRC3, CASP1, IRF1, SOD2, and STAT1 by the 24 hours cytokine treatment of Melligen cells.'
p1774
aS'Effects on cell proliferation, survival and cell migration were determined in PC3, DU145 and/or LNCaP cells depleted of DTX3L, ARTD8, ARTD9, STAT1 and/or IRF1 compared to their proficient control cells, respectively.'
p1775
aS'Quantification of ARTD9, DTX3L, IRF1, STAT1 and pSTAT1 protein levels. '
p1776
aS'Sub-cellular localization of endogenous STAT1 in DU145 and LNCaP cells and quantification of IRF1 protein levels in PC3, DU145 and LNCaP cells. '
p1777
as(S'SMAD1'
p1778
S'RUNX2'
p1779
S'increases'
p1780
tp1781
(lp1782
s(S'ZEB1'
p1783
S'TLX2'
p1784
S'increases'
p1785
tp1786
(lp1787
s(S'STAT5B'
p1788
S'IRF1'
p1789
S'increases'
p1790
tp1791
(lp1792
s(S'POU6F1'
p1793
S'CYP26A1'
p1794
S'increases'
p1795
tp1796
(lp1797
s(S'Vincristine'
p1798
S'HRAS MRNA'
p1799
S'increases'
p1800
tp1801
(lp1802
s(S'DAG'
p1803
S'RASGRP1'
p1804
S'adds_modification'
p1805
tp1806
(lp1807
s(S'PI3K'
p1808
S'PDK1'
p1809
S'increases_activity'
p1810
tp1811
(lp1812
S'These signalling cascades include a series of activation events involving Syk, Src, PI3K, PDK1, AKT, IKK, and I'
p1813
aS'The CA inhibition was likely due to the inhibition of PI3K and PDK1, important for NF-'
p1814
aS'PDK1 and its downstream target, Akt, are serine-theronine kinases that recognize the PI3K generated second messenger, PIP'
p1815
aS'Akt/PKB kinase activity depends on two Ras-mediated effector pathways: PI3K, which promotes the PIP3-dependent recruitment of Akt/PKB to the plasma membrane and regulates PDK1 phosphorylation of the Akt/PKB activation loop, and TORC2, which mediates Akt/PKB phosphorylation on the C-terminal hydrophobic motif ('
p1816
aS'SGK3-mediated activation of NHE3 is dependent on PI3K and PDK1.'
p1817
aS'We showed that both SGK2 and SGK3 contribute to NHE3 activation, but SGK3 uniquely colocalizes with NHE3 to recycling endosomes, enabling acute regulation of NHE3 via the PI3K-PDK1 pathway.'
p1818
aS'They are all activated through similar mechanisms involving upstream kinases PI3K and PDK1.'
p1819
aS'Several growth factors, including follicle stimulating hormone (FSH), stimulate PI3K to activate phosphoinositide-dependent protein kinase-1 (PDK1) resulting in phosphorylation of Akt and downstream transcription factors including the forkhead winged helix box O1 (FOXO1) triggering follicle activation and development ('
p1820
as(S'ETS2'
p1821
S'PAX4'
p1822
S'increases'
p1823
tp1824
(lp1825
s(S'NR3C1'
p1826
S'ONECUT1'
p1827
S'increases'
p1828
tp1829
(lp1830
s(S'CUX1'
p1831
S'CYP26A1'
p1832
S'increases'
p1833
tp1834
(lp1835
s(S'ZEB1'
p1836
S'GATA1'
p1837
S'increases'
p1838
tp1839
(lp1840
s(S'NRF1'
p1841
S'POU2F1'
p1842
S'increases'
p1843
tp1844
(lp1845
s(S'FOXJ2'
p1846
S'MECOM'
p1847
S'increases'
p1848
tp1849
(lp1850
s(S'MAZ'
p1851
S'MYCN'
p1852
S'increases'
p1853
tp1854
(lp1855
s(S'Hydrogen Peroxide'
p1856
S'HRAS MRNA'
p1857
S'increases'
p1858
tp1859
(lp1860
s(S'RASA1'
p1861
S'P-EPHBS:EFNBS'
p1862
S'binds'
p1863
tp1864
(lp1865
s(S'SPI1'
p1866
S'CEBPG'
p1867
S'increases'
p1868
tp1869
(lp1870
s(S'EGR1'
p1871
S'LEF1'
p1872
S'increases'
p1873
tp1874
(lp1875
s(S'RET51/GFRALPHA1/GDNF'
p1876
S'P62DOK'
p1877
S'binds'
p1878
tp1879
(lp1880
s(S'TFDP2'
p1881
S'CYP26A1'
p1882
S'increases'
p1883
tp1884
(lp1885
s(S'matrine'
p1886
S'NRAS MRNA'
p1887
S'increases'
p1888
tp1889
(lp1890
s(S'Isotretinoin'
p1891
S'KRAS MRNA'
p1892
S'decreases'
p1893
tp1894
(lp1895
s(S'PITX2'
p1896
S'FOXF2'
p1897
S'increases'
p1898
tp1899
(lp1900
s(S'MYOD1'
p1901
S'POU2F1'
p1902
S'increases'
p1903
tp1904
(lp1905
s(S'sodium arsenite'
p1906
S'KRAS PROTEIN'
p1907
S'increases'
p1908
tp1909
(lp1910
s(S'TCF4'
p1911
S'CBFA2T3'
p1912
S'increases'
p1913
tp1914
(lp1915
s(S'CYP26A1'
p1916
S'FOXA1'
p1917
S'increases'
p1918
tp1919
(lp1920
s(S'TP53'
p1921
S'CYP26A1'
p1922
S'increases'
p1923
tp1924
(lp1925
s(S'ATF3'
p1926
S'FOXD3'
p1927
S'increases'
p1928
tp1929
(lp1930
s(S'POU2F1'
p1931
S'NRAS'
p1932
S'increases'
p1933
tp1934
(lp1935
s(S'NRF1'
p1936
S'GABPB2'
p1937
S'increases'
p1938
tp1939
(lp1940
s(S'PAX4'
p1941
S'TLX2'
p1942
S'increases'
p1943
tp1944
(lp1945
s(S'PITX2'
p1946
S'FOXA1'
p1947
S'increases'
p1948
tp1949
(lp1950
s(S'GTF3A'
p1951
S'POU2F1'
p1952
S'increases'
p1953
tp1954
(lp1955
s(S'HLF'
p1956
S'FOXO3'
p1957
S'increases'
p1958
tp1959
(lp1960
s(S'PAX4'
p1961
S'FOXO4'
p1962
S'increases'
p1963
tp1964
(lp1965
s(S'CEBPA'
p1966
S'FOXD3'
p1967
S'increases'
p1968
tp1969
(lp1970
s(S'NFE2'
p1971
S'CYP26A1'
p1972
S'increases'
p1973
tp1974
(lp1975
s(S'MYB'
p1976
S'GABPB2'
p1977
S'increases'
p1978
tp1979
(lp1980
s(S'MYC'
p1981
S'CEBPA'
p1982
S'increases'
p1983
tp1984
(lp1985
s(S'ELK1'
p1986
S'EN1'
p1987
S'increases'
p1988
tp1989
(lp1990
s(S'E2F1'
p1991
S'CDC5L'
p1992
S'increases'
p1993
tp1994
(lp1995
s(S'YWHAZ (DIMER)'
p1996
S'RAF1'
p1997
S'binds'
p1998
tp1999
(lp2000
s(S'ATF6'
p2001
S'CYP26A1'
p2002
S'increases'
p2003
tp2004
(lp2005
s(S'sodium arsenite'
p2006
S'HRAS MRNA'
p2007
S'increases'
p2008
tp2009
(lp2010
s(S'EGR3'
p2011
S'CYP26A1'
p2012
S'increases'
p2013
tp2014
(lp2015
s(S'lead acetate'
p2016
S'HRAS PROTEIN'
p2017
S'increases_activity'
p2018
tp2019
(lp2020
s(S'REPIN1'
p2021
S'MYC'
p2022
S'increases'
p2023
tp2024
(lp2025
s(S'CEBPA'
p2026
S'NRAS'
p2027
S'increases'
p2028
tp2029
(lp2030
s(S'Quercetin'
p2031
S'NRAS MRNA'
p2032
S'decreases'
p2033
tp2034
(lp2035
s(S'14-3-3 E'
p2036
S'TERT'
p2037
S'binds'
p2038
tp2039
(lp2040
s(S'Antigen/IgE/Fc epsilon R1/LYN/SYK'
p2041
S'BTK'
p2042
S'adds_modification'
p2043
tp2044
(lp2045
s(S'HSF2'
p2046
S'CBFA2T3'
p2047
S'increases'
p2048
tp2049
(lp2050
s(S'Fluorouracil'
p2051
S'HRAS MRNA'
p2052
S'increases'
p2053
tp2054
(lp2055
s(S'STAT4'
p2056
S'MECOM'
p2057
S'increases'
p2058
tp2059
(lp2060
s(S'ETS2'
p2061
S'ETS1'
p2062
S'increases'
p2063
tp2064
(lp2065
S'In conclusion, we found that four out of four testable, known interactors (i.e., NFKB1, ETS1, ETS2, and SP3) and nine out of nine Y1H-detected interactions showed at least one site-specific, reproducibly detected binding peak, providing strong support for the observed Y1H interactions as well as the utility of the MARE assay to resolve DNA binding patterns for specific TFs with DNA elements of interest.'
p2066
as(S'CEBPG'
p2067
S'CYP26A1'
p2068
S'increases'
p2069
tp2070
(lp2071
s(S'Complex (PDGF receptor A/PDGF receptor B)'
p2072
S'NCK'
p2073
S'adds_modification'
p2074
tp2075
(lp2076
s(S'Fog1'
p2077
S'MYB'
p2078
S'decreases'
p2079
tp2080
(lp2081
s(S'CREB1'
p2082
S'FOXD3'
p2083
S'increases'
p2084
tp2085
(lp2086
s(S'Numb'
p2087
S'NICS'
p2088
S'translocates'
p2089
tp2090
(lp2091
s(S'STAT6'
p2092
S'STAT5A'
p2093
S'increases'
p2094
tp2095
(lp2096
S'The basal expression of phosphorylated Yes, Src and STAT5A, and the expression after radiotherapy of phosphorylated AKT, MSK1/2, Src, Lyn, Fyn, Hck, and STAT6, were correlated with radiosensitivity in the panel of HNSCC lines.'
p2097
as(S'RAF1/14-3-3'
p2098
S'BRAF/14-3-3'
p2099
S'binds'
p2100
tp2101
(lp2102
s(S'B-cell antigen/BCR complex/LYN/SYK/BLNK'
p2103
S'SHC/GRB2/SOS1'
p2104
S'increases_activity'
p2105
tp2106
(lp2107
s(S'IRF2'
p2108
S'CYP26A1'
p2109
S'increases'
p2110
tp2111
(lp2112
s(S'GATA6'
p2113
S'CYP26A1'
p2114
S'increases'
p2115
tp2116
(lp2117
s(S'HMGA1'
p2118
S'CYP26A1'
p2119
S'increases'
p2120
tp2121
(lp2122
s(S'MTF1'
p2123
S'FOXO4'
p2124
S'increases'
p2125
tp2126
(lp2127
s(S'STAT1'
p2128
S'GABPB2'
p2129
S'increases'
p2130
tp2131
(lp2132
s(S'manumycin'
p2133
S'HRAS PROTEIN'
p2134
S'decreases'
p2135
tp2136
(lp2137
s(S'STAT5A'
p2138
S'ETS1'
p2139
S'increases'
p2140
tp2141
(lp2142
s(S'SPI1'
p2143
S'CBFA2T3'
p2144
S'increases'
p2145
tp2146
(lp2147
s(S'GMCSF/GMR ALPHA/CSF2RB/JAK2 (DODECAMER)/SHC'
p2148
S'GRB2/SOS1'
p2149
S'binds'
p2150
tp2151
(lp2152
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p2153
S'NRAS PROTEIN'
p2154
S'increases'
p2155
tp2156
(lp2157
s(S'CDC5L'
p2158
S'CYP26A1'
p2159
S'increases'
p2160
tp2161
(lp2162
s(S'PAX4'
p2163
S'POU3F2'
p2164
S'increases'
p2165
tp2166
(lp2167
s(S'SPRED2'
p2168
S'HRAS'
p2169
S'binds'
p2170
tp2171
(lp2172
s(S'PITX2'
p2173
S'FOXO4'
p2174
S'increases'
p2175
tp2176
(lp2177
s(S'FOXD3'
p2178
S'CYP26A1'
p2179
S'increases'
p2180
tp2181
(lp2182
s(S'NFIL3'
p2183
S'FOXO3'
p2184
S'increases'
p2185
tp2186
(lp2187
s(S'MTF1'
p2188
S'POU2F1'
p2189
S'increases'
p2190
tp2191
(lp2192
s(S'TFCP2'
p2193
S'BACH1'
p2194
S'increases'
p2195
tp2196
(lp2197
s(S'NF1'
p2198
S'MECOM'
p2199
S'increases'
p2200
tp2201
(lp2202
s(S'FOXO3'
p2203
S'FOXD3'
p2204
S'increases'
p2205
tp2206
(lp2207
s(S'STAT5A'
p2208
S'TLX2'
p2209
S'increases'
p2210
tp2211
(lp2212
s(S'RIN1'
p2213
S'HRAS/GTP'
p2214
S'adds_modification'
p2215
tp2216
(lp2217
s(S'STAT5A'
p2218
S'CEBPG'
p2219
S'increases'
p2220
tp2221
(lp2222
s(S'DAG'
p2223
S'PKC'
p2224
S'increases_activity'
p2225
tp2226
(lp2227
S'They integrate several types of intracellular stimuli, including PLC and PKC activity, DAG levels, intracellular calcium levels and PIP'
p2228
aS'PKC isozymes are divided into three groups: classic (activated by DAG and Ca'
p2229
aS'It has been shown that activation of PKC by PDBu or diacylglycerol (DAG) enhances excitatory synaptic transmission in the hippocampus ['
p2230
aS'In summary, the current study demonstrates that DAG is an endogenous ligand for activating TRPV1 by binding at the capsaicin binding site but by acting independently of PKC and lipoxygenase pathway.'
p2231
aS'PLC activation also leads to the production diacylglycerol (DAG) which in turn activates protein kinase C (PKC).'
p2232
aS'Classical and novel PKCs contain a diacylglycerol (DAG)-binding C1 domain and are therefore regulated by activation of pathways that lead to DAG generation.'
p2233
aS'Atypical PKCs are DAG-insensitive and regulated in a different manner ['
p2234
aS'Several studies have implicated the DAG-sensitive classical and novel PKC isoforms in promoting malignant features of breast cancer cells.'
p2235
aS'Several studies have suggested that DAG-sensitive PKC isoforms contribute to the progression of breast cancer and the malignant characteristics of breast cancer cells.'
p2236
aS'Many biochemical mechanisms have been proposed to explain the structural and functional abnormalities associated with overexposure of the vascular tissues to hyperglycemia including advanced glycation end products (AGEs), increase in aldose reductase (AR) activity, free radicals acummulation (reactive oxygen intermediate pathway, ROI), resulting in oxidative stress and protein-kinase C activation (PKC) through diacylglycerol accumulation (DAG).'
p2237
aS'Various metabolic pathways triggered by hyperglycemia are involved, such as the polyol pathway, hexosamine pathway, and diacylglycerol (DAG)-protein kinase C (PKC) pathway ['
p2238
aS'To mimic the consequences of DAG overproduction associated with hyperglycemia, we treated PC and EC with PMA (a DAG analog) and determined the effects of PKC activation on the downstream HuR/VEGF pathway, similarly to a previous in vitro work on pericytes grown alone ['
p2239
aS'Protein kinase C (PKC) is associated with phosphorylation of serine/threonine residues in insulin receptors and is generated due to the synthesis of diacylglycerol (DAG) under the high intracellular concentration of glucose ['
p2240
aS'The hyperglycemia induced activation of the diacylglycerol (DAG)-protein kinase C (PKC) pathway has multiple adverse effects on the vascular function.'
p2241
aS'Hyperglycemia increases the levels of DAG, which in turn activates PKC.'
p2242
aS'DAG is the physiological activator of PKCs, and some PKC isoforms can activate PKDs ('
p2243
aS'Several signaling pathways activate PLCs to generate DAGs, physiological activators of PKCs ('
p2244
aS'A continuous hydrophobic surface generated by the phorbol ester or DAG facilitates the insertion of the C1 domain into lipid bilayers, which in cPKCs and nPKCs is followed by a conformational rearrangement that leads to kinase activation ('
p2245
aS'It is well established that C1 domains play a fundamental role in targeting PKC isozymes and other molecules from the cytosol to membranes both in response to phorbol esters and DAG generated upon receptor activation ('
p2246
aS'Our studies also provide evidence for a marked selectivity of C1 domains for binding to p23/Tmp21, because some C1 domains from PKC isozymes and potentially other phorbol ester/DAG receptors have the ability to bind p23/Tmp21.'
p2247
aS'Whether this is also true for other PKC isozymes or phorbol ester/DAG receptors such as PKD and RasGRP isozymes remains to be determined.'
p2248
aS'PMA activates critical DAG-dependent targets, including PKC and RasGRP1 ('
p2249
aS'mGlu: Metabotropic glutamate; SCA1: Spinocerebellar ataxia type-1; PAM: Positive allosteric modulator; NAM: Negative allosteric modulator; ATXN1: Ataxin-1; InsP3: Inositol-1,4,5-trisphosphate; DAG: Diacylglicerol; PKC: Protein kinase C; AMPA: 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid; LTD: Long term depression.'
p2250
as(S'HNF4A'
p2251
S'FOXA1'
p2252
S'increases'
p2253
tp2254
(lp2255
s(S'LEF1'
p2256
S'MAZ'
p2257
S'increases'
p2258
tp2259
(lp2260
s(S'hsa-miR-124-3p'
p2261
S'NRAS'
p2262
S'decreases'
p2263
tp2264
(lp2265
s(S'RAF1'
p2266
S'14-3-3 E'
p2267
S'binds'
p2268
tp2269
(lp2270
s(S'GATA1'
p2271
S'MYB'
p2272
S'decreases'
p2273
tp2274
(lp2275
s(S'LMO2'
p2276
S'GATA1'
p2277
S'increases'
p2278
tp2279
(lp2280
S'(B) Real-time PCR performed on Hel cells treated with cinnamon extracts showing decreased expression of Stat5b and of the erythroid markers GATA1, LMO2, HbA1, and RhAG; CD44 monocyte differentiation marker expression is increased after treatment with cinnamon extracts; ACTB was used as control housekeeping gene.'
p2281
as(S'HRAS/GTP'
p2282
S'RAF1'
p2283
S'increases_activity'
p2284
tp2285
(lp2286
s(S'MYCN'
p2287
S'RUNX2'
p2288
S'increases'
p2289
tp2290
(lp2291
s(S'STAT5B'
p2292
S'CYP26A1'
p2293
S'increases'
p2294
tp2295
(lp2296
s(S'ZIC2'
p2297
S'MYCN'
p2298
S'increases'
p2299
tp2300
(lp2301
s(S'FOXL1'
p2302
S'FOXD3'
p2303
S'increases'
p2304
tp2305
(lp2306
s(S'ZBTB18'
p2307
S'CBFA2T3'
p2308
S'increases'
p2309
tp2310
(lp2311
s(S'HSF1'
p2312
S'IRF1'
p2313
S'increases'
p2314
tp2315
(lp2316
s(S'SPZ1'
p2317
S'MAZ'
p2318
S'increases'
p2319
tp2320
(lp2321
s(S'SRY'
p2322
S'CYP26A1'
p2323
S'increases'
p2324
tp2325
(lp2326
s(S'FOXO4'
p2327
S'HOXA9'
p2328
S'increases'
p2329
tp2330
(lp2331
s(S'IGF-1R heterotetramer/IGF1/IRS1/GRB2/Sos'
p2332
S'HRAS/GDP'
p2333
S'increases_activity'
p2334
tp2335
(lp2336
s(S'hsa-miR-615-3p'
p2337
S'HRAS'
p2338
S'decreases'
p2339
tp2340
(lp2341
s(S'ESRRA'
p2342
S'FOXD3'
p2343
S'increases'
p2344
tp2345
(lp2346
s(S'ELK1'
p2347
S'CYP26A1'
p2348
S'increases'
p2349
tp2350
(lp2351
s(S'Hexane-1,6-Diol'
p2352
S'HRAS'
p2353
S'increases_activity'
p2354
tp2355
(lp2356
s(S'MAZ'
p2357
S'NRAS'
p2358
S'increases'
p2359
tp2360
(lp2361
s(S'MIF'
p2362
S'CYP26A1'
p2363
S'increases'
p2364
tp2365
(lp2366
s(S'AHR'
p2367
S'POU2F1'
p2368
S'increases'
p2369
tp2370
(lp2371
s(S'SMAD3'
p2372
S'CYP26A1'
p2373
S'increases'
p2374
tp2375
(lp2376
s(S'PI-3-4-5-P3'
p2377
S'GELSOLIN'
p2378
S'binds'
p2379
tp2380
(lp2381
s(S'ADP'
p2382
S'P-S724-IRE1 DIMER'
p2383
S'binds'
p2384
tp2385
(lp2386
s(S'testosterone enanthate'
p2387
S'KRAS MRNA'
p2388
S'increases'
p2389
tp2390
(lp2391
s(S'CYP26A1'
p2392
S'ONECUT1'
p2393
S'increases'
p2394
tp2395
(lp2396
s(S'Valproic Acid'
p2397
S'NRAS MRNA'
p2398
S'decreases'
p2399
tp2400
(lp2401
s(S'GTF2A2'
p2402
S'CYP26A1'
p2403
S'increases'
p2404
tp2405
(lp2406
s(S'CEBPA'
p2407
S'FOXO3'
p2408
S'increases'
p2409
tp2410
(lp2411
s(S'GATA3'
p2412
S'POU2F1'
p2413
S'increases'
p2414
tp2415
(lp2416
s(S'PI3K'
p2417
S'RAC1B/GDP'
p2418
S'increases_activity'
p2419
tp2420
(lp2421
s(S'CDC25C'
p2422
S'YWHAB'
p2423
S'binds'
p2424
tp2425
(lp2426
s(S'RAC1/GTP'
p2427
S'PAK1/BETAPIX/PKL/NCK1-2'
p2428
S'increases_activity'
p2429
tp2430
(lp2431
s(S'SMAD1'
p2432
S'CYP26A1'
p2433
S'increases'
p2434
tp2435
(lp2436
s(S'PI3K'
p2437
S'FAK'
p2438
S'adds_modification'
p2439
tp2440
(lp2441
S'Activated ERK phosphorylates paxillin on S83, promoting its association with activated FAK and PI3K and increasing cell spreading ('
p2442
aS'However, we found that luteolin treatment did not interrupt the phosphorylation of ERK as well as affected to a lesser extent on other key regulatory pathway such as MAPK-p38, FAK, and JNK, whereas possible due to luteolin produced the reduction of PI3K/AKT activation.'
p2443
aS'EGF stimulation of HER2-overexpressing cells promoted migration by phosphorylation of proteins that belong to different pathways, including PI3K, MAPK, catenins and FAK.'
p2444
aS'More specifically, EGF stimulation of HER2-overexpressing cells promoted migration by the phosphorylation of proteins from multiple pathways (e.g., PI3K, MAPK, catenins, and FAK), whereas HRG stimulation of HER2-overexpressing cells activated only a very specific subset of proteins in the canonical migration pathway, in particular FAK, Src, paxillin, and p130Cas.'
p2445
aS'Adhesion-dependent FAK activation leads to induction of downstream signaling pathways such as MEK/ERK, a major driver pathway for cell proliferation, or PI3K/Akt, a major cell survival and motility inducer.'
p2446
aS'We found that 4HPR inhibited phosphorylated FAK, a protein tyrosine kinase localized at the cell membrane that signals through the PI3K/AKT pathway.'
p2447
aS'CXCL13-CXCR5 interaction regulated LNCaP and PC3 cell migration and invasion through extracellular signal-regulated kinase 1/2 (ERK1/2) activation that was primarily dependent on the PI3Kp110 isoform(s), Src, and focal adhesion kinase (FAK), but not DOCK2.'
p2448
aS'To determine whether activated PI3Ks, Src, and FAK promoted invasiveness of PCa cells, we used corresponding pharmacological inhibitors and assessed their effect on cell invasion.'
p2449
aS'ATCC: American Type Culture Collection; BCA: bicinchoninic acid; DOCK2: dedicator of cytokinesis 2; ERK1/2: extracellular signal-regulated kinase 1/2; FAK: focal adhesion kinase; FBS: fetal bovine serum; HRP: horseradish peroxidase; JNK-MAPK: Janus kinase - mitogen activated protein kinase; MMP: matrix metalloproteinase; PCa: prostate cancer; PI3K: phosphoinositide-3 kinase; PIP2: phosphoinositide 4,5-biphosphate; PIP3: phosphoinositide 3,4,5-triphosphate; PTEN: phosphatase and tensin homolog deleted on chromosome ten; RPMI: Roswell Park Memorial Institute; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TTBS: Tris-Tween Buffered Saline.'
p2450
aS'PI3K and Shc interact with phospho-Y397 of FAK, leading to activation of pro-survival proteins such as Akt.'
p2451
aS'Previous studies revealed that growth factors stimulate angiogenesis via activating kinase signaling pathways, including PI3K/AKT, ERK1/2, FAK and p38/MAPK, to regulate endothelial cell migration, survival and vascular permeability ('
p2452
aS'An association with FAK and Src has long been established for PI3K (for example ['
p2453
aS'We also observed a striking increase in FAK phosphorylation with PI3K inhibition ('
p2454
aS'Furthermore, we show that TIM4 uses integrins as coreceptors to effect target engulfment via a FAK-, PI3K-, and RhoA/Rac1/Rac2-dependent pathway.'
p2455
aS'Similar to FAK, the PI3K/Akt pathway has been shown to regulate both EMT and survival in a variety of settings and can be regulated by matrix stiffness ('
p2456
aS'The effect of dihydroaustrasulfone alcohol is most likely achieved through the inhibition of FAK, which regulates MMP-2 expression through the MAPK and PI3K/AKT signaling pathways.'
p2457
as(S'NRF1'
p2458
S'MAX'
p2459
S'increases'
p2460
tp2461
(lp2462
s(S'FOXI1'
p2463
S'RUNX2'
p2464
S'increases'
p2465
tp2466
(lp2467
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p2468
S'HRAS MRNA'
p2469
S'increases'
p2470
tp2471
(lp2472
s(S'ETS1'
p2473
S'CBFA2T3'
p2474
S'increases'
p2475
tp2476
(lp2477
s(S'hsa-miR-98-5p'
p2478
S'NRAS'
p2479
S'decreases'
p2480
tp2481
(lp2482
s(S'PHOSPHORYLATED BRF1 (SER92, SER203):MRNA COMPLEX'
p2483
S'YWHAB'
p2484
S'binds'
p2485
tp2486
(lp2487
s(S'LMO2'
p2488
S'CYP26A1'
p2489
S'increases'
p2490
tp2491
(lp2492
s(S'SOS1'
p2493
S'GRB2:PFAK BOUND TO NCAM1:PFYN'
p2494
S'binds'
p2495
tp2496
(lp2497
s(S'GTF3A'
p2498
S'GATA6'
p2499
S'increases'
p2500
tp2501
(lp2502
s(S'ZIC2'
p2503
S'CYP26A1'
p2504
S'increases'
p2505
tp2506
(lp2507
s(S'PAX2'
p2508
S'POU3F2'
p2509
S'increases'
p2510
tp2511
(lp2512
s(S'CEBPD'
p2513
S'FOXO3'
p2514
S'increases'
p2515
tp2516
(lp2517
s(S'NF1'
p2518
S'CYP26A1'
p2519
S'increases'
p2520
tp2521
(lp2522
s(S'BRAF'
p2523
S'MEK2'
p2524
S'adds_modification'
p2525
tp2526
(lp2527
s(S'TFAP4'
p2528
S'RUNX1'
p2529
S'increases'
p2530
tp2531
(lp2532
s(S'FAK'
p2533
S'SOS'
p2534
S'binds'
p2535
tp2536
(lp2537
s(S'EGR1'
p2538
S'RUNX1'
p2539
S'increases'
p2540
tp2541
(lp2542
s(S'TCF4'
p2543
S'FOXO4'
p2544
S'increases'
p2545
tp2546
(lp2547
s(S'MAZ'
p2548
S'CBFA2T3'
p2549
S'increases'
p2550
tp2551
(lp2552
s(S'MEIS1'
p2553
S'HRAS'
p2554
S'increases'
p2555
tp2556
(lp2557
s(S'RELA'
p2558
S'CYP26A1'
p2559
S'increases'
p2560
tp2561
(lp2562
s(S'hsa-miR-877-3p'
p2563
S'NRAS'
p2564
S'decreases'
p2565
tp2566
(lp2567
s(S'MYC'
p2568
S'LEF1'
p2569
S'increases'
p2570
tp2571
(lp2572
s(S'FOXO4'
p2573
S'RUNX1'
p2574
S'increases'
p2575
tp2576
(lp2577
s(S'LEF1'
p2578
S'RUNX1'
p2579
S'increases'
p2580
tp2581
(lp2582
s(S'TFDP2'
p2583
S'GATA1'
p2584
S'increases'
p2585
tp2586
(lp2587
s(S'AHR'
p2588
S'CYP26A1'
p2589
S'increases'
p2590
tp2591
(lp2592
s(S'4-Nitroquinoline-1-oxide'
p2593
S'PTGS2 MRNA'
p2594
S'increases'
p2595
tp2596
(lp2597
s(S'TGIF'
p2598
S'FOXO3'
p2599
S'increases'
p2600
tp2601
(lp2602
s(S'FOXF2'
p2603
S'CEBPA'
p2604
S'increases'
p2605
tp2606
(lp2607
s(S'NFE2L1'
p2608
S'POU2F1'
p2609
S'increases'
p2610
tp2611
(lp2612
s(S'LHX3'
p2613
S'CYP26A1'
p2614
S'increases'
p2615
tp2616
(lp2617
s(S'HMGA1'
p2618
S'MEIS1'
p2619
S'increases'
p2620
tp2621
(lp2622
s(S'POU2F1'
p2623
S'CYP26A1'
p2624
S'increases'
p2625
tp2626
(lp2627
s(S'PRRX2'
p2628
S'HOXA9'
p2629
S'increases'
p2630
tp2631
(lp2632
s(S'ETS2'
p2633
S'CEBPG'
p2634
S'increases'
p2635
tp2636
(lp2637
s(S'hsa-miR-193b-3p'
p2638
S'KRAS'
p2639
S'decreases'
p2640
tp2641
(lp2642
s(S'RREB1'
p2643
S'RUNX1'
p2644
S'increases'
p2645
tp2646
(lp2647
s(S'IL2/IL2R BETA/GAMMA/JAK1/FYN/JAK3'
p2648
S'PI3K'
p2649
S'binds'
p2650
tp2651
(lp2652
s(S'ELK1'
p2653
S'MEIS1'
p2654
S'increases'
p2655
tp2656
(lp2657
s(S'CYP26A1'
p2658
S'HOXA9'
p2659
S'increases'
p2660
tp2661
(lp2662
s(S'SPZ1'
p2663
S'HOXA9'
p2664
S'increases'
p2665
tp2666
(lp2667
s(S'ERK1'
p2668
S'P-S218,222-MEK1'
p2669
S'binds'
p2670
tp2671
(lp2672
s(S'NHLH1'
p2673
S'MYC'
p2674
S'increases'
p2675
tp2676
(lp2677
s(S'Daunorubicin'
p2678
S'NRAS MRNA'
p2679
S'increases'
p2680
tp2681
(lp2682
s(S'HNF1A'
p2683
S'FOXA1'
p2684
S'increases'
p2685
tp2686
(lp2687
s(S'MYC'
p2688
S'ONECUT1'
p2689
S'increases'
p2690
tp2691
(lp2692
s(S'Vanadates'
p2693
S'HRAS PROTEIN'
p2694
S'increases'
p2695
tp2696
(lp2697
s(S'Purine nucleotide'
p2698
S'H+'
p2699
S'translocates'
p2700
tp2701
(lp2702
s(S'NFE2'
p2703
S'BACH1'
p2704
S'increases'
p2705
tp2706
(lp2707
s(S'EGR4'
p2708
S'CYP26A1'
p2709
S'increases'
p2710
tp2711
(lp2712
s(S'NRF1'
p2713
S'ONECUT1'
p2714
S'increases'
p2715
tp2716
(lp2717
s(S'GFI1'
p2718
S'HOXA9'
p2719
S'increases'
p2720
tp2721
(lp2722
s(S'NR1H4'
p2723
S'FOXD3'
p2724
S'increases'
p2725
tp2726
(lp2727
s(S'STAT6'
p2728
S'FOXA1'
p2729
S'increases'
p2730
tp2731
(lp2732
s(S'INSULIN RECEPTOR/INSULI/IRS1/GRB2/SHC'
p2733
S'SOS1'
p2734
S'binds'
p2735
tp2736
(lp2737
s(S'Tetrachlorodibenzodioxin'
p2738
S'KRAS MRNA'
p2739
S'increases'
p2740
tp2741
(lp2742
s(S'TCF3'
p2743
S'MYC'
p2744
S'increases'
p2745
tp2746
(lp2747
g1216
as(S'BACH1'
p2748
S'EN1'
p2749
S'increases'
p2750
tp2751
(lp2752
s(S'RFX1'
p2753
S'CYP26A1'
p2754
S'increases'
p2755
tp2756
(lp2757
s(S'ZEB1'
p2758
S'FOXD3'
p2759
S'increases'
p2760
tp2761
(lp2762
s(S'IRF7'
p2763
S'EN1'
p2764
S'increases'
p2765
tp2766
(lp2767
s(S'GAB2/GRB2/SOS1'
p2768
S'IL2/IL2R ALPHA/BETA/GAMMA/JAK1/LCK/JAK3/SHC'
p2769
S'binds'
p2770
tp2771
(lp2772
s(S'GATA3'
p2773
S'FOXA1'
p2774
S'increases'
p2775
tp2776
(lp2777
S'It is known that FOXA1 and GATA3 are important regulatory proteins in their own right.'
p2778
aS'The expression clones encoding ESR1, FOXA1, and GATA3 were purchased from Genecopoeia and verified by sequencing.'
p2779
aS'List of previously reported E2-regulated genes that regulate in our MCF-7 and transfected MDA-MB-231-ER+FOXA1+GATA3 cells'
p2780
aS'List of luminal and basal marker genes with ER, FOXA1 and GATA3 binding'
p2781
aS'FOXA1 and GATA3 are essential components of E'
p2782
as(S'TFAP4'
p2783
S'CYP26A1'
p2784
S'increases'
p2785
tp2786
(lp2787
s(S'FOXF2'
p2788
S'MECOM'
p2789
S'increases'
p2790
tp2791
(lp2792
s(S'NF1'
p2793
S'POU2F1'
p2794
S'increases'
p2795
tp2796
(lp2797
s(S'IRF1'
p2798
S'FOXA1'
p2799
S'increases'
p2800
tp2801
(lp2802
s(S'Rho Family GTPase-active'
p2803
S'PIP5K1A'
p2804
S'increases_activity'
p2805
tp2806
(lp2807
s(S'POU6F1'
p2808
S'EN1'
p2809
S'increases'
p2810
tp2811
(lp2812
s(S'TCF4'
p2813
S'LEF1'
p2814
S'increases'
p2815
tp2816
(lp2817
s(S'MAZ'
p2818
S'FOXO3'
p2819
S'increases'
p2820
tp2821
(lp2822
s(S'POU3F2'
p2823
S'MECOM'
p2824
S'increases'
p2825
tp2826
(lp2827
s(S'GTF3A'
p2828
S'CYP26A1'
p2829
S'increases'
p2830
tp2831
(lp2832
s(S'PI-3-4-5-P3'
p2833
S'AKT2'
p2834
S'adds_modification'
p2835
tp2836
(lp2837
s(S'VSX1'
p2838
S'POU2F1'
p2839
S'increases'
p2840
tp2841
(lp2842
s(S'PHOSPHORYLATED TTP:MRNA COMPLEX'
p2843
S'YWHAB'
p2844
S'binds'
p2845
tp2846
(lp2847
s(S'MEIS1'
p2848
S'MYC'
p2849
S'increases'
p2850
tp2851
(lp2852
s(S'Complex (PDGF receptor A/PDGF receptor B)'
p2853
S'RASGAP'
p2854
S'adds_modification'
p2855
tp2856
(lp2857
s(S'RORA'
p2858
S'CYP26A1'
p2859
S'increases'
p2860
tp2861
(lp2862
s(S'ATF4'
p2863
S'CDC5L'
p2864
S'increases'
p2865
tp2866
(lp2867
s(S'SHC/RasGAP'
p2868
S'RAS FAMILY/GTP'
p2869
S'increases_activity'
p2870
tp2871
(lp2872
s(S'NKX2-1'
p2873
S'MYC'
p2874
S'increases'
p2875
tp2876
(lp2877
s(S'NF1'
p2878
S'SRF'
p2879
S'increases'
p2880
tp2881
(lp2882
s(S'STAT4'
p2883
S'NRAS'
p2884
S'increases'
p2885
tp2886
(lp2887
s(S'POU6F1'
p2888
S'MEIS1'
p2889
S'increases'
p2890
tp2891
(lp2892
s(S'P-KIT COMPLEX'
p2893
S'GRB2:SOS1'
p2894
S'binds'
p2895
tp2896
(lp2897
s(S'MYCN'
p2898
S'MAX'
p2899
S'increases'
p2900
tp2901
(lp2902
s(S'STAT5A'
p2903
S'CYP26A1'
p2904
S'increases'
p2905
tp2906
(lp2907
s(S'GATA3'
p2908
S'EN1'
p2909
S'increases'
p2910
tp2911
(lp2912
s(S'E4F1'
p2913
S'FOXD3'
p2914
S'increases'
p2915
tp2916
(lp2917
s(S'MYB'
p2918
S'ONECUT1'
p2919
S'increases'
p2920
tp2921
(lp2922
s(S'Cadmium Chloride'
p2923
S'NRAS PROTEIN'
p2924
S'increases'
p2925
tp2926
(lp2927
s(S'Deoxycholic Acid'
p2928
S'HRAS PROTEIN'
p2929
S'increases_activity'
p2930
tp2931
(lp2932
s(S'HLF'
p2933
S'CYP26A1'
p2934
S'increases'
p2935
tp2936
(lp2937
s(S'GMCSF/GMR ALPHA/CSF2RB/JAK2 (DIMER)'
p2938
S'YWHAZ'
p2939
S'binds'
p2940
tp2941
(lp2942
s(S'HNF1A'
p2943
S'FOXF2'
p2944
S'increases'
p2945
tp2946
(lp2947
s(S'FOXF2'
p2948
S'GATA6'
p2949
S'increases'
p2950
tp2951
(lp2952
s(S'Arsenic'
p2953
S'GSS PROTEIN'
p2954
S'increases'
p2955
tp2956
(lp2957
s(S'COMPLEX (SOS/GRB2)'
p2958
S'FGFR1-4'
p2959
S'binds'
p2960
tp2961
(lp2962
s(S'MYOD1'
p2963
S'NRAS'
p2964
S'increases'
p2965
tp2966
(lp2967
s(S'MECOM'
p2968
S'CYP26A1'
p2969
S'increases'
p2970
tp2971
(lp2972
s(S'PBX1'
p2973
S'CYP26A1'
p2974
S'increases'
p2975
tp2976
(lp2977
s(S'MAZ'
p2978
S'MEIS1'
p2979
S'increases'
p2980
tp2981
(lp2982
s(S'PAX4'
p2983
S'ELK1'
p2984
S'increases'
p2985
tp2986
(lp2987
s(S'ESRRA'
p2988
S'MECOM'
p2989
S'increases'
p2990
tp2991
(lp2992
s(S'CEBPD'
p2993
S'TLX2'
p2994
S'increases'
p2995
tp2996
(lp2997
s(S'CRX'
p2998
S'FOXA1'
p2999
S'increases'
p3000
tp3001
(lp3002
s(S'GABPB1'
p3003
S'NRAS'
p3004
S'increases'
p3005
tp3006
(lp3007
s(S'CRX'
p3008
S'MEIS1'
p3009
S'increases'
p3010
tp3011
(lp3012
s(S'pirinixic acid/PPARA protein'
p3013
S'KRAS MRNA'
p3014
S'increases'
p3015
tp3016
(lp3017
s(S'BACH2'
p3018
S'FOXA1'
p3019
S'increases'
p3020
tp3021
(lp3022
s(S'JUN'
p3023
S'MECOM'
p3024
S'increases'
p3025
tp3026
(lp3027
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p3028
S'KRAS MRNA'
p3029
S'decreases'
p3030
tp3031
(lp3032
s(S'SRY'
p3033
S'FOXO4'
p3034
S'increases'
p3035
tp3036
(lp3037
s(S'PI3K'
p3038
S'AKT1'
p3039
S'adds_modification'
p3040
tp3041
(lp3042
S'Activation of the PI3K-AKT pathway leads to phosphorylation of AKT1 ['
p3043
aS'PI3K: Phosphoinositide 3-kinases; AKT1: v-akt murine thymoma viral oncogene homolog 1; UAS: upstream activation sequence; CMV: Cytomegalovirus.'
p3044
aS'Although we observed no overt apoptosis in PDAC cells treated either with the PI3K inhibitor Ly294002 or by interference with AKT1 expression using siRNAs (unpublished data), inhibition of the PI3K/AKT signaling sensitizes PDAC cells towards therapeutic induction of apoptosis ['
p3045
aS'AKT1, a serine/threonin kinase also known as PKB, functions as a key mediator of the PI3K/AKT pathway.'
p3046
aS'PTEN is a major negative regulator of PI3K and loss of PTEN results in increased AKT1 kinase activity.'
p3047
aS'Overexpression of PI3K induces an invasive phenotype in breast and ovarian cancer cells, and similar effects are observed in cells overexpressing AKT2, but not AKT1 or AKT3, in vitro and in vivo ('
p3048
as(S'GATA3'
p3049
S'CYP26A1'
p3050
S'increases'
p3051
tp3052
(lp3053
s(S'RAS:GTP'
p3054
S'P-EPHBS:EFNBS:RASA1'
p3055
S'binds'
p3056
tp3057
(lp3058
s(S'STAT5A'
p3059
S'MECOM'
p3060
S'increases'
p3061
tp3062
(lp3063
s(S'RAS family/GTP'
p3064
S'RAF1'
p3065
S'increases_activity'
p3066
tp3067
(lp3068
s(S'RHOA/GTP'
p3069
S'PLD1-2'
p3070
S'increases_activity'
p3071
tp3072
(lp3073
s(S'FOXJ2'
p3074
S'CYP26A1'
p3075
S'increases'
p3076
tp3077
(lp3078
s(S'LEF1'
p3079
S'MECOM'
p3080
S'increases'
p3081
tp3082
(lp3083
s(S'GABPB2'
p3084
S'CDC5L'
p3085
S'increases'
p3086
tp3087
(lp3088
s(S'ESRRA'
p3089
S'CYP26A1'
p3090
S'increases'
p3091
tp3092
(lp3093
s(S'PI-3-4-5-P3'
p3094
S'WAVE2/NAP1/SRA1/ABI1/HSPC300'
p3095
S'translocates'
p3096
tp3097
(lp3098
s(S'CUX1'
p3099
S'MECOM'
p3100
S'increases'
p3101
tp3102
(lp3103
s(S'MAX'
p3104
S'CYP26A1'
p3105
S'increases'
p3106
tp3107
(lp3108
s(S'RXRB'
p3109
S'FOXD3'
p3110
S'increases'
p3111
tp3112
(lp3113
s(S'IRF1'
p3114
S'NRAS'
p3115
S'increases'
p3116
tp3117
(lp3118
s(S'MECOM'
p3119
S'MAX'
p3120
S'increases'
p3121
tp3122
(lp3123
s(S'PAX6'
p3124
S'CYP26A1'
p3125
S'increases'
p3126
tp3127
(lp3128
s(S'GRB2/SOS1'
p3129
S'EGFR/EGFR/EGF/EGF/P46 SHC'
p3130
S'binds'
p3131
tp3132
(lp3133
s(S'POU6F1'
p3134
S'POU2F1'
p3135
S'increases'
p3136
tp3137
(lp3138
s(S'RUNX1'
p3139
S'MYOD1'
p3140
S'increases'
p3141
tp3142
(lp3143
s(S'COMPLEX (GRB2/SOS)'
p3144
S'EGFR'
p3145
S'binds'
p3146
tp3147
(lp3148
s(S'MAZ'
p3149
S'MECOM'
p3150
S'increases'
p3151
tp3152
(lp3153
s(S'REPIN1'
p3154
S'EN1'
p3155
S'increases'
p3156
tp3157
(lp3158
s(S'RAS family/GTP'
p3159
S'RAF1'
p3160
S'adds_modification'
p3161
tp3162
(lp3163
s(S'E4F1'
p3164
S'CYP26A1'
p3165
S'increases'
p3166
tp3167
(lp3168
s(S'Rac'
p3169
S'MEKK1-5'
p3170
S'adds_modification'
p3171
tp3172
(lp3173
s(S'HAND1'
p3174
S'CYP26A1'
p3175
S'increases'
p3176
tp3177
(lp3178
s(S'Quercetin'
p3179
S'NRAS PROTEIN'
p3180
S'decreases'
p3181
tp3182
(lp3183
s(S'HRAS:GTP'
p3184
S'CRAF'
p3185
S'binds'
p3186
tp3187
(lp3188
s(S'REPIN1'
p3189
S'FOXA1'
p3190
S'increases'
p3191
tp3192
(lp3193
s(S'hsa-miR-155-5p'
p3194
S'KRAS'
p3195
S'decreases'
p3196
tp3197
(lp3198
s(S'PAX4'
p3199
S'EN1'
p3200
S'increases'
p3201
tp3202
(lp3203
s(S'FOXN1'
p3204
S'JUN'
p3205
S'increases'
p3206
tp3207
(lp3208
s(S'TFCP2'
p3209
S'GATA1'
p3210
S'increases'
p3211
tp3212
(lp3213
s(S'SHC'
p3214
S'GRAP2'
p3215
S'binds'
p3216
tp3217
(lp3218
s(S'CEBPG'
p3219
S'NRAS'
p3220
S'increases'
p3221
tp3222
(lp3223
s(S'FOXN1'
p3224
S'FOXO4'
p3225
S'increases'
p3226
tp3227
(lp3228
s(S'IL2/IL2R ALPHA/BETA/GAMMA/JAK1/LCK/JAK3/IRS1-2'
p3229
S'PI3K'
p3230
S'binds'
p3231
tp3232
(lp3233
s(S'POU1F1'
p3234
S'EN1'
p3235
S'increases'
p3236
tp3237
(lp3238
s(S'FOXJ1'
p3239
S'POU2F1'
p3240
S'increases'
p3241
tp3242
(lp3243
s(S'YY1'
p3244
S'POU2F1'
p3245
S'increases'
p3246
tp3247
(lp3248
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p3249
S'NRAS MRNA'
p3250
S'increases'
p3251
tp3252
(lp3253
s(S'EGF/EGFR'
p3254
S'HRAS/GDP'
p3255
S'increases_activity'
p3256
tp3257
(lp3258
s(S'TFAP4'
p3259
S'GABPB2'
p3260
S'increases'
p3261
tp3262
(lp3263
s(S'TFAP2A'
p3264
S'POU3F2'
p3265
S'increases'
p3266
tp3267
(lp3268
s(S'TCF12'
p3269
S'CBFA2T3'
p3270
S'increases'
p3271
tp3272
(lp3273
s(S'STAT3'
p3274
S'IRF1'
p3275
S'increases'
p3276
tp3277
(lp3278
s(S'MYOD1'
p3279
S'GATA1'
p3280
S'increases'
p3281
tp3282
(lp3283
s(S'REPIN1'
p3284
S'HRAS'
p3285
S'increases'
p3286
tp3287
(lp3288
s(S'PAX4'
p3289
S'MAX'
p3290
S'increases'
p3291
tp3292
(lp3293
s(S'PAX2'
p3294
S'FOXA1'
p3295
S'increases'
p3296
tp3297
(lp3298
s(S'Lipopolysaccharides'
p3299
S'HRAS PROTEIN'
p3300
S'increases_activity'
p3301
tp3302
(lp3303
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p3304
S'KRAS MRNA'
p3305
S'increases'
p3306
tp3307
(lp3308
s(S'REPIN1'
p3309
S'GATA1'
p3310
S'increases'
p3311
tp3312
(lp3313
s(S'Formaldehyde'
p3314
S'HRAS MRNA'
p3315
S'increases'
p3316
tp3317
(lp3318
s(S'ESRRA'
p3319
S'STAT5A'
p3320
S'increases'
p3321
tp3322
(lp3323
s(S'farnesylthiosalicylic acid'
p3324
S'HRAS PROTEIN'
p3325
S'decreases'
p3326
tp3327
(lp3328
s(S'JUN'
p3329
S'RUNX1'
p3330
S'increases'
p3331
tp3332
(lp3333
s(S'FOXD3'
p3334
S'RUNX1'
p3335
S'increases'
p3336
tp3337
(lp3338
s(S'SOX9'
p3339
S'CYP26A1'
p3340
S'increases'
p3341
tp3342
(lp3343
s(S'hexabromocyclododecane'
p3344
S'HRAS MRNA'
p3345
S'increases'
p3346
tp3347
(lp3348
s(S'RUNX2'
p3349
S'KRAS'
p3350
S'increases'
p3351
tp3352
(lp3353
s(S'PGR'
p3354
S'CYP26A1'
p3355
S'increases'
p3356
tp3357
(lp3358
s(S'CYP26A1'
p3359
S'MAZ'
p3360
S'increases'
p3361
tp3362
(lp3363
s(S'RAC1/GTP'
p3364
S'AKT1'
p3365
S'adds_modification'
p3366
tp3367
(lp3368
s(S'FOXO3'
p3369
S'CYP26A1'
p3370
S'increases'
p3371
tp3372
(lp3373
s(S'MAX'
p3374
S'SRF'
p3375
S'increases'
p3376
tp3377
(lp3378
s(S'RUNX2'
p3379
S'NRAS'
p3380
S'increases'
p3381
tp3382
(lp3383
s(S'HSF2'
p3384
S'CYP26A1'
p3385
S'increases'
p3386
tp3387
(lp3388
s(S'IL2/IL2R ALPHA/BETA/GAMMA/JAK1/LCK/JAK3/SHC/GRB2/SOS1/GAB2/SHP2'
p3389
S'PI3K'
p3390
S'binds'
p3391
tp3392
(lp3393
s(S'SPI1'
p3394
S'STAT5A'
p3395
S'increases'
p3396
tp3397
(lp3398
s(S'ZHX2'
p3399
S'MYC'
p3400
S'increases'
p3401
tp3402
(lp3403
s(S'RAF1-BRAF'
p3404
S'MEK1-2'
p3405
S'increases_activity'
p3406
tp3407
(lp3408
s(S'SHC'
p3409
S'GRB2'
p3410
S'binds'
p3411
tp3412
(lp3413
S'We produced Strep-HA tagged versions of GRB2, SHC1, ERRFI, UBS3B, ERBB2, GRP78, AP2M1, and CDC37.'
p3414
aS'GRB2, SHC1, ERRFI, and UBS3B were found both in EGFR-mutant lung cancer cell lines and in AALE cells with mutant EGFR as a bait and thus represented logical choices to further examine as secondary baits.'
p3415
aS'In addition, GRB2 and SHC1 were chosen based on their roles in linking EGFR to downstream MAPK signaling, while ERRFI and UBS3B were chosen based on the previous studies suggesting their roles in mediating RTK signaling.'
p3416
aS'In HCC827ER cells with EGFR mutation and MET overexpression, the degree of overlap was reduced with loss of EGFR, GRB2, and SHC1 protein dependence.'
p3417
aS'We interpreted our results to mean that EGFR signaling to MAPK through GRB2/SHC1 becomes less important in these cells that use MET to propagate survival signaling.'
p3418
aS'We further defined specificity of components of the 14 core network for cells dependent on mutant EGFR for survival and identified EGFR, GRB2, MK12, SHC1, ARAF, CD11B, ARHG5, GLU2B, and CD11A as especially vulnerable in EGFR-mutated and EGFR-dependent lung cancer cell lines.'
p3419
aS'This list included the novel guanine exchange factor ARHG5 in addition to adaptor proteins GRB2 and SHC1.'
p3420
as(S'RB1'
p3421
S'GATA1'
p3422
S'increases'
p3423
tp3424
(lp3425
s(S'TCF3'
p3426
S'FOXJ2'
p3427
S'increases'
p3428
tp3429
(lp3430
s(S'FOXJ2'
p3431
S'NRAS'
p3432
S'increases'
p3433
tp3434
(lp3435
s(S'REPIN1'
p3436
S'LEF1'
p3437
S'increases'
p3438
tp3439
(lp3440
s(S'Aflatoxin B1'
p3441
S'HRAS MRNA'
p3442
S'increases'
p3443
tp3444
(lp3445
s(S'PAX4'
p3446
S'MEIS1'
p3447
S'increases'
p3448
tp3449
(lp3450
s(S'FOXF2'
p3451
S'FOXD3'
p3452
S'increases'
p3453
tp3454
(lp3455
s(S'CBFA2T3'
p3456
S'RUNX1'
p3457
S'increases'
p3458
tp3459
(lp3460
s(S'FOXC1'
p3461
S'HOXA9'
p3462
S'increases'
p3463
tp3464
(lp3465
s(S'DBP'
p3466
S'CYP26A1'
p3467
S'increases'
p3468
tp3469
(lp3470
s(S'TGIF'
p3471
S'EN1'
p3472
S'increases'
p3473
tp3474
(lp3475
s(S'PI-3-4-5-P3'
p3476
S'P62DOK'
p3477
S'adds_modification'
p3478
tp3479
(lp3480
s(S'JUN'
p3481
S'TLX2'
p3482
S'increases'
p3483
tp3484
(lp3485
s(S'Benzo(a)pyrene'
p3486
S'HRAS MRNA'
p3487
S'increases'
p3488
tp3489
(lp3490
s(S'STAT4'
p3491
S'CYP26A1'
p3492
S'increases'
p3493
tp3494
(lp3495
s(S'EGFR/EGFR/EGF/EGF'
p3496
S'SRC'
p3497
S'adds_modification'
p3498
tp3499
(lp3500
s(S'FOXQ1'
p3501
S'FOXD3'
p3502
S'increases'
p3503
tp3504
(lp3505
s(S'FOXJ1'
p3506
S'NRAS'
p3507
S'increases'
p3508
tp3509
(lp3510
s(S'TCF3'
p3511
S'POU2F1'
p3512
S'increases'
p3513
tp3514
(lp3515
s(S'MYB'
p3516
S'CYP26A1'
p3517
S'increases'
p3518
tp3519
(lp3520
s(S'GATA4'
p3521
S'CYP26A1'
p3522
S'increases'
p3523
tp3524
(lp3525
s(S'ELK1'
p3526
S'STAT4'
p3527
S'increases'
p3528
tp3529
(lp3530
s(S'CYP26A1'
p3531
S'LEF1'
p3532
S'increases'
p3533
tp3534
(lp3535
s(S"Guanosine-5'-Diphosphate"
p3536
S'HRAS'
p3537
S'increases_activity'
p3538
tp3539
(lp3540
s(S'ETV4'
p3541
S'CYP26A1'
p3542
S'increases'
p3543
tp3544
(lp3545
s(S'EPHRIN B/EPHB2'
p3546
S'RASGAP'
p3547
S'binds'
p3548
tp3549
(lp3550
s(S'ESR1'
p3551
S'FOXF2'
p3552
S'increases'
p3553
tp3554
(lp3555
s(S'CDC5L'
p3556
S'FOXA1'
p3557
S'increases'
p3558
tp3559
(lp3560
s(S'MAZ'
p3561
S'HOXA9'
p3562
S'increases'
p3563
tp3564
(lp3565
s(S'HIF1A'
p3566
S'MAX'
p3567
S'increases'
p3568
tp3569
(lp3570
s(S'FOXN1'
p3571
S'HOXA9'
p3572
S'increases'
p3573
tp3574
(lp3575
s(S'LEF1'
p3576
S'BACH1'
p3577
S'increases'
p3578
tp3579
(lp3580
s(S'PDX1'
p3581
S'FOXO3'
p3582
S'increases'
p3583
tp3584
(lp3585
s(S'CBFA2T3'
p3586
S'CYP26A1'
p3587
S'increases'
p3588
tp3589
(lp3590
s(S'Rabex5'
p3591
S'HRAS/GTP'
p3592
S'adds_modification'
p3593
tp3594
(lp3595
s(S'CBFA2T3'
p3596
S'RUNX2'
p3597
S'increases'
p3598
tp3599
(lp3600
s(S'PI-3-4-5-P3'
p3601
S'ARAP3'
p3602
S'translocates'
p3603
tp3604
(lp3605
s(S'CART1'
p3606
S'CYP26A1'
p3607
S'increases'
p3608
tp3609
(lp3610
s(S'Arsenic'
p3611
S'NRAS MRNA'
p3612
S'increases'
p3613
tp3614
(lp3615
s(S'NRF1'
p3616
S'CDC5L'
p3617
S'increases'
p3618
tp3619
(lp3620
s(S'Quercetin'
p3621
S'HRAS PROTEIN'
p3622
S'decreases'
p3623
tp3624
(lp3625
s(S"N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE"
p3626
S'HRAS'
p3627
S'increases_activity'
p3628
tp3629
(lp3630
s(S'TFDP1'
p3631
S'FOXD3'
p3632
S'increases'
p3633
tp3634
(lp3635
s(S'AR'
p3636
S'TLX2'
p3637
S'increases'
p3638
tp3639
(lp3640
s(S'hsa-miR-181c-5p'
p3641
S'KRAS'
p3642
S'decreases'
p3643
tp3644
(lp3645
s(S'SMAD3'
p3646
S'CBFA2T3'
p3647
S'increases'
p3648
tp3649
(lp3650
s(S'HOXA9'
p3651
S'NRAS'
p3652
S'increases'
p3653
tp3654
(lp3655
s(S'PITX2'
p3656
S'CYP26A1'
p3657
S'increases'
p3658
tp3659
(lp3660
s(S'ATF3'
p3661
S'CYP26A1'
p3662
S'increases'
p3663
tp3664
(lp3665
s(S'E2F1'
p3666
S'MAZ'
p3667
S'increases'
p3668
tp3669
(lp3670
s(S'Ethyl Methanesulfonate'
p3671
S'HRAS MRNA'
p3672
S'increases'
p3673
tp3674
(lp3675
s(S'LMO2'
p3676
S'FOXA1'
p3677
S'increases'
p3678
tp3679
(lp3680
s(S'FOXC1'
p3681
S'POU2F1'
p3682
S'increases'
p3683
tp3684
(lp3685
s(S'DDIT3'
p3686
S'CYP26A1'
p3687
S'increases'
p3688
tp3689
(lp3690
s(S'PAX8'
p3691
S'CYP26A1'
p3692
S'increases'
p3693
tp3694
(lp3695
s(S'LHX3'
p3696
S'EN1'
p3697
S'increases'
p3698
tp3699
(lp3700
s(S'KAT2B'
p3701
S'CYP26A1'
p3702
S'increases'
p3703
tp3704
(lp3705
s(S'P100'
p3706
S'MYB'
p3707
S'binds'
p3708
tp3709
(lp3710
s(S'SOX9'
p3711
S'FOXA1'
p3712
S'increases'
p3713
tp3714
(lp3715
s(S'HIF1A'
p3716
S'EN1'
p3717
S'increases'
p3718
tp3719
(lp3720
s(S'REPIN1'
p3721
S'RUNX1'
p3722
S'increases'
p3723
tp3724
(lp3725
s(S'MYOD1'
p3726
S'BACH1'
p3727
S'increases'
p3728
tp3729
(lp3730
s(S'EBF2'
p3731
S'REPIN1'
p3732
S'increases'
p3733
tp3734
(lp3735
s(S'bisphenol A'
p3736
S'HRAS MRNA'
p3737
S'increases'
p3738
tp3739
(lp3740
s(S'E2F1'
p3741
S'EN1'
p3742
S'increases'
p3743
tp3744
(lp3745
s(S'MYC/Max/MIZ-1'
p3746
S'GALECTIN-1'
p3747
S'decreases'
p3748
tp3749
(lp3750
s(S'PI-3-4-5-P3'
p3751
S'WAVE2/NAP1/SRA1/ABI1/HSPC300'
p3752
S'adds_modification'
p3753
tp3754
(lp3755
s(S'FOXF2'
p3756
S'FOXO3'
p3757
S'increases'
p3758
tp3759
(lp3760
s(S'REPIN1'
p3761
S'STAT5A'
p3762
S'increases'
p3763
tp3764
(lp3765
s(S'RUNX1'
p3766
S'NRAS'
p3767
S'increases'
p3768
tp3769
(lp3770
S'Genomic DNA was also tested for mutations in 19 genes that are recurrently mutated in myeloid neoplasms, including ASXL1, EZH2, RUNX1, IDH1, IDH2, KRAS, NRAS and TET2.'
p3771
as(S'benzo(a)pyrene 7,8-dihydrodiol'
p3772
S'HRAS MRNA'
p3773
S'increases'
p3774
tp3775
(lp3776
s(S'RAC1/GTP'
p3777
S'PAK1 (DIMER)'
p3778
S'adds_modification'
p3779
tp3780
(lp3781
s(S'PAX4'
p3782
S'POU2F1'
p3783
S'increases'
p3784
tp3785
(lp3786
s(S'MYOD1'
p3787
S'CBFA2T3'
p3788
S'increases'
p3789
tp3790
(lp3791
s(S'STAT5A'
p3792
S'RUNX2'
p3793
S'increases'
p3794
tp3795
(lp3796
s(S'EBF2'
p3797
S'FOXJ2'
p3798
S'increases'
p3799
tp3800
(lp3801
s(S'Estradiol'
p3802
S'KRAS MRNA'
p3803
S'increases'
p3804
tp3805
(lp3806
s(S'RXRB'
p3807
S'CYP26A1'
p3808
S'increases'
p3809
tp3810
(lp3811
s(S'bisphenol A'
p3812
S'KRAS MRNA'
p3813
S'decreases'
p3814
tp3815
(lp3816
s(S'COMPLEX (GRB2/SOS)'
p3817
S'FGFR1-4'
p3818
S'binds'
p3819
tp3820
(lp3821
s(S'POU2F1'
p3822
S'RUNX1'
p3823
S'increases'
p3824
tp3825
(lp3826
s(S'TCF3'
p3827
S'TLX2'
p3828
S'increases'
p3829
tp3830
(lp3831
s(S'SPZ1'
p3832
S'POU2F1'
p3833
S'increases'
p3834
tp3835
(lp3836
s(S'TFAP4'
p3837
S'FOXO4'
p3838
S'increases'
p3839
tp3840
(lp3841
s(S'OR5I1'
p3842
S'MECOM'
p3843
S'increases'
p3844
tp3845
(lp3846
s(S'Rho Family GTPase-active'
p3847
S'JNK1'
p3848
S'adds_modification'
p3849
tp3850
(lp3851
s(S'TFDP1'
p3852
S'POU2F1'
p3853
S'increases'
p3854
tp3855
(lp3856
s(S'AHR'
p3857
S'MAX'
p3858
S'increases'
p3859
tp3860
(lp3861
s(S'BACH1'
p3862
S'CYP26A1'
p3863
S'increases'
p3864
tp3865
(lp3866
s(S'ZBTB14'
p3867
S'MAZ'
p3868
S'increases'
p3869
tp3870
(lp3871
s(S'TCF3'
p3872
S'FOXO4'
p3873
S'increases'
p3874
tp3875
(lp3876
s(S'MASTERMIND'
p3877
S'NICS'
p3878
S'binds'
p3879
tp3880
(lp3881
s(S'BPTF'
p3882
S'FOXO4'
p3883
S'increases'
p3884
tp3885
(lp3886
s(S'MYOD1'
p3887
S'RUNX1'
p3888
S'increases'
p3889
tp3890
(lp3891
s(S'JUN'
p3892
S'CYP26A1'
p3893
S'increases'
p3894
tp3895
(lp3896
s(S'BPTF'
p3897
S'CYP26A1'
p3898
S'increases'
p3899
tp3900
(lp3901
s(S'POU3F1'
p3902
S'CYP26A1'
p3903
S'increases'
p3904
tp3905
(lp3906
s(S'NRF1'
p3907
S'CYP26A1'
p3908
S'increases'
p3909
tp3910
(lp3911
s(S'TFAP2C'
p3912
S'POU3F2'
p3913
S'increases'
p3914
tp3915
(lp3916
s(S'NFAT1-C-4-INACTIVE2'
p3917
S'YWHAQ'
p3918
S'binds'
p3919
tp3920
(lp3921
s(S'STAT6'
p3922
S'ONECUT1'
p3923
S'increases'
p3924
tp3925
(lp3926
s(S'RUNX1'
p3927
S'RUNX2'
p3928
S'increases'
p3929
tp3930
(lp3931
s(S'ZIC3'
p3932
S'MYCN'
p3933
S'increases'
p3934
tp3935
(lp3936
s(S'CYP26A1'
p3937
S'MAX'
p3938
S'increases'
p3939
tp3940
(lp3941
s(S'ETS2'
p3942
S'FOXO4'
p3943
S'increases'
p3944
tp3945
(lp3946
s(S'GATA6'
p3947
S'FOXA1'
p3948
S'increases'
p3949
tp3950
(lp3951
s(S'Doxorubicin'
p3952
S'HRAS MRNA'
p3953
S'increases'
p3954
tp3955
(lp3956
s(S'PPARA'
p3957
S'HOXA9'
p3958
S'increases'
p3959
tp3960
(lp3961
s(S'REPIN1'
p3962
S'GABPB2'
p3963
S'increases'
p3964
tp3965
(lp3966
s(S'FOXN1'
p3967
S'FOXA1'
p3968
S'increases'
p3969
tp3970
(lp3971
s(S'Dronabinol'
p3972
S'KRAS MRNA'
p3973
S'increases'
p3974
tp3975
(lp3976
s(S'FOXO1'
p3977
S'RUNX1'
p3978
S'increases'
p3979
tp3980
(lp3981
s(S'SMAD4'
p3982
S'HOXA9'
p3983
S'increases'
p3984
tp3985
(lp3986
s(S'PAX4'
p3987
S'JUN'
p3988
S'increases'
p3989
tp3990
(lp3991
s(S'Raf-1'
p3992
S'MEK'
p3993
S'adds_modification'
p3994
tp3995
(lp3996
g684
ag686
ag692
ag705
ag707
ag708
ag709
ag710
ag716
as(S'PIM1'
p3997
S'MYC/MAX'
p3998
S'binds'
p3999
tp4000
(lp4001
s(S'YY1'
p4002
S'MECOM'
p4003
S'increases'
p4004
tp4005
(lp4006
s(S'NRF1'
p4007
S'MAZ'
p4008
S'increases'
p4009
tp4010
(lp4011
s(S'GATA1'
p4012
S'MECOM'
p4013
S'increases'
p4014
tp4015
(lp4016
s(S'PDGF/PDGFRA'
p4017
S'SHC/GRB2/SOS1'
p4018
S'increases_activity'
p4019
tp4020
(lp4021
s(S'GRB2/SOS1'
p4022
S'FAK'
p4023
S'binds'
p4024
tp4025
(lp4026
s(S'HNF4A'
p4027
S'HOXA9'
p4028
S'increases'
p4029
tp4030
(lp4031
s(S'FOXA2'
p4032
S'CYP26A1'
p4033
S'increases'
p4034
tp4035
(lp4036
s(S'FOXI1'
p4037
S'CYP26A1'
p4038
S'increases'
p4039
tp4040
(lp4041
s(S'GRB2 BOUND TO TIE2'
p4042
S'SOS1'
p4043
S'binds'
p4044
tp4045
(lp4046
s(S'PHOSPHORYLATED BRF1 (SER54, SER92, SER203):MRNA COMPLEX'
p4047
S'YWHAB'
p4048
S'binds'
p4049
tp4050
(lp4051
s(S'COMPLEX (GRB2/SOS)'
p4052
S'GAB'
p4053
S'binds'
p4054
tp4055
(lp4056
s(S'NFE2'
p4057
S'TLX2'
p4058
S'increases'
p4059
tp4060
(lp4061
s(S'MAX'
p4062
S'FOXF2'
p4063
S'increases'
p4064
tp4065
(lp4066
s(S'GRB2:SOS1'
p4067
S'ACTIVATED FGFR:P-FRS2'
p4068
S'binds'
p4069
tp4070
(lp4071
s(S'FOXO4'
p4072
S'MECOM'
p4073
S'increases'
p4074
tp4075
(lp4076
s(S'TCF3'
p4077
S'LEF1'
p4078
S'increases'
p4079
tp4080
(lp4081
s(S'ZIC1'
p4082
S'LEF1'
p4083
S'increases'
p4084
tp4085
(lp4086
s(S'NFIL3'
p4087
S'CYP26A1'
p4088
S'increases'
p4089
tp4090
(lp4091
s(S'RAF1'
p4092
S'MEK1'
p4093
S'increases_activity'
p4094
tp4095
(lp4096
s(S'AR'
p4097
S'FOXA1'
p4098
S'increases'
p4099
tp4100
(lp4101
s(S'POU2F1'
p4102
S'POU3F2'
p4103
S'increases'
p4104
tp4105
(lp4106
s(S'PCBP1'
p4107
S'MAZ'
p4108
S'increases'
p4109
tp4110
(lp4111
s(S'LEF1'
p4112
S'HOXA9'
p4113
S'increases'
p4114
tp4115
(lp4116
s(S'NR6A1'
p4117
S'CYP26A1'
p4118
S'increases'
p4119
tp4120
(lp4121
s(S'PI3K'
p4122
S'BTK'
p4123
S'translocates'
p4124
tp4125
(lp4126
S'Recruitment of PI3K leads to the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) and subsequent BTK and AKT activation.'
p4127
as(S'AHR'
p4128
S'RUNX1'
p4129
S'increases'
p4130
tp4131
(lp4132
s(S'NR1H4'
p4133
S'CYP26A1'
p4134
S'increases'
p4135
tp4136
(lp4137
s(S'NR2F2'
p4138
S'CYP26A1'
p4139
S'increases'
p4140
tp4141
(lp4142
s(S'GNB1/GNG2'
p4143
S'PI3K'
p4144
S'binds'
p4145
tp4146
(lp4147
s(S'RHOA/GTP'
p4148
S'PKN2'
p4149
S'increases_activity'
p4150
tp4151
(lp4152
s(S'MAZ'
p4153
S'LEF1'
p4154
S'increases'
p4155
tp4156
(lp4157
s(S'RFX1'
p4158
S'MECOM'
p4159
S'increases'
p4160
tp4161
(lp4162
s(S'RUNX1'
p4163
S'HOXA9'
p4164
S'increases'
p4165
tp4166
(lp4167
s(S'FOXL1'
p4168
S'POU2F1'
p4169
S'increases'
p4170
tp4171
(lp4172
s(S'GRB2:SOS1'
p4173
S'PHOSPHORYLATED ERBB2:EGFR HETERODIMERS'
p4174
S'binds'
p4175
tp4176
(lp4177
s(S'TFAP4'
p4178
S'MYCN'
p4179
S'increases'
p4180
tp4181
(lp4182
s(S'E2F1'
p4183
S'GATA1'
p4184
S'increases'
p4185
tp4186
(lp4187
s(S'PTF1A'
p4188
S'GATA6'
p4189
S'increases'
p4190
tp4191
(lp4192
s(S'REL'
p4193
S'CYP26A1'
p4194
S'increases'
p4195
tp4196
(lp4197
s(S'MTF1'
p4198
S'JUN'
p4199
S'increases'
p4200
tp4201
(lp4202
s(S'ZEB1'
p4203
S'REPIN1'
p4204
S'increases'
p4205
tp4206
(lp4207
s(S'IRF8'
p4208
S'GATA6'
p4209
S'increases'
p4210
tp4211
(lp4212
s(S'P-Y349,350-SHC1:PHOSPHORYLATED ERBB2 HETERODIMERS'
p4213
S'GRB2:SOS1'
p4214
S'binds'
p4215
tp4216
(lp4217
s(S'BACH2'
p4218
S'EN1'
p4219
S'increases'
p4220
tp4221
(lp4222
s(S'GFI1'
p4223
S'MEIS1'
p4224
S'increases'
p4225
tp4226
(lp4227
s(S'FOXN1'
p4228
S'LEF1'
p4229
S'increases'
p4230
tp4231
(lp4232
s(S'CYP26A1'
p4233
S'JUN'
p4234
S'increases'
p4235
tp4236
(lp4237
s(S'TCF3'
p4238
S'ONECUT1'
p4239
S'increases'
p4240
tp4241
(lp4242
s(S'FOXF2'
p4243
S'POU2F1'
p4244
S'increases'
p4245
tp4246
(lp4247
s(S'MAZ'
p4248
S'MAX'
p4249
S'increases'
p4250
tp4251
(lp4252
s(S'FOXN1'
p4253
S'CYP26A1'
p4254
S'increases'
p4255
tp4256
(lp4257
s(S'HNF1A'
p4258
S'FOXD3'
p4259
S'increases'
p4260
tp4261
(lp4262
s(S'EGR2'
p4263
S'RUNX1'
p4264
S'increases'
p4265
tp4266
(lp4267
s(S'MYC'
p4268
S'RUNX2'
p4269
S'increases'
p4270
tp4271
(lp4272
s(S'TFAP2A'
p4273
S'IRF1'
p4274
S'increases'
p4275
tp4276
(lp4277
s(S'FOXO4'
p4278
S'YY1'
p4279
S'increases'
p4280
tp4281
(lp4282
s(S'VEGFR2 (dimer)/VEGFA (dimer)'
p4283
S'SRC'
p4284
S'adds_modification'
p4285
tp4286
(lp4287
s(S'resveratrol'
p4288
S'KRAS MRNA'
p4289
S'decreases'
p4290
tp4291
(lp4292
s(S'FOXO4'
p4293
S'CYP26A1'
p4294
S'increases'
p4295
tp4296
(lp4297
s(S'STAT3'
p4298
S'FOXO4'
p4299
S'increases'
p4300
tp4301
(lp4302
s(S'GRB2/SOS1'
p4303
S'FRS2 FAMILY/SHP2'
p4304
S'binds'
p4305
tp4306
(lp4307
s(S'LEF1'
p4308
S'CYP26A1'
p4309
S'increases'
p4310
tp4311
(lp4312
s(S'GTF2A2'
p4313
S'SRF'
p4314
S'increases'
p4315
tp4316
(lp4317
s(S'PPARA'
p4318
S'STAT5A'
p4319
S'increases'
p4320
tp4321
(lp4322
s(S'hsa-miR-143-3p'
p4323
S'KRAS'
p4324
S'decreases'
p4325
tp4326
(lp4327
s(S'GFI1'
p4328
S'CYP26A1'
p4329
S'increases'
p4330
tp4331
(lp4332
s(S'RAC1/GTP'
p4333
S'MKK4-MKK7'
p4334
S'increases_activity'
p4335
tp4336
(lp4337
s(S'REPIN1'
p4338
S'ETS1'
p4339
S'increases'
p4340
tp4341
(lp4342
s(S'ZIC1'
p4343
S'GATA6'
p4344
S'increases'
p4345
tp4346
(lp4347
s(S'INTERLEUKIN RECEPTOR COMPLEXES WITH ACTIVATED SHC1'
p4348
S'GRB2:SOS1'
p4349
S'binds'
p4350
tp4351
(lp4352
s(S'Selenium'
p4353
S'HRAS MRNA'
p4354
S'increases'
p4355
tp4356
(lp4357
s(S'HOXA4'
p4358
S'CYP26A1'
p4359
S'increases'
p4360
tp4361
(lp4362
s(S'NKX2-1'
p4363
S'POU2F1'
p4364
S'increases'
p4365
tp4366
(lp4367
s(S'VSX1'
p4368
S'MAX'
p4369
S'increases'
p4370
tp4371
(lp4372
s(S'FOXD1'
p4373
S'FOXD3'
p4374
S'increases'
p4375
tp4376
(lp4377
s(S'MAX'
p4378
S'NRAS'
p4379
S'increases'
p4380
tp4381
(lp4382
s(S'HOXA9'
p4383
S'TCF3'
p4384
S'increases'
p4385
tp4386
(lp4387
s(S'IRF1'
p4388
S'CYP26A1'
p4389
S'increases'
p4390
tp4391
(lp4392
s(S'HRAS'
p4393
S'RAF1'
p4394
S'adds_modification'
p4395
tp4396
(lp4397
s(S'CUX1'
p4398
S'HOXA9'
p4399
S'increases'
p4400
tp4401
(lp4402
s(S'ZHX2'
p4403
S'FOXA1'
p4404
S'increases'
p4405
tp4406
(lp4407
s(S'TFDP1'
p4408
S'MYC'
p4409
S'increases'
p4410
tp4411
(lp4412
g1541
as(S'RAC1/GTP'
p4413
S'PAK1'
p4414
S'increases_activity'
p4415
tp4416
(lp4417
s(S'AHR'
p4418
S'MAZ'
p4419
S'increases'
p4420
tp4421
(lp4422
s(S'BRAF/14-3-3'
p4423
S'KSR/14-3-3 /MEK1-2'
p4424
S'increases_activity'
p4425
tp4426
(lp4427
s(S'PPARA'
p4428
S'CYP26A1'
p4429
S'increases'
p4430
tp4431
(lp4432
s(S'REPIN1'
p4433
S'SRF'
p4434
S'increases'
p4435
tp4436
(lp4437
s(S'PAX5'
p4438
S'SRF'
p4439
S'increases'
p4440
tp4441
(lp4442
s(S'PAX4'
p4443
S'FOXJ2'
p4444
S'increases'
p4445
tp4446
(lp4447
s(S'REPIN1'
p4448
S'MYCN'
p4449
S'increases'
p4450
tp4451
(lp4452
s(S'RALA/GTP'
p4453
S'SRC'
p4454
S'adds_modification'
p4455
tp4456
(lp4457
s(S'FOXO4'
p4458
S'ETS1'
p4459
S'increases'
p4460
tp4461
(lp4462
s(S'TFDP1'
p4463
S'CDC5L'
p4464
S'increases'
p4465
tp4466
(lp4467
s(S'TFDP1'
p4468
S'CYP26A1'
p4469
S'increases'
p4470
tp4471
(lp4472
s(S'GATA6'
p4473
S'RUNX2'
p4474
S'increases'
p4475
tp4476
(lp4477
s(S'FOXM1'
p4478
S'CYP26A1'
p4479
S'increases'
p4480
tp4481
(lp4482
s(S'sodium arsenite'
p4483
S'HRAS PROTEIN'
p4484
S'increases'
p4485
tp4486
(lp4487
s(S'STAT5A'
p4488
S'RUNX1'
p4489
S'increases'
p4490
tp4491
(lp4492
s(S'CEBPA'
p4493
S'EN1'
p4494
S'increases'
p4495
tp4496
(lp4497
s(S'MSX1'
p4498
S'POU2F1'
p4499
S'increases'
p4500
tp4501
(lp4502
s(S'NHLH1'
p4503
S'CBFA2T3'
p4504
S'increases'
p4505
tp4506
(lp4507
s(S'Parathion'
p4508
S'HRAS PROTEIN'
p4509
S'increases'
p4510
tp4511
(lp4512
s(S'SMAD4'
p4513
S'CYP26A1'
p4514
S'increases'
p4515
tp4516
(lp4517
s(S'E2F1'
p4518
S'MYC'
p4519
S'increases'
p4520
tp4521
(lp4522
S'To investigate the primary target of miR-34a that may help to explain the association between the increased miR-34a overexpression and cisplatin chemosensitivity, we initially measured the expression of some well-known targets of miR-34a in 5637, T24 and HT-1376 cells following cisplatin treatment, including MYC, TP53, BCL2, NOTCH1, CDK6, SIRT1, E2F1, CDK4, HGF, NOTCH2, SOX2 and CD44.'
p4523
aS'To investigate the primary target of miR-34a that could be the potential mechanism underlying the association between the increased miR-34a expression and cisplatin chemosensitivity, we initially measured the expression of some well-known targets of miR-34a in 5637, T24 and HT-1376 cells following cisplatin treatment, including MYC, BCL2, NOTCH1, CDK6, SIRT1, E2F1, CDK4, HGF, NOTCH2, SOX2 and CD44 ['
p4524
aS'First, the malignancy ITAI genes MYC, E2F1, and p21 were measured in an additional set of primary normal and malignant lung samples to more firmly establish the threshold separating them.'
p4525
aS'MYC TA level was not decreased considerably in the A549/p21 stable clones compared to the parental A549 in the context of a five-fold decrease in E2F1 TA level.'
p4526
aS'This is in contrast to reports that in some contexts E2F1 is a transcription factor for MYC ['
p4527
aS'GSEA identified enriched gene expression patterns in TN samples that share common promoter motifs associated with SOX9, E2F1, HIF1A, HMGA1, MYC BACH2, CEBPB, and GCNF/NR6A1.'
p4528
as(S'CYP26A1'
p4529
S'FOXO3'
p4530
S'increases'
p4531
tp4532
(lp4533
s(S'TCF3'
p4534
S'CBFA2T3'
p4535
S'increases'
p4536
tp4537
(lp4538
s(S'ZHX2'
p4539
S'FOXF2'
p4540
S'increases'
p4541
tp4542
(lp4543
s(S'POU2F1'
p4544
S'MECOM'
p4545
S'increases'
p4546
tp4547
(lp4548
s(S'CYP26A1'
p4549
S'POU2F1'
p4550
S'increases'
p4551
tp4552
(lp4553
s(S'MYOD1'
p4554
S'CYP26A1'
p4555
S'increases'
p4556
tp4557
(lp4558
s(S'RAF'
p4559
S'COMPLEX (RAS/GTP)'
p4560
S'binds'
p4561
tp4562
(lp4563
s(S'RET51/GFRalpha1/GDNF/DOK1'
p4564
S'HRAS/GDP'
p4565
S'increases_activity'
p4566
tp4567
(lp4568
s(S'MAFG'
p4569
S'CYP26A1'
p4570
S'increases'
p4571
tp4572
(lp4573
s(S'CRX'
p4574
S'CYP26A1'
p4575
S'increases'
p4576
tp4577
(lp4578
s(S'hsa-miR-126-3p'
p4579
S'KRAS'
p4580
S'decreases'
p4581
tp4582
(lp4583
s(S'EBF2'
p4584
S'CYP26A1'
p4585
S'increases'
p4586
tp4587
(lp4588
s(S'RUNX1'
p4589
S'CYP26A1'
p4590
S'increases'
p4591
tp4592
(lp4593
s(S'HOXA5'
p4594
S'FOXA1'
p4595
S'increases'
p4596
tp4597
(lp4598
s(S'benzo(a)pyrene-3,6-quinone'
p4599
S'HRAS MRNA'
p4600
S'increases'
p4601
tp4602
(lp4603
s(S'K 7174'
p4604
S'HRAS MRNA'
p4605
S'decreases'
p4606
tp4607
(lp4608
s(S'LEF1'
p4609
S'NRAS'
p4610
S'increases'
p4611
tp4612
(lp4613
s(S'SPI1'
p4614
S'FOXA1'
p4615
S'increases'
p4616
tp4617
(lp4618
s(S'hsa-let-7b-5p'
p4619
S'NRAS'
p4620
S'decreases'
p4621
tp4622
(lp4623
s(S'CEBPA'
p4624
S'JUN'
p4625
S'increases'
p4626
tp4627
(lp4628
s(S'GABPB2'
p4629
S'CYP26A1'
p4630
S'increases'
p4631
tp4632
(lp4633
s(S'PI-3-4-5-P3'
p4634
S'MTOR'
p4635
S'increases_activity'
p4636
tp4637
(lp4638
s(S'GRB2:SOS1'
p4639
S'EGF:P-6Y-EGFR'
p4640
S'binds'
p4641
tp4642
(lp4643
s(S'HNF1A'
p4644
S'CYP26A1'
p4645
S'increases'
p4646
tp4647
(lp4648
s(S'HIF1A'
p4649
S'FOXO4'
p4650
S'increases'
p4651
tp4652
(lp4653
s(S'FOXJ1'
p4654
S'HOXA9'
p4655
S'increases'
p4656
tp4657
(lp4658
s(S'hsa-miR-96-5p'
p4659
S'KRAS'
p4660
S'decreases'
p4661
tp4662
(lp4663
s(S'SRC'
p4664
S'SYNDECAN-2/RASGAP'
p4665
S'binds'
p4666
tp4667
(lp4668
s(S'FOXA1'
p4669
S'MEIS1'
p4670
S'increases'
p4671
tp4672
(lp4673
s(S'LEF1'
p4674
S'MEIS1'
p4675
S'increases'
p4676
tp4677
(lp4678
s(S'PAX3'
p4679
S'CYP26A1'
p4680
S'increases'
p4681
tp4682
(lp4683
s(S'PAX4'
p4684
S'HOXA9'
p4685
S'increases'
p4686
tp4687
(lp4688
s(S'hsa-miR-18a-3p'
p4689
S'KRAS'
p4690
S'decreases'
p4691
tp4692
(lp4693
s(S'FOXF2'
p4694
S'EN1'
p4695
S'increases'
p4696
tp4697
(lp4698
s(S'Pyk2'
p4699
S'SRC FAMILY KINASES'
p4700
S'increases_activity'
p4701
tp4702
(lp4703
s(S'TP53'
p4704
S'HOXA9'
p4705
S'increases'
p4706
tp4707
(lp4708
s(S'Genistein'
p4709
S'KRAS MRNA'
p4710
S'decreases'
p4711
tp4712
(lp4713
s(S'POU1F1'
p4714
S'CYP26A1'
p4715
S'increases'
p4716
tp4717
(lp4718
s(S'manumycin'
p4719
S'KRAS PROTEIN'
p4720
S'decreases_activity'
p4721
tp4722
(lp4723
s(S'Ginkgo biloba extract 761'
p4724
S'GCLC PROTEIN'
p4725
S'increases'
p4726
tp4727
(lp4728
s(S'GATA1'
p4729
S'NRAS'
p4730
S'increases'
p4731
tp4732
(lp4733
s(S'CBFA2T3'
p4734
S'FOXF2'
p4735
S'increases'
p4736
tp4737
(lp4738
s(S'PCBP1'
p4739
S'ELK1'
p4740
S'increases'
p4741
tp4742
(lp4743
s(S'MYC'
p4744
S'FOXF2'
p4745
S'increases'
p4746
tp4747
(lp4748
s(S'hsa-mir-622'
p4749
S'KRAS'
p4750
S'decreases'
p4751
tp4752
(lp4753
s(S'TCF3'
p4754
S'MAZ'
p4755
S'increases'
p4756
tp4757
(lp4758
s(S'STAT2'
p4759
S'MEIS1'
p4760
S'increases'
p4761
tp4762
(lp4763
s(S'CYP26A1'
p4764
S'YY1'
p4765
S'increases'
p4766
tp4767
(lp4768
s(S'CYP26A1'
p4769
S'EN1'
p4770
S'increases'
p4771
tp4772
(lp4773
s(S'GRB2/SOS1'
p4774
S'SHC'
p4775
S'binds'
p4776
tp4777
(lp4778
s(S'BAD'
p4779
S'YWHAZ'
p4780
S'binds'
p4781
tp4782
(lp4783
s(S'SPI1'
p4784
S'MAX'
p4785
S'increases'
p4786
tp4787
(lp4788
s(S'PI-3-4-5-P3'
p4789
S'CENTA1'
p4790
S'translocates'
p4791
tp4792
(lp4793
s(S'XBP1'
p4794
S'CYP26A1'
p4795
S'increases'
p4796
tp4797
(lp4798
s(S'PAX4'
p4799
S'NRAS'
p4800
S'increases'
p4801
tp4802
(lp4803
s(S'PI3K'
p4804
S'EPHRIN A1/EPHA2'
p4805
S'binds'
p4806
tp4807
(lp4808
s(S'POU1F1'
p4809
S'MEIS1'
p4810
S'increases'
p4811
tp4812
(lp4813
s(S'NR3C1'
p4814
S'ETS1'
p4815
S'increases'
p4816
tp4817
(lp4818
s(S'MAZ'
p4819
S'POU3F2'
p4820
S'increases'
p4821
tp4822
(lp4823
s(S'Estradiol'
p4824
S'HRAS MRNA'
p4825
S'increases'
p4826
tp4827
(lp4828
s(S'Aflatoxin B1'
p4829
S'HRAS PROTEIN'
p4830
S'increases'
p4831
tp4832
(lp4833
s(S'ETV7'
p4834
S'STAT4'
p4835
S'increases'
p4836
tp4837
(lp4838
s(S'PBX1'
p4839
S'LEF1'
p4840
S'increases'
p4841
tp4842
(lp4843
s(S'CEBPB'
p4844
S'CYP26A1'
p4845
S'increases'
p4846
tp4847
(lp4848
s(S'MAZ'
p4849
S'JUN'
p4850
S'increases'
p4851
tp4852
(lp4853
s(S'FOXF2'
p4854
S'MYC'
p4855
S'increases'
p4856
tp4857
(lp4858
s(S'FOXJ2'
p4859
S'HOXA9'
p4860
S'increases'
p4861
tp4862
(lp4863
s(S'Capsaicin'
p4864
S'HRAS MRNA'
p4865
S'increases'
p4866
tp4867
(lp4868
s(S'POU3F1'
p4869
S'GATA6'
p4870
S'increases'
p4871
tp4872
(lp4873
s(S'EIF2A'
p4874
S'14-3-3 E'
p4875
S'binds'
p4876
tp4877
(lp4878
s(S'RAS family/GTP'
p4879
S'RAF1-BRAF'
p4880
S'increases_activity'
p4881
tp4882
(lp4883
s(S'GATA6'
p4884
S'GATA1'
p4885
S'increases'
p4886
tp4887
(lp4888
s(S'RASA1'
p4889
S'PHOSPHO PDGF BETA RECEPTOR: PDGF CHAIN B HOMODIMER'
p4890
S'binds'
p4891
tp4892
(lp4893
s(S'CART1'
p4894
S'POU2F1'
p4895
S'increases'
p4896
tp4897
(lp4898
s(S'ZIC3'
p4899
S'POU2F1'
p4900
S'increases'
p4901
tp4902
(lp4903
s(S'TCF4'
p4904
S'FOXA1'
p4905
S'increases'
p4906
tp4907
(lp4908
s(S'PKC theta'
p4909
S'RASGRP1'
p4910
S'adds_modification'
p4911
tp4912
(lp4913
s(S'PTF1A'
p4914
S'STAT5A'
p4915
S'increases'
p4916
tp4917
(lp4918
s(S'SPI1'
p4919
S'FOXO4'
p4920
S'increases'
p4921
tp4922
(lp4923
s(S'HNF1A'
p4924
S'GATA6'
p4925
S'increases'
p4926
tp4927
(lp4928
s(S'FOXJ1'
p4929
S'RUNX1'
p4930
S'increases'
p4931
tp4932
(lp4933
s(S'STAT2'
p4934
S'GATA6'
p4935
S'increases'
p4936
tp4937
(lp4938
s(S'RAS FAMILY/GTP'
p4939
S'PI3K'
p4940
S'binds'
p4941
tp4942
(lp4943
s(S'PAX4'
p4944
S'IRF1'
p4945
S'increases'
p4946
tp4947
(lp4948
s(S'PAX3'
p4949
S'HOXA9'
p4950
S'increases'
p4951
tp4952
(lp4953
s(S'MYB'
p4954
S'MAZ'
p4955
S'increases'
p4956
tp4957
(lp4958
s(S"Guanosine-5'-Triphosphate"
p4959
S'HRAS'
p4960
S'increases_activity'
p4961
tp4962
(lp4963
s(S'alpha9/beta1 Integrin/Tenascin C'
p4964
S'SRC'
p4965
S'adds_modification'
p4966
tp4967
(lp4968
s(S'RAF1'
p4969
S'MEK1'
p4970
S'adds_modification'
p4971
tp4972
(lp4973
s(S'JUN'
p4974
S'FOXA1'
p4975
S'increases'
p4976
tp4977
(lp4978
S'Here, using massive parallel sequencing, we analyzed the areas of open chromatin, and genome-wide occupancy of six histone methylation/acetylation marks in MCF-7 cells, and two factors likely to be co-localized with ER binding, FOXA1 and AP1 (FOS and JUN).'
p4979
as(S'NFE2L2'
p4980
S'BACH1'
p4981
S'increases'
p4982
tp4983
(lp4984
s(S'CUX1'
p4985
S'FOXD3'
p4986
S'increases'
p4987
tp4988
(lp4989
s(S'JUN'
p4990
S'EN1'
p4991
S'increases'
p4992
tp4993
(lp4994
s(S'ESR1'
p4995
S'CYP26A1'
p4996
S'increases'
p4997
tp4998
(lp4999
s(S'ESRRA'
p5000
S'FOXA1'
p5001
S'increases'
p5002
tp5003
(lp5004
s(S'POU2F1'
p5005
S'MEIS1'
p5006
S'increases'
p5007
tp5008
(lp5009
s(S'TFCP2'
p5010
S'FOXA1'
p5011
S'increases'
p5012
tp5013
(lp5014
s(S'PI-3-4-5-P3'
p5015
S'PDK1'
p5016
S'increases_activity'
p5017
tp5018
(lp5019
s(S'TCF3'
p5020
S'FOXA1'
p5021
S'increases'
p5022
tp5023
(lp5024
s(S'STAT3'
p5025
S'CYP26A1'
p5026
S'increases'
p5027
tp5028
(lp5029
s(S'CYP26A1'
p5030
S'POU3F2'
p5031
S'increases'
p5032
tp5033
(lp5034
s(S'Curcumin'
p5035
S'KRAS MRNA'
p5036
S'decreases'
p5037
tp5038
(lp5039
s(S'STAT1'
p5040
S'CYP26A1'
p5041
S'increases'
p5042
tp5043
(lp5044
s(S'GFI1'
p5045
S'POU2F1'
p5046
S'increases'
p5047
tp5048
(lp5049
s(S'ZIC1'
p5050
S'POU2F1'
p5051
S'increases'
p5052
tp5053
(lp5054
s(S'PI-3-4-5-P3'
p5055
S'AKT3'
p5056
S'adds_modification'
p5057
tp5058
(lp5059
s(S'BACH1'
p5060
S'NRAS'
p5061
S'increases'
p5062
tp5063
(lp5064
s(S'SCF/KIT'
p5065
S'SHC/GRB2/SOS1'
p5066
S'increases_activity'
p5067
tp5068
(lp5069
s(S'CDX2'
p5070
S'CYP26A1'
p5071
S'increases'
p5072
tp5073
(lp5074
s(S'RET51/GFRalpha1/GDNF/DOK/RasGAP/NCK'
p5075
S'HRAS/GDP'
p5076
S'decreases_activity'
p5077
tp5078
(lp5079
s(S'BETAPIX'
p5080
S'RAC1/GTP'
p5081
S'binds'
p5082
tp5083
(lp5084
s(S'RHOA/GTP'
p5085
S'CITRON'
p5086
S'increases_activity'
p5087
tp5088
(lp5089
s(S'P-SHC1:GRB2:SOS'
p5090
S'P-5Y-LAT-2'
p5091
S'binds'
p5092
tp5093
(lp5094
s(S'PAX4'
p5095
S'CYP26A1'
p5096
S'increases'
p5097
tp5098
(lp5099
s(S'TCF3'
p5100
S'KRAS'
p5101
S'increases'
p5102
tp5103
(lp5104
s(S'GRB2:SOS1'
p5105
S'PHOSPHORYLATED ERBB2:ERBB4 HETERODIMERS'
p5106
S'binds'
p5107
tp5108
(lp5109
s(S'CDX2'
p5110
S'MEIS1'
p5111
S'increases'
p5112
tp5113
(lp5114
s(S'SP3'
p5115
S'RUNX1'
p5116
S'increases'
p5117
tp5118
(lp5119
s(S'REST'
p5120
S'CYP26A1'
p5121
S'increases'
p5122
tp5123
(lp5124
s(S'PTF1A'
p5125
S'CYP26A1'
p5126
S'increases'
p5127
tp5128
(lp5129
s(S'PI-3-4-5-P3'
p5130
S'PI3K/GAB1'
p5131
S'translocates'
p5132
tp5133
(lp5134
s(S'LMO2'
p5135
S'FOXO4'
p5136
S'increases'
p5137
tp5138
(lp5139
s(S'STAT4'
p5140
S'ETS1'
p5141
S'increases'
p5142
tp5143
(lp5144
s(S'GTF2A2'
p5145
S'HOXA9'
p5146
S'increases'
p5147
tp5148
(lp5149
s(S'FOXF2'
p5150
S'POU3F2'
p5151
S'increases'
p5152
tp5153
(lp5154
s(S'GATA1'
p5155
S'GABPB2'
p5156
S'increases'
p5157
tp5158
(lp5159
s(S'Polychlorinated Biphenyls'
p5160
S'KRAS MRNA'
p5161
S'decreases'
p5162
tp5163
(lp5164
s(S'GRB2/SOS1'
p5165
S'EGF/EGFR DIMER/SHC'
p5166
S'binds'
p5167
tp5168
(lp5169
s(S'CYP26A1'
p5170
S'FOXF2'
p5171
S'increases'
p5172
tp5173
(lp5174
s(S'EGR1'
p5175
S'CYP26A1'
p5176
S'increases'
p5177
tp5178
(lp5179
s(S'MAX'
p5180
S'FOXO3'
p5181
S'increases'
p5182
tp5183
(lp5184
s(S'T-DHT/AR/PELP1'
p5185
S'SRC'
p5186
S'binds'
p5187
tp5188
(lp5189
s(S'CUX1'
p5190
S'FOXF2'
p5191
S'increases'
p5192
tp5193
(lp5194
s(S'CEBPD'
p5195
S'CYP26A1'
p5196
S'increases'
p5197
tp5198
(lp5199
s(S'CBFA2T3'
p5200
S'NRAS'
p5201
S'increases'
p5202
tp5203
(lp5204
s(S'Cisplatin'
p5205
S'HRAS MRNA'
p5206
S'translocates'
p5207
tp5208
(lp5209
s(S'BAD/BCL-X(L)'
p5210
S'YWHAZ'
p5211
S'binds'
p5212
tp5213
(lp5214
s(S'GATA1'
p5215
S'FOXA1'
p5216
S'increases'
p5217
tp5218
(lp5219
s(S'RREB1'
p5220
S'CYP26A1'
p5221
S'increases'
p5222
tp5223
(lp5224
s(S'STAT4'
p5225
S'RUNX2'
p5226
S'increases'
p5227
tp5228
(lp5229
s(S'FOXD3'
p5230
S'NRAS'
p5231
S'increases'
p5232
tp5233
(lp5234
S'They include NRAS, Erbb3 and Src, and the transcription factor FOXD3 (Fig'
p5235
as(S'NDEL1'
p5236
S'14-3-3 E'
p5237
S'binds'
p5238
tp5239
(lp5240
s(S'CYP26A1'
p5241
S'REPIN1'
p5242
S'increases'
p5243
tp5244
(lp5245
s(S'MAF'
p5246
S'CDC5L'
p5247
S'increases'
p5248
tp5249
(lp5250
s(S'CYP26A1'
p5251
S'ELK1'
p5252
S'increases'
p5253
tp5254
(lp5255
s(S'MYC'
p5256
S'FOXD3'
p5257
S'increases'
p5258
tp5259
(lp5260
s(S'MAX'
p5261
S'FOXD3'
p5262
S'increases'
p5263
tp5264
(lp5265
s(S'POU1F1'
p5266
S'GATA6'
p5267
S'increases'
p5268
tp5269
(lp5270
s(S'POU2F1'
p5271
S'STAT4'
p5272
S'increases'
p5273
tp5274
(lp5275
s(S'GTF3A'
p5276
S'FOXO3'
p5277
S'increases'
p5278
tp5279
(lp5280
s(S'MYB'
p5281
S'FOXF2'
p5282
S'increases'
p5283
tp5284
(lp5285
s(S'ZIC3'
p5286
S'CYP26A1'
p5287
S'increases'
p5288
tp5289
(lp5290
s(S'POU2F1'
p5291
S'EN1'
p5292
S'increases'
p5293
tp5294
(lp5295
s(S'JUN'
p5296
S'STAT1'
p5297
S'increases'
p5298
tp5299
(lp5300
s(S'TEF'
p5301
S'CYP26A1'
p5302
S'increases'
p5303
tp5304
(lp5305
s(S'MAF'
p5306
S'CYP26A1'
p5307
S'increases'
p5308
tp5309
(lp5310
s(S'PAX4'
p5311
S'GATA6'
p5312
S'increases'
p5313
tp5314
(lp5315
s(S'ZIC2'
p5316
S'GATA6'
p5317
S'increases'
p5318
tp5319
(lp5320
s(S'hsa-miR-181d-5p'
p5321
S'HRAS'
p5322
S'decreases'
p5323
tp5324
(lp5325
s(S'BACH2'
p5326
S'CYP26A1'
p5327
S'increases'
p5328
tp5329
(lp5330
s(S'TCF12'
p5331
S'CYP26A1'
p5332
S'increases'
p5333
tp5334
(lp5335
s(S'GATA1'
p5336
S'FOXO4'
p5337
S'increases'
p5338
tp5339
(lp5340
s(S'RFX1'
p5341
S'FOXD3'
p5342
S'increases'
p5343
tp5344
(lp5345
s(S'FOXJ1'
p5346
S'CYP26A1'
p5347
S'increases'
p5348
tp5349
(lp5350
s(S'GTF2A2'
p5351
S'POU2F1'
p5352
S'increases'
p5353
tp5354
(lp5355
s(S'YY1'
p5356
S'SRF'
p5357
S'increases'
p5358
tp5359
(lp5360
S'The conserved elements in exon 1c are related to binding sites for three transcription factors involved in neuronal gene regulation: Pou6f1, YY1, and REST/NSRF (Ballas and Mandel '
p5361
as(S'AHR'
p5362
S'REPIN1'
p5363
S'increases'
p5364
tp5365
(lp5366
s(S'MAZ'
p5367
S'CYP26A1'
p5368
S'increases'
p5369
tp5370
(lp5371
s(S'Quercetin'
p5372
S'HRAS MRNA'
p5373
S'increases'
p5374
tp5375
(lp5376
s(S'ELK1'
p5377
S'NRAS'
p5378
S'increases'
p5379
tp5380
(lp5381
s(S'HIF1A'
p5382
S'ONECUT1'
p5383
S'increases'
p5384
tp5385
(lp5386
s(S'FOXF2'
p5387
S'CYP26A1'
p5388
S'increases'
p5389
tp5390
(lp5391
s(S'SOX9'
p5392
S'ETS1'
p5393
S'increases'
p5394
tp5395
(lp5396
s(S'HSF1'
p5397
S'JUN'
p5398
S'increases'
p5399
tp5400
(lp5401
s(S'CEBPA'
p5402
S'CYP26A1'
p5403
S'increases'
p5404
tp5405
(lp5406
s(S'NR1H4'
p5407
S'MEIS1'
p5408
S'increases'
p5409
tp5410
(lp5411
s(S'SMAD1'
p5412
S'GATA1'
p5413
S'increases'
p5414
tp5415
(lp5416
s(S'Quercetin'
p5417
S'HRAS MRNA'
p5418
S'decreases'
p5419
tp5420
(lp5421
s(S'Glycyrrhetinic Acid'
p5422
S'HRAS PROTEIN'
p5423
S'decreases'
p5424
tp5425
(lp5426
s(S'HOXA4'
p5427
S'POU2F1'
p5428
S'increases'
p5429
tp5430
(lp5431
s(S'FOXQ1'
p5432
S'CYP26A1'
p5433
S'increases'
p5434
tp5435
(lp5436
s(S'FOXI1'
p5437
S'CEBPA'
p5438
S'increases'
p5439
tp5440
(lp5441
s(S'GTF3A'
p5442
S'MYCN'
p5443
S'increases'
p5444
tp5445
(lp5446
s(S'LMO2'
p5447
S'IRF1'
p5448
S'increases'
p5449
tp5450
(lp5451
s(S'FOXO1'
p5452
S'CYP26A1'
p5453
S'increases'
p5454
tp5455
(lp5456
s(S'Copper Sulfate'
p5457
S'NRAS MRNA'
p5458
S'increases'
p5459
tp5460
(lp5461
s(S'TFAP2A'
p5462
S'CYP26A1'
p5463
S'increases'
p5464
tp5465
(lp5466
s(S'FOXJ1'
p5467
S'EN1'
p5468
S'increases'
p5469
tp5470
(lp5471
s(S'MEIS1'
p5472
S'RUNX1'
p5473
S'increases'
p5474
tp5475
(lp5476
s(S'MAZ'
p5477
S'FOXA1'
p5478
S'increases'
p5479
tp5480
(lp5481
s(S'ETS1'
p5482
S'FOXO4'
p5483
S'increases'
p5484
tp5485
(lp5486
s(S'ZBTB14'
p5487
S'FOXD3'
p5488
S'increases'
p5489
tp5490
(lp5491
s(S'FOXC1'
p5492
S'LEF1'
p5493
S'increases'
p5494
tp5495
(lp5496
s(S'IRF1'
p5497
S'EN1'
p5498
S'increases'
p5499
tp5500
(lp5501
s(S'NR3C1'
p5502
S'CYP26A1'
p5503
S'increases'
p5504
tp5505
(lp5506
s(S'VSX1'
p5507
S'BACH1'
p5508
S'increases'
p5509
tp5510
(lp5511
s(S'CYP26A1'
p5512
S'ETS1'
p5513
S'increases'
p5514
tp5515
(lp5516
s(S'CEBPA'
p5517
S'MEIS1'
p5518
S'increases'
p5519
tp5520
(lp5521
s(S'ELF1'
p5522
S'FOXO4'
p5523
S'increases'
p5524
tp5525
(lp5526
s(S'RXRA'
p5527
S'CYP26A1'
p5528
S'increases'
p5529
tp5530
(lp5531
s(S'CREB1'
p5532
S'CYP26A1'
p5533
S'increases'
p5534
tp5535
(lp5536
s(S'IRF7'
p5537
S'GATA6'
p5538
S'increases'
p5539
tp5540
(lp5541
s(S'ZEB1'
p5542
S'CYP26A1'
p5543
S'increases'
p5544
tp5545
(lp5546
s(S'AR'
p5547
S'CYP26A1'
p5548
S'increases'
p5549
tp5550
(lp5551
s(S'TFDP2'
p5552
S'MYC'
p5553
S'increases'
p5554
tp5555
(lp5556
s(S'hsa-mir-217'
p5557
S'KRAS'
p5558
S'decreases'
p5559
tp5560
(lp5561
s(S'MEK'
p5562
S'ERK'
p5563
S'adds_modification'
p5564
tp5565
(lp5566
g660
aS'Complex formation is independent of MEK1 kinase activity but requires phosphorylation of T292 on MEK1 by activated ERK.'
p5567
ag661
aS'The dual specificity kinases MEK1 and MEK2 are activated by RAF and mediate phosphorylation of ERK1 and ERK2 ('
p5568
aS'MEK1 and MEK2 also bind differentially to scaffolds such as MP1, which plays a role in ERK1 activation at late endosomes ('
p5569
aS'We have recently reported that MEK1 is essential for the regulation of the timing and strength of ERK signaling.'
p5570
aS'By phosphorylating the T292 site in the proline-rich region of MEK1, ERK exerts negative feedback control on MEK1/MEK2 dimers.'
p5571
aS'If MEK1 is absent, this control is disabled, leading to increased ERK signaling ('
p5572
aS'Indeed, MEK inhibitors blocked both ERK and T292 phosphorylation, concomitantly increasing AKT phosphorylation ('
p5573
aS'In this case, however, the WOX1/MEK1 complex dissociates upon ERK activation ('
p5574
ag662
aS'Phosphorylation and expression of AKT, ERK, MEK1, and tubulin (loading control) were determined by immunoblotting (E).'
p5575
aS'This site proved essential to mediate MFN1-dependent mitochondrial elongation and apoptosis regulation by the MEK/ERK cascade.'
p5576
aS'Moreover, neuronal apoptosis following oxygen glucose deprivation and MEK/ERK activation required an intact MFN1'
p5577
aS'Since both the MEK/ERK pathway and changes in mitochondrial morphology have been implicated in the modulation of apoptosis ('
p5578
aS'To better understand the physiological relevance of MEK/ERK modulation of mitochondrial morphology and permeabilization, we turned our attention to oxidative stress, during which MEK/ERK are activated.'
p5579
aS'This activation of the receptor then induces the activation of intracellular effectors via intracellular signaling pathways, including one where rapidly accelerated fibrosarcoma (RAF) activates the dual kinase, mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK), which then activates the ERK pathway.'
p5580
aS'Although miR-4689 and siRNA-mediated silencing of MEK1 and MEK2 had similar effects on ERK phosphorylation ('
p5581
aS'We selected for therapeutic miRNAs, mainly by evaluating the RAF/MEK/ERK pathway, and measuring SRE activity after treatment with specific miRNAs.'
p5582
aS'After screening for SRE/AP1 activity, we identified miR-4689 and miR-4685-3p as potent inhibitors in the RAF/MEK/ERK or MEKK/SEK/JNK pathway.'
p5583
aS'Earlier studies have shown that targeting either the RAF/MEK/ERK or the PI3K/AKT pathway alone was not sufficient to regulate the entire EGFR signaling pathway, because one signal transduction branch could compensate for diminished signaling in another branch.'
p5584
aS'JAK-2 is linked to several other pathways including STAT-5 and the RAS-MEK-ERK-MAPK cascade.'
p5585
ag663
aS'administration of PD98059, an ERK upstream kinase (MEK) inhibitor, completely blocked the formalin-induced inflammatory nociceptive responses.'
p5586
aS'Intrathecal administration of the MEK inhibitor, U0126, prevented both mechanical and thermal hypersensitivity from 1 hr to 2 d. p-ERK1/2 and p-p38 were expressed in neurons in distinct regions of the L4/L5 dorsal horn; p-ERK1/2 was mainly in lamina I, while p-p38 was mainly in lamina II of the dorsal horn.'
p5587
aS"ANOVA: Analysis of variance; BV: Bee venom; CFA: Complete Freund's adjuvant; DMSO: Dimethyl sulfoxide; DRG: Dorsal root ganglia; ERK: Extracellular signal-regulated protein kinase; IR: Immunoreactivity; JNK: c-Jun N-terminal kinase; MAPK: Mitogen activated protein kinase; MEK: MAPK/ERK kinase."
p5588
aS'administration of MEK1/2 inhibitor PD98059 caused significant inhibition of the head-withdrawal reflex after Glu injection itself into the tongue or whisker pad skin, and also inhibited the heat head-withdrawal reflex and ERK phosphorylation in Glu-injected rats.'
p5589
aS'In order to block the ERK phosphorylation in neurons and TG primary afferent terminals in the Vc and C1-C2, MEK1/2 inhibitor PD98059 (CalBiochem, San Diego, CA) was i.t.'
p5590
aS'We acutely blocked ERK activation in the CeA by infusing the MEK inhibitor U0126 into the right or the left hemisphere and then measured the behavioral effects on inflammation-induced mechanical hypersensitivity in mice.'
p5591
aS'Here, we show that LTP induced by three different induction protocols were completely blocked by the MAPK/ERK kinase (MEK) inhibitor applied postsynaptically.'
p5592
aS'In this study, we demonstrated that ERK activation is required for the induction of LTP in the ACC and that the MEK inhibitors did not affect the maintenance phase of cingulate LTP.'
p5593
aS'This study was designed to use Western blot analysis to investigate the role of mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK 1/2), PKA and PKC in regulating the phosphorylation of CREB in the spinal cord of rats following intraplantar capsaicin injection.'
p5594
aS'Recently, mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK 1/2) was reported to play a critical role in spinal dorsal horn neurons in response to various painful stimuli ['
p5595
aS'Increased spinal ERK phosphorylation is important for pain behaviors based on the MEK inhibitor studies.'
p5596
aS'Since ERKs are the only known substrates of MEK, the MEK inhibitor, UO126 (Cell Signaling, Danvers, Massachusetts, USA) was used to produce ERK inactivation.'
p5597
aS'The MAPKs family contains at least three protein kinases in series: JNK, p38 MAP kinase and MEK (a kinase immediately upstream of ERK that phosphorylates the tyrosine and threonine residues on ERK1/2 required for activation).'
p5598
aS'These studies have utilized pharmacological inhibition of MEK to demonstrate a role for ERK signaling in pain, but this approach cannot distinguish between effects of ERK in neuronal and non-neuronal cells.'
p5599
aS'In addition, spinal ERK phosphorylation following formalin injection was significantly reduced in the DN MEK mice.'
p5600
aS'Further examination of the effects of suppression of MEK function on a downstream target of ERK phosphorylation, the A-type potassium channel, showed that the ERK-dependent modulation of the A-type currents is significantly reduced in neurons from DN MEK mice compared to littermate wild type controls.'
p5601
aS'Our results demonstrate that the neuronal MEK-ERK pathway is indeed an important intracellular cascade that is associated with formalin-induced inflammatory pain and thermal hyperalgesia.'
p5602
aS'Activated raf phosphorylates MEK which phosphorylates ERK1 and ERK2 on tyrosine and threonine residues.'
p5603
aS'To study the importance of ERKs in nociception, most studies mentioned above have utilized intrathecal pharmacological inhibition of MEK using either PD 98059 or U0126, which may inhibit MEK function in both neuronal and non-neuronal cells.'
p5604
aS'We next investigated whether the reduced inflammatory nociception was associated with reduced ERK activation in the DN MEK mice.'
p5605
aS'Extracellular signal-regulated kinases have a central role in nociceptive sensitization in the spinal cord; we therefore examined activation of ERK at this site in either wild type or DN MEK mice following formalin injection.'
p5606
aS'Although basal phosphorylated ERK is minimal in mouse spinal cords without noxious stimuli, we investigated whether expression of the DN MEK transgene would alter basal ERK activation in the DN MEK mice.'
p5607
aS'There was no significant difference in the amount of basal phospho-ERK1 or phospho-ERK2 between the wild type and DN MEK mice spinal cords in either male or female mice (Fig '
p5608
aS'Basal phosphorylation of ERK is similar in the wild type and DN MEK mice spinal cords.'
p5609
aS'Reduced phospho-ERK in DN MEK mice spinal cords 15 minutes after 2 % formalin injection in the hind paw.'
p5610
aS'A, Representative immunoblots of ipsilateral (ipsi) and contralateral (contra) mouse spinal cord homogenates from a wild type or a DN MEK mouse using a phospho-ERK 1/2 antibody (top) or a total ERK 1/2 antibody (bottom).'
p5611
aS'#p < 0.05, significant differences in ipsilateral phospho-ERK between the wild type and DN MEK mice.'
p5612
aS'To further investigate whether there is a functional deficit of the MEK-ERK cascade specifically in spinal cord neurons of the DN MEK mice, we asked whether ERK regulation of a downstream target, the transient A-type potassium channel, is altered in these mice.'
p5613
aS'The present study reports several important findings regarding the role of the neuronal MEK-ERK cascade in nociception.'
p5614
aS'The DN MEK mutant mice present a functional reduction of the activity of neuronal MEK, the kinase that selectively activates ERK 1 and ERK 2 ['
p5615
aS'A recent paper reported decreased basal ERK activity in the hippocampi of the DN MEK mice ['
p5616
aS'Reduction of thermal hyperalgesia in the DN MEK mice is possibly due to decreased central sensitization since we showed clearly that spinal ERK activation following formalin injection was decreased in these mice.'
p5617
aS'In this study we examined cross sections of the sciatic nerves of the DN MEK mice in order to determine whether reduced ERK activation following formalin injection was due to reduced number of unmyelinated peripheral fibers.'
p5618
aS'The current studies further show that ERK-mediated modulation of A-type potassium channels is impaired in spinal dorsal horn neurons from DN MEK mice.'
p5619
aS'We tested a MEK inhibitor, U0126, which is an upstream regulator of ERK1/2 ['
p5620
aS'Finally, intrathecal injection of the MEK1 inhibitor PD98059 blocked both reduced hind-limb grip force and pERK1/2 induction in MIA-OA rats.'
p5621
aS'To examine the functional role of spinal pERK in mediating nociceptive behavior, the MEK (ERK1/2 kinase) inhibitor PD98059 was tested in 3-wk MIA-OA rats.'
p5622
aS'It was observed that increased spinal ERK1/2 phosphorylation in 3-wk MIA-OA rats was blocked by the MEK inhibitor PD98059 when examined 30 min following acute intrathecal administration, as would be expected.'
p5623
aS'The effects of a MEK inhibitor on MIA-induced pain behavior and pERK1/2 expression were evaluated.'
p5624
aS'injection of MEK inhibitor caused significant attenuation of ERK phosphorylation in Vc and C1-C2 neurons and in nocifensive behaviors to heat, cold and mechanical stimuli in the capsaicin-treated rats.'
p5625
aS'administration of the MEK inhibitor PD98059 causes a significant reduction of ERK phosphorylation in Vc neurons as well as spinal DH neurons ['
p5626
aS'The MEK1/2 inhibitor PD98059 was used as the inhibitor for ERK phosphorylation.'
p5627
aS'NGF-evoked CGRP up-regulation is also blocked by inhibition of the MEK/ERK pathway with specific MEK inhibitors U0126 and PD98059, but not by inhibition of the PI3K/Akt pathway with inhibitor LY294002.'
p5628
aS'Prevention of ERK activity with a MEK inhibitor PD98059 that blocks both ERK1/2 and ERK5 attenuates retrograde NGF-induced CGRP up-regulation in the DRG neuronal soma.'
p5629
aS'Examination of retrograde pathways that are initiated by NGF leading to CGRP expression in DRG shows that application of specific inhibitors against the MEK/ERK pathway blocks retrograde NGF-induced CGRP up-regulation in the sensory neuronal cell body, while inhibition of the PI3K/Akt pathway has no effect.'
p5630
aS'administration of MEK1/2 inhibitor PD98059 caused significant suppression of the number of pERK-LI cells in Vc and C1-C2 compared to vehicle-administrated rats, and depressed the mechanical allodynia and heat hyperalgesia in CNX rats.'
p5631
ag664
ag665
aS'\nUnsupervised clustering of melanoma cell lines based on the VIP scores >1 from each individual cell line model (excluding pMEK and pERK).'
p5632
aS'To develop an overall metric of adaptive response in RAF and MEK inhibitor-treated melanoma cells, we correlated target inhibition (as measured by pERK'
p5633
aS'\nComparison of the level of 1-h pERK inhibition between two cell lines (C32 and WM1552C) treated with four RAF inhibitors and one MEK inhibitor.\n'
p5634
aS'As relevant readouts of molecular and phenotypic responses, we chose phospho-protein levels of seven regulators of survival, proliferation and protein synthesis (p-AKT-S473, p-ERK-T202/Y204, p-MEK-S217/S221, p-eIF4E-S209, p-c-RAF-S289/S296/S301, p-P70S6K-S371 and pS6-S235/S236) as well as flow cytometric observation of two phenotypic processes (cell cycle arrest and apoptosis) ('
p5635
aS'For each treatment, we used western blots to detect levels of the proteins phospho-AKT, phospho-ERK, phospho-MEK, phospho-eIF4E, phospho-c-RAF, phospho-p70S6K and phospho pS6.'
p5636
aS'We also investigated a hypothesis resulting from preliminary examination of the experimental data and model simulation results: the differential sensitivity of EGF- and HRG-stimulated ERK activity to the MEK inhibitor U0126.'
p5637
aS'A key insight that emerges from the data and analysis described above is that the transience of ERK phosphorylation does not simply reflect a slow dephosphorylation of ERK following the rapid adaptation of MEK by negative feedback.'
p5638
aS'This implies that adaptation of MEK is not necessary, and that substrate interactions are sufficient, to explain the adaptation of ERK phosphorylation.'
p5639
aS'To show this, we fit to the ERK data a variant of the model in which MEK activity is held constant.'
p5640
aS'Increasing the input strength yields greater ERK phosphorylation by active MEK in the cytosol, resulting in greater influx of ERK into the nucleus.'
p5641
aS'From a process control perspective, one might conjecture that the pathway, subject as it is to strong negative feedback affecting MEK, is tuned so that mobilization of active ERK is not accompanied by dramatic overshoot.'
p5642
aS'The time scale associated with the decay of nuclear ERK or EKAR following MEK inhibition was defined as '
p5643
aS'Activated ERK governs negative feedback through desensitization of MEK phosphorylation.'
p5644
aS'As expected, exposure to PLX4720 led to down-regulation of the phosphorylation state of kinases within the MAPK pathway: phospho-MEK, phospho-ERK1/2 and phospho-p90RSK (Fig'
p5645
aS'\nMEK, ERK and p90RSK phosphorylation levels.\n'
p5646
aS'Two highly related isoforms, MEK1/2 and ERK1/2, respectively, act similarly in most experimental settings suggesting that they are functionally redundant ('
p5647
aS'Signal transmission through this pathway involves activation by dual phosphorylation of MEK and ERK, respectively.'
p5648
aS'In a processive mechanism a single molecule of MEK binds ERK, catalyses phosphorylation of both threonine and tyrosine of the conserved TEY motif in the ERK activation loop, and subsequently dissociates.'
p5649
aS'For subsequent ERK activation, a single-step processive model and a two-step distributive model were compared considering both MEK1/2 and ERK1/2 isoforms.'
p5650
aS'It has been suggested that under physiological conditions only a minor pool of MEK and ERK is engaged by scaffolds ('
p5651
aS'To analyse whether a possible cross-reaction with single-phosphorylated MEK/ERK would affect our results, we stimulated primary CFU-E cells for different times and loaded the cellular lysates on two gels in triplicates.'
p5652
aS'The first blot was analysed with the polyclonal antibodies that were used in this study, the second blot with monoclonal antibodies that specifically only recognise double-phosphorylated MEK or double-phosphorylated ERK and do not cross-react with the single-phosphorylated species ('
p5653
aS'The effect of enzyme saturation was analysed by establishing two additional models by adding complex formation to the phosphorylation reactions of MEK and ERK as shown in '
p5654
aS'In a systematic effort to identify novel substrates of ERK1/2, we have capitalized on advances in mass spectrometry (MS) instrumentation, quantitative phosphoproteomics and bioinformatics to measure the dynamic changes in phosphorylation of ERK1/2 consensus sequences in response to cell stimulation and pharmacological inhibition of MEK1/2 in intestinal epithelial cells.'
p5655
aS'Selection of phosphopeptides whose relative abundance is regulated positively upon serum stimulation and negatively following MEK1/2 inhibition resulted in a list of 155 candidate ERK1/2 substrates (232 phosphorylation sites) ('
p5656
ag667
aS'To directly test these cell cycle and apoptosis predictions, we inhibited ERK activation using the MEK inhibitor PD98059, at either the same time as doxorubicin treatment, or 2 h later.'
p5657
aS'In future work, it will be crucial to determine under what genetic background and DNA-damaging conditions ERK1/2 is pro-survival and under what conditions it can promote apoptosis in order to effectively implement chemotherapeutic regimens that combine DNA damaging chemotherapeutic agents with MEK inhibitors.'
p5658
aS'Serial dilutions of phosphorylated human recombinant ERK2 (Proteinkinase, Biaffin GmbH & Co KG, Germany) and of phosphorylated human recombinant MEK1 (Millipore, Billerica, MA) were prepared in RPPA lysis buffer.'
p5659
aS'Using the model, we predict that in contrast to single inhibition, combined inactivation of MEK and EGFR could inactivate both endpoints of RAS, ERK and AKT.'
p5660
aS'When we compared the model predictions with the data, we found that our literature model failed to explain an increase of MEK and ERK phosphorylation after IGF treatment that was visible in multiple cells.'
p5661
aS'Interestingly, this increase in ERK phosphorylation did not coincide with an increase in MEK levels, thus the effect of IKK inhibition on ERK cannot be explained via upstream components in the pathway.'
p5662
aS'All cells show negative response coefficients for feedback regulation from ERK via EGFR back to MEK (orange box in '
p5663
ag669
ag670
aS'Cells were treated with MEK inhibitor UO126 (Alexis Biochemicals, CA) to block MEK-ERK pathway.'
p5664
aS'Over activity of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) pathway is the hallmark of the majority of melanomas, which is frequently due to mutations in '
p5665
aS'Some of the more sensitive cell lines to the combination therapy showed higher basal levels of p-MEK and p-ERK than the more resistant cell lines.'
p5666
aS'Sensitive cell lines showed higher level of p-MEK and p-ERK as opposed to the more resistant cell lines that had lower baseline levels of these two phosphoproteins.'
p5667
aS'The aim of this study was to investigate whether the oncogenic phenotype in the human muscle-derived Rhabdomyosarcoma (RD) cell line and in non muscle-derived human tumor cell lines (SW403, IGR39 and PC3) can be blocked by disrupting the c-Myc pathway either by means of pharmacological MEK/ERK inhibition or by direct inactivation of the c-Myc protein.'
p5668
aS'We demonstrate that, in all the tumor cell lines used, the MEK/ERK inhibitor U0126 rapidly induces c-Myc de-phosphorylation, which is followed by a marked reduction in its expression level, by inhibition of proliferation and by reversion of anchorage-independent growth.'
p5669
aS'Our data provide evidence of the key role played by the MEK/ERK pathway in the growth arrest and transformation phenotype of Rhabdomyosarcoma and of non muscle-derived tumor cell lines.'
p5670
aS'In fact, MEK/ERK inhibitor, U0126, induces growth arrest, anchorage-dependent growth of these cell lines.'
p5671
aS'Both the c-Myc and Ras/MEK/ERK pathways play an important role in the progression of the G1-cell cycle phase by enhancing cyclins expression ['
p5672
aS'Given the synergistic relationship between MEK/ERK and c-Myc in cell growth and malignant transformation, the blocking of the MEK/ERK pathway ['
p5673
aS'Since we found that U0126, a MEK/ERK pathway inhibitor, induces p21'
p5674
aS'We found that the disruption of the MEK/ERK pathway, by means of the MEK inhibitor U0126, dramatically decreased c-Myc expression level, inducing growth inhibition and reversion of anchorage-independent growth in all the cell lines used.'
p5675
aS'MEK/ERK inhibition affects c-Myc phosphorylation and expression in RD cells. '
p5676
aS'To investigate whether the anti-growth and anti-oncogenic effects of MEK/ERK inhibition are peculiarity of soft tissue-derived tumor cell lines, such as RD, we used IGR39 melanoma-, SW403 colon adenocarcinoma-, PC3 prostate-derived human tumor cell lines, C2C12 and NI3T3 as control untransformed muscle and non-muscle cell lines.'
p5677
aS'We first investigated, in time course experiments either with or without U0126, the effects of MEK/ERK inhibition on the c-Myc phosphorylation level and expression.'
p5678
aS'These data show that cell transformation of different tumor-derived cell lines is halted by inhibition of MEK/ERK pathway followed by c-Myc down-regulation.'
p5679
aS'The pharmacological inhibitors of Ras/MEK/ERK signalling are arousing considerable interest on account of their potential therapeutic uses ['
p5680
aS'In an attempt to determine the specific role of c-Myc in sustaining aberrant growth as well as cell transformation and inhibition of differentiation, we used RD cells on account of their ability to undergo growth arrest and myogenic differentiation upon MEK/ERK inhibition ['
p5681
aS'Our data provide evidence that the cooperation between MEK/ERK and c-Myc pathways play a major role in the expression of transformed phenotype in muscle and non muscle-derived transformed cell lines.'
p5682
aS'In conclusion these data strongly suggest that the targeting of c-Myc by means of the MEK/ERK inhibitor can be tested as a promising strategy in anti-cancer therapy.'
p5683
aS'RD, rhabdomyosarcoma cell line; MEK, Mitogen-activated protein Extracellular Kinase; ERK, Extracellular signal-Regulated protein Kinase.'
p5684
aS'Growth factors can activate ERK1/2, and ERK1/2 activation is closely related to cancer cell migration and invasion, which may be regulated by the upstream kinase MEK1/2 via the growth factor-induced metastasis-associated pathway ['
p5685
aS'To determine whether EGF affects the migration and invasion of IBDC cells via ERK1/2 signaling, BT474 cells were treated with EGF in the presence or absence of ERK1/2 siRNA or the MEK/ERK pathway inhibitor, U0126.'
p5686
aS'ERK1/2 are important regulators of progression and metastasis in a variety of cancers via the MEK/ERK/AP-1 signaling pathway ['
p5687
aS'ERK1/2 is activated by MEK1/2 ['
p5688
aS'However, OPN-induced phosphorylation of p70S6 kinase at Thr-421/Ser-424 is being controlled by MEK/ERK pathway.'
p5689
aS'Moreover, OPN-induced phosphorylation of p70S6 kinase at Thr-421/Ser-424 is being controlled by MEK/ERK pathway.'
p5690
aS'Moreover, the results deciphered the role of OPN and rapamycin in regulating mTOR and p70S6 kinase phosphorylations and involvement of MEK/ERK pathway in this process.'
p5691
aS'Sorafenib is a multikinase inhibitor targeting the MAP kinase pathway (RAF/MEK/ERK) as well as several other receptor tyrosine kinases including VEGFR, PDGFR, FLT3, Ret and c-kit ['
p5692
aS'MEK1/2 and its downstream kinases ERK1/2 have been implicated in radioresistance in HNSCC before, although the effect of pathway inhibition on radiosensitivity is inconsistent\n['
p5693
aS'FICZ causes changes in signaling events that are known to drive differentiation, and notably augments the RA-induced sustained activation of the RAF/MEK/ERK axis of the mitogen-activated protein kinase (MAPK) cascade.'
p5694
aS'This process requires sustained activation of MAPK signaling along the RAF/MEK/ERK axis ['
p5695
aS'The RA-regulated RAF/MEK/ERK axis has been found to be associated with a number of signaling regulatory molecules in a putative signalsome that propels RA-induced differentiation.'
p5696
aS'Specifically, FICZ augments RAF/MEK/ERK axis MAPK signaling, Src-family kinase activation and the RA-dependent upregulation of VAV1, c-Cbl, pY458 p85PI3K, and IRF-1 expression.'
p5697
aS'Considering that PHB forms a signaling complex with CRAF to regulate RAF-MEK-ERK pathway, we demonstrated that PHB was highly expressed in human pancreatic cancer and depletion of PHB reduced in vitro invasion of RAS-driven cancer cells.'
p5698
aS'Using the MEK1/2 inhibitor, U0126 and stably transfected shERK1 and shERK2 MM cell lines, we show that inhibition of both ERK1 and 2 sensitizes MM cells to Dox.'
p5699
aS'We have shown that uPA and uPAR downregulation inhibits invasion in SNB19 glioma cells by decreasing phosphorylation of the Ras-activated FAK, p38MAPK, JNK and ERK1/2, as well as the MEK-activated phosphatidylinositol 3-kinase, AKT and mTOR pathway, indicative of a feedback signaling mechanism of the uPAR/uPA system ['
p5700
ag2446
aS'Consistently, major downstream signaling pathways such as PI3kinase/Akt as well as MEK/ERK were only activated upon cell adhesion on fibronectin whenever the cytoplasmic domain of CD98hc was present.'
p5701
aS'Indeed, the inhibition of ERK pathway resulting from treatment with UO126, a MEK-specific inhibitor, did not affect phosphorylation of ERM (Figure '
p5702
ag1259
aS'Here we found that exposure of HepG2 cells to GCDA results in activation of ERK1 and ERK2 and phosphorylation of Mcl-1 in a PD98059 (MEK inhibitor)-sensitive manner.'
p5703
aS'In this context, 6-ME inhibited in a dose dependent manner the phosphorylation of MEK1/2, the only known upstream activator of ERK1/2.'
p5704
aS'6-ME inhibits VEGF- and FGF2-induced proliferation of ECs by targeting the phosphorylation of MEK1/2 and it downstream substrate ERK1/2, both key components of the mitogenic MAPK pathway.'
p5705
aS'Thus, inhibition of MEK1/2 and consequently ERK1/2 phophorylation was the sole cardinal effect of 6-ME on the signaling cascade of VEGF in HUVECs; activation of AKT and P38 were unaffected.'
p5706
aS'The molecular target of 6-ME is upstream of MEK1/2 inhibiting phosphorylation of MEK1/2 and ERK1/2 kinases that are important components of the mitogenic MAPK pathway.'
p5707
aS'Downstream targets such as phosphorylated Shc, MEK1,2 and ERK2 also decline.'
p5708
aS'S298 in MEK1 is targeted by p21-activated kinase (PAK) in response to integrin signaling and stimulates the association of MEK1 with ERK ['
p5709
aS'Akt: Protein kinase B; CI: Combination index; DMSO: Dimethyl sulfoxide; ELISA: Enzyme-linked immunosorbent assay; ERK: Extracellular signal-regulated kinase; IGF-1R: Insulin-like growth factor 1 receptor; MAPK: Mitogen-activated protein kinase; MEK: Mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; mTOR: Mammalian target of rapamycin; PI3K: Phosphoinositide 3-kinase; '
p5710
aS'Inhibition of ERK1 and ERK2 (ERK1/2) is a promising strategy to address both innate and acquired resistance to BRAFi and MEKi, regardless of the upstream mechanism(s) of MAPK reactivation.'
p5711
aS'SCH772984 is a potent, ATP competitive and non-competitive inhibitor of ERK 1/2, with additional allosteric properties that inhibit ERK activation/phosphorylation by MEK ['
p5712
aS'We next examined whether cells inherently resistant to BRAFi could be sensitive to a MEK inhibitor (MEKi) or ERKi.'
p5713
aS'To address whether there are differences in MEK inhibition or ERK inhibition on apoptosis, we performed cell cycle analysis on three melanoma cell lines with distinct sensitivity profile to SCH772984: M263 (sensitive), M255 (intermediately sensitive) and M370 (resistant).'
p5714
aS'Previously published reports have documented promising preclinical activity of ERK inhibition in BRAFi or MEKi resistant cell line models ['
p5715
aS'Primary antibodies included pERK Thr202/Tyr204, total ERK, pMEK Ser217/221, total MEK, pAKT Ser473, total AKT, pRSK, total RSK, beta-actin (all from Cell Signaling Technology, Danvers, MA).'
p5716
ag671
ag672
ag673
aS'Downstream of the receptor, the following inhibitors were used; the PI3K inhibitor LY294002, small molecular inhibitor of MEK called U0126 (thus downstream inhibition of extracellular-related kinase (ERK1 and ERK2) mediated responses), a small molecule inhibitor of JAK (Janus Kinase) called AG490 and an inhibitor of its partner signal transducers and activators of transcription-3 (STAT3) called Stattic (Figure '
p5717
aS'Furthermore, our data verified a role for HMGB1 in the regulation of the Beclin1-PI3K-III complex through the mitogen-activated protein kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway.'
p5718
aS'In addition, we found that HMGB1 promoted Beclin-1-PI3K-III core complex formation through the MEK/ERK1/2 pathway.'
p5719
aS'Furthermore, HMGB1 promotes Beclin-1-PI3K-III complex formation, potentially through the MEK/ERK1/2 pathway.'
p5720
aS'In addition, we verified that the activation of the MEK-ERK1/2 signaling pathway was involved in HMGB1-mediated formation of the Beclin-1-PI3K-III complex.'
p5721
aS'HMGB1 promotes the formation of Beclin-1-PI3K-III complex through activating the MEK/ERK1/2 signaling pathway, thereby regulating autophagosome formation.'
p5722
aS'Because TQ affects the central RAF/MEK/ERK1/2 pathway, the combination of TQ with targeted therapies is worth considering for future anticancer treatments.'
p5723
aS'PAK1 has been described as a scaffold for ERK1/2/MEK to recruit MEK to RAF at the membrane ['
p5724
aS'Our data provide evidence of the key role played by the MEK/ERK pathway in the growth arrest of Rhabdomyosarcoma cells.'
p5725
aS'The results of this study suggest that the targeting of MEK/ERKs to rescue p21'
p5726
aS'The MEK/ERK pathways control the growth and survival of a broad spectrum of human tumors ['
p5727
aS'In order to identify the molecular mechanism of G1 arrest following ERK activation and MEK/ERK inhibition in RD cells (see '
p5728
aS'Unlike TPA, MEK/ERK inhibition induces p21'
p5729
aS'In order to establish whether sustained activation of the MEK/ERK pathway plays a role in post-transcriptional-mediated p21'
p5730
aS'The apparently contrasting result regarding the activation or inhibition of the MEK/ERK pathway, both as a cause of growth arrest and myogenic differentiation, might reflect the involvement of other MAPK pathways, MAPK-p38 being the most likely candidate.'
p5731
aS'Both the MEK-ERK inhibitor and TPA induce myogenic-specific gene expression, with MHC accumulation in U0126-treated cells occurring earlier than in TPA-treated cells.'
p5732
aS'In this study we highlight the importance of targeting the MEK/ERK pathway as a means of restoring the expression of the tumor suppressor p21'
p5733
aS'RD, rhabdomyosarcoma cell line; MEK, Mitogen-activated protein Extracellular Kinase; ERK, Extracellular signal-Regulated protein Kinase.'
p5734
ag674
aS'Constitutive activation of MEK/ERK has been reported in cancer cells ['
p5735
aS'As the activator of Ras/MEK/ERK pathway, Grb2-Sos1 complex is crucial for regulating cell proliferation, tumorigenesis, early embryonic stem cell fate and normal development ['
p5736
aS'Having established that ERK signalling levels were high in OE33 cells we used the MEK inhibitor U0126 to block ERK signalling and investigated its effect on OE33 cell invasion and proliferation.'
p5737
aS'The RAS/RAF/MEK/ERK (RAS/ERK) and PI3K/AKT signaling pathways regulate gene expression programs that promote cell growth, proliferation, motility, and survival ['
p5738
aS'RAS/ERK signaling can be initiated by tyrosine kinase receptors that activate RAS, followed by the RAF/MEK/ERK kinase cascade, resulting in phosphorylated ERK (pERK).'
p5739
aS'Antibodies for immunoblotting were: ERK (sc-94) and pERK (sc-7383) from Santa Cruz Biotechnology, ETV5 (ab102010) and ETV1 (ab81086) from Abcam, pAKT (S473) and pMEK (9121) from Cell Signaling, Tubulin (T-9026) from Sigma, ETV4 (ARP32263_P050) from Aviva Systems Biology, and ERG (9FY) from Biocare Medical.'
p5740
aS'RAS/ERK: RAS/RAF/MEK/ERK pathway; pERK: Phosphorylated ERK; pAKT: phosphorylated AKT.'
p5741
aS'MEK and ERK phosphorylation are hallmarks of activation of the RAS signaling pathway which stimulates cell proliferation ['
p5742
ag1260
aS'Against this background we have hypothesized a new strategy to down-regulate in cancer cells the mitogenic RAS/MEK/ERK pathway ['
p5743
aS'Evidence that the RAS/MEK/ERK signaling pathway plays a central role in melanoma has been reported ['
p5744
aS'Melanoma B78-H1 cells are characterized by a hyperactive RAS/MEK/ERK pathway.'
p5745
ag676
ag678
aS'EGFR activation induces Ras/MEK/ERK phosphorylation, and phosphorylated ERK activates various transcription factors.'
p5746
aS'The RAS/RAF/MEK/ERK and RAS/PI3K/PTEN/AKT signaling pathways are cascades regulated by phosphorylation and dephosphorylation by specific kinases, phosphatases, as well as GTP/GDP exchange proteins, adaptor proteins and scaffolding proteins ['
p5747
aS'The increase in phosphorylated ERK could be inhibited by MEK (ERK) inhibitor U0126 (Fig. '
p5748
ag679
aS'It is known that A375MM cells rely on the activation of two main signaling pathways that sustain proliferation: RAF-MEK-ERK (MAPK) and PI3K-AKT-mTOR (AKT) signalling.'
p5749
aS'Exposure to MEK162 reduced ERK1/2 phosphorylation, and induced apoptosis.'
p5750
aS'MEK1/2 are members of the RAS/RAF/MEK/ERK signaling pathway, and inhibition of MEK might result in decreased pathway activation in N-RAS and B-RAF mutant melanomas.'
p5751
aS'ERK1/2 isoforms are the immediate downstream substrates and best studied effectors of dual specificity kinases MEK1/2.'
p5752
aS'To assess the effect of MEK1/2 inhibition on ERK1/2 activation state (phosphorylation at T202/Y204 sites), melanoma cultures were treated with MEK162 and compared with untreated controls.'
p5753
aS'To assess the effect of MEK1/2 inhibition on phospho-ERK1/2 or PARP cleavage, melanoma cells were treated with MEK162 or DMSO.'
p5754
ag680
ag681
aS'Therefore, the MEK-ERK cascade seems to play an important role in intestinal transformation.'
p5755
aS'caMEK, constitutively activated MEK; COX-2, cyclooxygenase-2; DOX, doxycycline; ERK, extracellular signal-regulated protein kinase; HDAC, histone deacetylase; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; NaB, sodium butyrate'
p5756
ag682
aS'We next determined whether inhibition of other pathways such as the AKT/mTOR, MEK/ERK or SRC pathway would have a similar effect.'
p5757
aS'During an examination of the individual pathways identified by the two pathway analysis methods, we noted a recurring involvement of the mitogen-activated protein kinase kinase (MEK)/ERK signaling pathway.'
p5758
aS'Brain lysates were evaluated with antibodies against RAS, t-MEK, p-MEK and p-ERK.'
p5759
aS'Mitogen-activated protein kinase kinase (MEK) is upstream of ERK.'
p5760
aS'At 30 min after treatment with the MEK inhibitor PD98059, the level of p-ERK was significantly reduced compared with the p-ERK level following control treatment.'
p5761
ag684
aS'Upon VEGF binding to VEGF receptor 2 (R2), the main functional receptor tyrosine kinases of VEGF are activated, and a cascade of events are initiated, including the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) and RAF/MEK/ERK signaling pathways, which stimulate endothelial cell proliferation, migration and tube formation ('
p5762
aS'The PI3K/Akt and RAF/MEK-ERK pathways are involved in VEGF-induced angiogenesis.'
p5763
ag685
aS'We dissected one of the pathways, the ERK cascade, and, in particular, we analyzed the src family, MEK and ERK kinases.'
p5764
aS'The MEK1/2 protein complex is the physiological activator of ERK1/2, that, in turn, upon activation, can either enter the nucleus and start the gene expression process, or be retained in the cytoplasm to activate other signaling molecules (Fig. '
p5765
aS'Following Fab D18 treatment, no significant variations of phospho-ERK levels were found either in ScGT1 or GT1 cells, whereas a significant decrease in D18 treated GT1 was found with regards to phospho-MEK levels (Fig. '
p5766
aS'The monoclonal antibodies against the phosphorylated and non-phosphorylated forms of the src family [Src Family Antibody #2109 and phospho-Src Family (Tyr416) antibody #2101), MEK1/2 (MEK1/2 Antibody #9122 and phospho-MEK1/2 (Ser217/221) (41G9) rabbit mAb #9154] and ERK 1/2 [p42 MAP Kinase (3A7) mouse mAb #9107 and phospho-p44/42 Map Kinase (Thr202/Tyr204) Ab #9101] were purchased from Cell Signaling Technology.'
p5767
aS"Student's t test was used to determine significant differences among the src family, MEK 1/2, ERK 1/2 phosphorylation, among prion infected and uninfected, and between Fab D18 treated and quinacrine treated cell lines."
p5768
ag687
aS'It has been reported that there is cross-talk between the MEK/ERK and Akt pathways in non-RGC cell types ['
p5769
ag688
ag689
aS'One Unit of ERK1/2 is equivalent to the amount of ERK1/2 derived from 40 pg of ERK1/2 which was phosphorylated by MEK1.'
p5770
aS'ERK1/2 activity was inhibited by intravitreal injection of U0126, a highly selective inhibitor of mitogen-activated protein kinase 1/2 (MEK1/2).'
p5771
aS'Inhibition of ERK activation using MEK inhibitor U0126 led to decreased accumulation of RIP3 but not of RIP1 in the IR-injured rat retina. '
p5772
aS'Chemical inhibitors for p38 (SB203580), mitogen-activated protein kinase kinase and extracellular regulated kinase (MEK/ERK; PD98059), Janus kinase protein (JNK; SP600125), protein kinase A (PKA; H89), phosphoinositide 3-kinase (PI3K; wortmannin), and P2 receptors (suramin) were all from Sigma (St Louis, MO).'
p5773
aS'Effects of inhibition of p38, MEK/ERK, JNK, PKA, PI3K, and P2 receptor pathways on the upregulation of six genes induced by CMS.'
p5774
aS'In most tissues, the insulin receptor activates two main signaling pathways: a) the mitogen-activated protein kinase (MAPK) cascade (e.g., mitogen-activated protein kinasem kinase [MEK] and extracellular regulated kinase [ERK]) and b) the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway.'
p5775
aS'With negative lenses, insulin did not stimulate the MEK/ERK signaling cascade.'
p5776
aS'Because insulin binding to the insulin receptor was shown to activate the MEK/ERK pathway and the PI3K/Akt- pathway, selective inhibitors were used to separate the inputs.'
p5777
aS'U0126 was used to block the activation of ERK 1/2 that occurs by inhibiting the activity of MEK.'
p5778
aS'Western blots were used to find out whether insulin activates the MEK/ERK and/or PI3K/Akt pathway in the retina.'
p5779
aS'Depending on the stimuli and the phosphorylated IRS, two different pathways are activated: the PI3K/Akt and MEK/ERK pathways.'
p5780
aS'In summary, the current study may show that insulin activates the PI3K/Akt pathway in eyes with normal vision and eyes treated with positive and negative lenses but stimulates eye growth through the MEK/ERK pathway in eyes with normal vision and eyes treated with positive lenses.'
p5781
ag690
aS'For example, during drosophila eye development, the catalytic subunit of PP-2A is found to be implicated in the regulation of the R7 photoreceptor specification through both positive and negative regulation of the MEK/ERK signaling pathway ['
p5782
aS'These results show that proliferative responses of SFs to muscarinic receptor stimulation are mediated via the activation of the classical MEK-ERK-MAPK cascade.'
p5783
aS'Previous studies have demonstrated that FGF10 attenuated DNA damage and apoptosis of epithelial cells in part by MEK/ERK-dependent signaling that affects the mitochondria-regulated death pathway ['
p5784
aS'The signal is propagated through the RAS-RAF-MEK-ERK proteins into the nucleus regulating cell proliferation, survival, and differentiation.'
p5785
aS'Evidences show that the mitogen-activated protein/extracellular signal-regulated kinase (MEK)-extracellular signal-regulated kinase (ERK)--murine double minute 2 (MDM2)-p53 pathway plays a critical role in the regulation of MGMT expression.it has been shown that, in stem-like glioblastoma cells, MEK inhibition reduced MDM2 expression and that inhibition of either MEK or MDM2 resulted in p53 activation accompanied by p53-dependent downregulation of MGMT expression ('
p5786
aS'In the U0126 experiment, 199 phosphopeptides exhibited the same triangular response pattern as the activation loop phosphosites of ERK1/2 and should therefore be direct or indirect downstream substrates of MEK1/2 after EGF stimulation.'
p5787
aS'MEK/ERK pathway might play a noxious role in spinal cord IRI via participating in inflammatory reactions and cytokine production ['
p5788
aS'U0126 is a specific inhibitor of MAPK/ERK kinases 1/2 (MEK1/2) ['
p5789
aS'Through this pathway, the MEKKs/MLKs-SEK/MKKs-JNK/p38 pathway may be activated, leading to ATF2 phosphorylation at Thr69 and Thr71 sites without involvement of ERK ['
p5790
aS'Thereafter, ERKs are activated by MEKs and regulate a large number of nuclear and cytosolic proteins ['
p5791
aS'As the important pathways in eukaryocyte, Ras/MEK/ERK\ncascade pathway and JAK/STAT cascade pathway may be closely\ninterrelated.'
p5792
ag693
aS'PKC activates the MEK/ERK pathways at several levels ['
p5793
aS'   This review will critically evaluate the extent to which several molecules, including, sphingosine-1-phosphate (S1P), IL-7-receptor (IL-7R), spleen tyrosine kinase (SyK), MEK/ERK 1/2, Mitogen-activated protein kinase 5/p38 kinase regulated/activated protein kinase (MK5/PRAK), microRNA (miRNA), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and inhibitors of proteasome activity, appear to be promising novel experimental targets for future drug development for the treatment of inflammatory arthritis.'
p5794
ag694
ag695
ag696
aS'Activation of MEK 1/2 and ERK 1/2 by MAP3K.'
p5795
ag697
aS'The MEK/ERK inhibitor U0126, antibodies against the phosphorylated form of ERK, p38, c-Jun N-terminal kinase (JNK), and total inhibitor of kappa B (I'
p5796
aS'To determine whether PG could inhibit adipogenesis via the ERK or p38 signaling pathway, we used the specific mitogen-activated protein kinase (MEK) inhibitor PD98059 to inhibit ERK phosphorylation.'
p5797
aS'MEK is an upstream kinase of ERK.'
p5798
aS'ERK activation can be prevented by blocking MEK activity('
p5799
aS'The activation of RANK by RANKL leads to distinct signaling cascades mediated by c-Jun N-terminal Kinase 1/2 (JNK1/2), p38 and extracellular signal-regulated kinase 1/2 (ERK1/2) MAP kinases regulated by the activation of MEK1 in osteoclast precursors, which are critical for RANKL-induced osteoclast differentiation ('
p5800
aS'We next evaluated the effect of the FP receptor antagonist (AL8810), EP2 receptor antagonist (AH6809), EP4 receptor antagonist (ONOAE2227) and chemical inhibitors of PLC (U73122), PKC (GF109203x), PKA (4C3MQ), EGFR (AG1478) and ERK1/2 kinase (MEK; PD98059) on the PGE'
p5801
aS'As both peptides could clearly stimulate the phosphorylation of ERK we next investigated if they could also phosphorylate the upstream regulators of ERK: MEK and c-RAF.'
p5802
aS'Enolase 2 is symbolized as ENO2, platelet-type 6-phosphofructokinase as PFKP, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as PFKFB4, aldolase C as ALDOC, mannose-6-phosphate isomerase as MPI, phosphoglycerate kinase 1 as PGK1, liver-type 6-phosphofructokinase as PFKL, glucose-6-phosphate isomerase as GPI, triosephosphate isomerase as TPI, hexokinase as HK, glutamic pyruvate transaminase 2 as GPT2, pyruvate dehydrogenase kinase isoenzyme 1 as PDK1, fucosyltransferase 11 as FUT11, stanniocalcin 2 as STC2, pyruvate dehydrogenase kinase isozyme 3 as PDK3, Cas-Br-M ecotropic retroviral transforming sequence as CBL, cAMP responsive element binding protein 1 as CREB1 (CREB-A and CREB-B), growth factor receptor-bound protein 10 as GRB10, glycogen synthase as GYS1, insulin receptor as INSR, mitogen-activated protein kinase kinase 1 as MAP2K1 (=MEK1), mitogen-activated protein kinase kinase 7 as MAPK7 (=ERK5), neural precursor cell expressed developmentally downregulated 4-like as NEDD4L, and glutamate dehydrogenase as GLUD.'
p5803
ag698
aS'(A) Knockdown of GRK2 expression and activation of EGFR, as indicated by ERK1/2-T202 and MEK1/2-S217 phosphorylation, after 5-min treatment with 100 ng/ml EGF ('
p5804
aS'As expected, overexpression of caMEK1 in C2C12 cells resulted in constitutive activation of ERK1/2 ('
p5805
aS'Several signaling proteins, including ERK2 and MEK1, have a conserved sequence motif (TPT or SPS), in which phosphorylation of these residues will induce translocation into the nucleus in a Ran-independent manner ('
p5806
aS'RhoA activity was significantly increased with increased matrix stiffness in vehicle control and UO126 treatment, which suggests that its regulation did not occur downstream of MEK and ERK1/2; n = 6 and *p < 0.05.'
p5807
aS'RAS and MEK1/2 are upstream signaling molecules of ERK1/2 pathway in Met signaling ('
p5808
aS'To confirm the role of the Ras/MEK1/2/ERK1/2 pathway, EC were infected with adenovirus DN Ras or CA MEK1.'
p5809
aS'To confirm that HGF activation of ERK1/2 is necessary to inhibit Ang II-induced apoptosis in explant tissue, we first used chemical MEK1/2 inhibitor U0126.'
p5810
aS'We suspect that signaling through the MAPK pathway (i.e., MEK1/2 to ERK1/2) in response to CXCR4 signaling drives the invasive phenotype of breast tumor cells and can be sustained in a manner that, once initiated, is independent of CXCR4 activation.'
p5811
aS'Upstream MAP2K of ERK, MEK1, is considered to be one of the most important regulators of ERK localization (Reszka '
p5812
aS'The subcellular localization of endogenous and exogenous JNK1 and MKK7 in resting 293T cells mimics that of endogenous and exogenous ERK and MEK1, respectively (Lenormand '
p5813
aS'Thus, phosphorylation of JNK might lead to conformational changes of the protein and consequent release from MKK7 within 30 min after UV treatment, similar to the release of ERK from MEK1 upon ERK phosphorylation (Fukuda '
p5814
aS'The following antibodies were used: pSmad2 (3108; Cell Signaling, Danvers, MA), Smad2/3 (SC-133098; Santa Cruz Biotechnology), ezrin (E8897; Sigma-Aldrich), ppERK1/2 (M9692; Sigma-Aldrich), ERK2 (SC-154; Santa Cruz Biotechnology), pMEK (9154; Cell Signaling), MEK (2352; Cell Signaling), and lamin A/C (SC-376248; Santa Cruz Biotechnology).'
p5815
aS'Our results showed that all mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (MAPK), and protein kinase C (PKC) inhibitors could block PMA-induced translocation of actin into nuclei, whereas treatment with inhibitors of c-Jun NH'
p5816
aS'It is a serine/threonine kinase and is activated by a mitogen-activated protein (MAP)-kinase/ERK kinase (MEK).'
p5817
ag699
ag700
ag701
ag702
ag703
aS'The MEK-ERK pathway regulates CRNA by elevating the levels of cyclin D1.'
p5818
aS'The inhibition of p35-cdk5 activity results in enhanced MEK-ERK signaling, leading to CRNA.'
p5819
aS'Cyclin D1 contributes to an increase in MEK-ERK signaling via a positive feedback loop.'
p5820
aS'Next we probed whether MEK-ERK signaling was responsible for CRNA.'
p5821
aS'Aberrant MEK-ERK signaling and enhanced cyclin D1 expression prevent p35-mediated cdk5 activation.'
p5822
aS'Collectively these studies demonstrate that neurotoxic stimuli such as amyloid peptide cause aberrant activation of MEK-ERK signaling and promote cell cycle reentry by increasing cyclin D1 levels.'
p5823
aS'Subsequently, cyclin D1 may attenuate p35-cdk5 association and activity, which may further contribute to aberrant MEK-ERK signaling, resulting in neuronal cell death ('
p5824
aS'Neurotoxic signals might trigger aberrant activation of the MEK-ERK pathway, resulting in an increase in cyclin D1 levels, which can be by transcription factor STAT3.'
p5825
aS'Cyclin D1 prevents p35-mediated cdk5 activation, which might facilitate the increase in MEK-ERK signaling activity.'
p5826
aS'Increased expression of PEA-15 activates Ras leading to activation of MEK1/2 and resulting activation of ERK1/2 ('
p5827
ag711
aS'PEA-15 must bind to ERK1/2 to activate MEK1/2 and ERK1/2.'
p5828
aS'Each of these mutations abrogated the capacity of PEA-15 to activate MEK1/2 and ERK1/2.'
p5829
ag712
aS'The MAPK signaling pathway (MEK/ERK1/2 and PI3K) and transcription factors NF-kB and AP-1/c-Jun were inhibited, then Cx43 expression was assessed using Western blot analysis, and MMP-9 activity was assessed using gelatin zymography.'
p5830
aS'To determine if MMP-9 enzyme activity is involved in MAPK signaling and the regulation of Cx43, LY294002 (PI3K inhibitor) and U0126 (MEK/ERK inhibitor) were applied, respectively, and MMP-9 activity was measured using zymography.'
p5831
aS'To assess the roles of MMPs and MAPK signaling in the regulation of Cx43 gene expression in H9c2 cardiomyocytes, the MMP inhibitor doxycycline, MEK/ERK 1/2 inhibitor U0126, and PI3K inhibitor LY294002 were used in the present study.'
p5832
aS"In the present study our aim was to\ninvestigate whether the GTPase Rac1 was an upstream signal that led to the\nactivation of MEK/ERK1/2, JNK1/2 or Akt pathways upon VACV or CPXV' infections."
p5833
aS'In the past decade, our group has shown that VACV and CPXV also stimulate\nMEK/ERK/1/2/Egr-1 cascade as well as JNK1/2 and PI3K/Akt pathways during infection.'
p5834
aS'We have shown previously that the orthopoxviruses VACV and CPXV, which\nare phylogenetically close, activate the same signalling cascades such as\nMEK1/2/ERK1/2/Egr-1; however, while the stimulation of this pathway is beneficial\nfor VACV replication, the biological significance for CPXV life cycle is still not\nelucidated ('
p5835
aS'We also provide evidence that Rac1 is not a component of the\nMEK1/2/ERK1/2 pathway during VACV infection.'
p5836
aS'The signaling modules in the ERK5 pathway are composed of MEKK2/MEKK3, MEK5 and ERK5 ('
p5837
aS'The signaling modules in the ERK5 pathway are composed of MEKK2/MEKK3, MEK5, and ERK5.'
p5838
aS'In order to determine whether the activation of mitogen-activated protein kinase kinase (MEK)/ERK pathway was required for increased ZFN activity, a specific inhibitor of MEK1/2 GSK1120212 was used to prevent phosphorylation of ERK and the effect on CCR5 disruption in PMA or bryostatin-activated HSPC was measured.'
p5839
aS'The MEK/ERK pathway has been shown to be activated by APRIL in myeloma cells ('
p5840
aS'To investigate whether MEK/ERK signaling in the MAP kinase cascade contributes to APRIL-promoted axon elongation from hippocampal pyramidal cells, we first tested whether APRIL activates ERK1 and ERK2 in these neurons.'
p5841
aS'To ascertain if activation of ERK1 and ERK2 contributes to APRIL-promoted axon growth, we examined whether PD98059, a selective inhibitor of MEK1 and MEK2, the kinases that phosphorylate and activate ERK1 and ERK2 ('
p5842
aS'MEK (upstream kinase of ERK1/2) has been reported to induce similar morphological changes to those seen in our experiments ('
p5843
aS'We next tested the role of the ERK1/2 MAPK pathway in Jo2-mediated cell killing and in the cytoprotection afforded by CO. MLEC were treated with the ERK1/2 pathway inhibitor PD 98059, which specifically targets MEK1, the upstream regulator of ERK1/2.'
p5844
aS'Among these, the Ras/MAP kinase-ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) pathway and PI3K/Akt pathway have long been established.'
p5845
aS'PI3K/Akt and MEK/ERK signaling pathways are involved in the regulation of proliferation and migration of glioblastoma cells ['
p5846
aS'The above results show that the PI3K/Akt and MEK/ERK signaling pathways are regulated by xyloketal B.'
p5847
aS'Next, we measured whether TRPM7 blocked by carvacrol could regulate both PI3K/Akt and MEK/ERK signaling pathways.'
p5848
aS'In this study, we demonstrate that: (1) xyloketal B reduces cell viability, proliferation, and migration of glioblastoma U251 cell lines; (2) xyloketal B downregulates the PI3K/Akt and MEK/ERK signaling pathways; and (3) xyloketal B blocks the TRPM7 current without altering the TRPM7 protein expression in U251 cells.'
p5849
aS'The mechanism by which TRPM7 regulates the PI3K/Akt and MEK/ERK pathways remains unclear.'
p5850
aS'In summary, our findings indicate that the effects of marine compound xyloketal B in anti-proliferation and migration of U251 cells are mediated by inhibition of TRPM7 and regulation of the PI3K/Akt and MEK/ERK signaling pathways.'
p5851
aS'Marine compound xyloketal B reduces cell viability, proliferation, and migration through inhibition of TRPM7 and modulation of the PI3K/Akt and MEK/ERK signaling pathways.'
p5852
aS'Autophagy is also negatively regulated by the MEK/ERK signaling pathway ['
p5853
ag714
ag717
ag718
ag719
ag720
ag721
ag722
aS'This study provides the first evidence that DA can inhibit PDGF-BB-induced VSMC migration and proliferation, the effect of which may inhibit the activations of MEK/ERK and PI3K/AKT cascades and STAT3 as well as PCNA expression ('
p5854
aS'The MEK inhibitor U0126, which inhibits the phosphorylation of ERK1/2 without affecting p38, JNK, or other MAP kinase pathway components ['
p5855
aS'Primary antibodies (all from Cell Signaling Technology, unless otherwise specified) were rabbit polyclonal anti-ERK1/2 (#9102), mouse monoclonal anti-pT202/Y204-ERK1/2 (#9106), mouse monoclonal anti-MEK1/2 (#4694), rabbit monoclonal anti-pS217/S221-MEK1/2 (#9154), mouse monoclonal anti-GluA2 (MAB397, Merck Millipore), rabbit polyclonal anti-pS880-GluA2 (ab52180, Abcam), rabbit polyclonal anti-pY869/Y873/Y876-GluA2 (#3921), rabbit monoclonal anti-Src (#2109), rabbit monoclonal anti-pY416-Src (#6943), and rabbit monoclonal anti-GAPDH (#2118).'
p5856
aS'The purpose of their study was to verify the risk of the development of mutations in selected genes in the RAS/RAF/MEK/ERK signaling pathway during the culturing of melanocytes in various growth media.'
p5857
aS'PD98059, an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK/ERK), affected the expression of the ERK1/2 pathway stimulated with LPS, which is a special inhibitor of the ERK1/2 pathway ['
p5858
aS'In a previous paper, it was reported that the two HAART drugs RTV and AZT substantially increased the phosphorylation of ERK2 in HPAECs, and a MEK/ERK inhibitor effectively blocked RTV- or AZT-induced reductions in eNOS protein levels in HPAECs; this indicated that MAPK signaling is involved in the development of endothelial dysfunction induced by HAART drugs ['
p5859
ag723
ag724
ag725
as(S'ZBTB18'
p5860
S'ONECUT1'
p5861
S'increases'
p5862
tp5863
(lp5864
s(S'TGIF'
p5865
S'MAX'
p5866
S'increases'
p5867
tp5868
(lp5869
s(S'ETS1'
p5870
S'NRAS'
p5871
S'increases'
p5872
tp5873
(lp5874
s(S'KLF12'
p5875
S'GATA1'
p5876
S'increases'
p5877
tp5878
(lp5879
s(S'HRAS/GTP'
p5880
S'PAK2'
p5881
S'increases_activity'
p5882
tp5883
(lp5884
s(S'CYP26A1'
p5885
S'FOXD3'
p5886
S'increases'
p5887
tp5888
(lp5889
s(S'LMO2'
p5890
S'RUNX1'
p5891
S'increases'
p5892
tp5893
(lp5894
g1216
as(S'MLK3'
p5895
S'MKK3/6'
p5896
S'adds_modification'
p5897
tp5898
(lp5899
s(S'TAK'
p5900
S'MKK3/6'
p5901
S'adds_modification'
p5902
tp5903
(lp5904
S'The functional significance of the p38/MKK3/6/TAK1 pathway for AP-1 activation and inflammatory responses has been well defined ['
p5905
as(S'GRB2:SOS1'
p5906
S'HB-EGF:P-6Y-EGFR DIMER'
p5907
S'binds'
p5908
tp5909
(lp5910
s(S'FOXO4'
p5911
S'NRAS'
p5912
S'increases'
p5913
tp5914
(lp5915
s(S'MECOM'
p5916
S'NRAS'
p5917
S'increases'
p5918
tp5919
(lp5920
s(S'KLF12'
p5921
S'CYP26A1'
p5922
S'increases'
p5923
tp5924
(lp5925
s(S'RAS family/GTP/PI3K'
p5926
S'TRPV1'
p5927
S'adds_modification'
p5928
tp5929
(lp5930
s(S'hsa-let-7a-5p'
p5931
S'NRAS'
p5932
S'decreases'
p5933
tp5934
(lp5935
s(S'NF1'
p5936
S'HOXA9'
p5937
S'increases'
p5938
tp5939
(lp5940
s(S'REPIN1'
p5941
S'FOXD3'
p5942
S'increases'
p5943
tp5944
(lp5945
s(S'CYP26A1'
p5946
S'FOXJ2'
p5947
S'increases'
p5948
tp5949
(lp5950
s(S'FOXO4'
p5951
S'MEIS1'
p5952
S'increases'
p5953
tp5954
(lp5955
s(S'EBF2'
p5956
S'MECOM'
p5957
S'increases'
p5958
tp5959
(lp5960
s(S'ETS1'
p5961
S'FOXO3'
p5962
S'increases'
p5963
tp5964
(lp5965
s(S'SP3'
p5966
S'CYP26A1'
p5967
S'increases'
p5968
tp5969
(lp5970
s(S'LNXp80'
p5971
S'NUMB'
p5972
S'decreases'
p5973
tp5974
(lp5975
s(S'RUNX2'
p5976
S'CYP26A1'
p5977
S'increases'
p5978
tp5979
(lp5980
s(S'AHR'
p5981
S'FOXO3'
p5982
S'increases'
p5983
tp5984
(lp5985
s(S'VSX1'
p5986
S'FOXF2'
p5987
S'increases'
p5988
tp5989
(lp5990
s(S'BPTF'
p5991
S'RUNX1'
p5992
S'increases'
p5993
tp5994
(lp5995
s(S'7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide'
p5996
S'HRAS PROTEIN'
p5997
S'increases'
p5998
tp5999
(lp6000
s(S'TCF3'
p6001
S'POU3F2'
p6002
S'increases'
p6003
tp6004
(lp6005
s(S'TCF3'
p6006
S'IRF1'
p6007
S'increases'
p6008
tp6009
(lp6010
s(S'SREBF1'
p6011
S'EN1'
p6012
S'increases'
p6013
tp6014
(lp6015
s(S'FOXO4'
p6016
S'RUNX2'
p6017
S'increases'
p6018
tp6019
(lp6020
s(S'hsa-miR-181a-5p'
p6021
S'HRAS'
p6022
S'decreases'
p6023
tp6024
(lp6025
s(S'Myb'
p6026
S'NRAS'
p6027
S'decreases'
p6028
tp6029
(lp6030
s(S'HSPA8'
p6031
S'ADP'
p6032
S'binds'
p6033
tp6034
(lp6035
s(S'SOCS3'
p6036
S'RASGAP'
p6037
S'binds'
p6038
tp6039
(lp6040
s(S'ONECUT1'
p6041
S'NRAS'
p6042
S'increases'
p6043
tp6044
(lp6045
s(S'PITX2'
p6046
S'EN1'
p6047
S'increases'
p6048
tp6049
(lp6050
s(S'HGF(dimer)/MET(dimer)'
p6051
S'SRC'
p6052
S'adds_modification'
p6053
tp6054
(lp6055
s(S'2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine'
p6056
S'HRAS PROTEIN'
p6057
S'increases'
p6058
tp6059
(lp6060
s(S'GFI1'
p6061
S'POU3F2'
p6062
S'increases'
p6063
tp6064
(lp6065
s(S'FARNESYL DIPHOSPHATE'
p6066
S'KRAS'
p6067
S'increases_activity'
p6068
tp6069
(lp6070
s(S'IL2/IL2R BETA/GAMMA/JAK1/LCK/JAK3'
p6071
S'PI3K'
p6072
S'binds'
p6073
tp6074
(lp6075
s(S'GTF3A'
p6076
S'MECOM'
p6077
S'increases'
p6078
tp6079
(lp6080
s(S'EGR2'
p6081
S'CYP26A1'
p6082
S'increases'
p6083
tp6084
(lp6085
s(S'RUNX1'
p6086
S'FOXF2'
p6087
S'increases'
p6088
tp6089
(lp6090
s(S'IL3/IL3RA/CSF2RB (DODECAMER)'
p6091
S'YWHAZ'
p6092
S'binds'
p6093
tp6094
(lp6095
s(S'RAF1'
p6096
S'BRAF'
p6097
S'binds'
p6098
tp6099
(lp6100
s(S'MYC'
p6101
S'CYP26A1'
p6102
S'increases'
p6103
tp6104
(lp6105
s(S'UBP1'
p6106
S'CYP26A1'
p6107
S'increases'
p6108
tp6109
(lp6110
s(S'MTF1'
p6111
S'REPIN1'
p6112
S'increases'
p6113
tp6114
(lp6115
s(S'HNF1A'
p6116
S'RUNX1'
p6117
S'increases'
p6118
tp6119
(lp6120
s(S'NHLH1'
p6121
S'FOXA1'
p6122
S'increases'
p6123
tp6124
(lp6125
s(S'HLF'
p6126
S'FOXA1'
p6127
S'increases'
p6128
tp6129
(lp6130
s(S'MEIS1'
p6131
S'GATA6'
p6132
S'increases'
p6133
tp6134
(lp6135
s(S'PDGF-BB/PDGFRB (DIMER)/SHP2'
p6136
S'GRB2/SOS1'
p6137
S'binds'
p6138
tp6139
(lp6140
s(S'ZBTB14'
p6141
S'EN1'
p6142
S'increases'
p6143
tp6144
(lp6145
s(S'alpha6/beta4 Integrin'
p6146
S'HRAS/GDP'
p6147
S'increases_activity'
p6148
tp6149
(lp6150
s(S'ErbB2'
p6151
S'HRAS/GDP'
p6152
S'increases_activity'
p6153
tp6154
(lp6155
s(S'MEIS1'
p6156
S'FOXO3'
p6157
S'increases'
p6158
tp6159
(lp6160
s(S'RELA'
p6161
S'IRF1'
p6162
S'increases'
p6163
tp6164
(lp6165
s(S'MYCN'
p6166
S'FOXO3'
p6167
S'increases'
p6168
tp6169
(lp6170
s(S'RHOA/GTP'
p6171
S'DIA'
p6172
S'increases_activity'
p6173
tp6174
(lp6175
s(S'Fluorouracil'
p6176
S'KRAS PROTEIN'
p6177
S'decreases'
p6178
tp6179
(lp6180
s(S'ATF2'
p6181
S'CYP26A1'
p6182
S'increases'
p6183
tp6184
(lp6185
s(S'GNAI2/GTP'
p6186
S'SRC FAMILY KINASES'
p6187
S'increases_activity'
p6188
tp6189
(lp6190
s(S'HAND1'
p6191
S'POU2F1'
p6192
S'increases'
p6193
tp6194
(lp6195
s(S'PI5K Type 1 family'
p6196
S'PI-4-P'
p6197
S'translocates'
p6198
tp6199
(lp6200
s(S'HSF1'
p6201
S'CBFA2T3'
p6202
S'increases'
p6203
tp6204
(lp6205
s(S'BACH1'
p6206
S'FOXA1'
p6207
S'increases'
p6208
tp6209
(lp6210
s(S'PI-3-4-5-P3'
p6211
S'SGK1'
p6212
S'adds_modification'
p6213
tp6214
(lp6215
s(S'hsa-miR-20a-5p'
p6216
S'NRAS'
p6217
S'decreases'
p6218
tp6219
(lp6220
s(S'CYP26A1'
p6221
S'MECOM'
p6222
S'increases'
p6223
tp6224
(lp6225
s(S'FOXF2'
p6226
S'RUNX1'
p6227
S'increases'
p6228
tp6229
(lp6230
s(S'EGR2'
p6231
S'SRF'
p6232
S'increases'
p6233
tp6234
(lp6235
s(S'LEF1'
p6236
S'FOXD3'
p6237
S'increases'
p6238
tp6239
(lp6240
s(S'TFAP2C'
p6241
S'MECOM'
p6242
S'increases'
p6243
tp6244
(lp6245
s(S'SHC'
p6246
S'GRB2/SOS1'
p6247
S'binds'
p6248
tp6249
(lp6250
s(S'CA2+'
p6251
S'CAM'
p6252
S'binds'
p6253
tp6254
(lp6255
s(S'MYC'
p6256
S'POU3F2'
p6257
S'increases'
p6258
tp6259
(lp6260
s(S'PAX8'
p6261
S'HOXA9'
p6262
S'increases'
p6263
tp6264
(lp6265
s(S'TFDP2'
p6266
S'CDC5L'
p6267
S'increases'
p6268
tp6269
(lp6270
s(S'RAF1/14-3-3'
p6271
S'KSR/14-3-3 /MEK1-2'
p6272
S'increases_activity'
p6273
tp6274
(lp6275
s(S'DDIT3'
p6276
S'MEIS1'
p6277
S'increases'
p6278
tp6279
(lp6280
s(S'GNB1/GNG2'
p6281
S'HRAS/GDP'
p6282
S'increases_activity'
p6283
tp6284
(lp6285
s(S'ACTIVATED FGFR MUTANTS:P-FRS2ALPHA'
p6286
S'GRB2:SOS1'
p6287
S'binds'
p6288
tp6289
(lp6290
s(S'HIF1A'
p6291
S'CYP26A1'
p6292
S'increases'
p6293
tp6294
(lp6295
s(S'RAF1-BRAF'
p6296
S'ERK1-2'
p6297
S'increases_activity'
p6298
tp6299
(lp6300
s(S'SMAD4'
p6301
S'CBFA2T3'
p6302
S'increases'
p6303
tp6304
(lp6305
s(S'resveratrol'
p6306
S'HRAS PROTEIN'
p6307
S'increases'
p6308
tp6309
(lp6310
s(S'Malathion'
p6311
S'HRAS MRNA'
p6312
S'increases'
p6313
tp6314
(lp6315
s(S'NRF1'
p6316
S'FOXO4'
p6317
S'increases'
p6318
tp6319
(lp6320
s(S'CREB1'
p6321
S'JUN'
p6322
S'increases'
p6323
tp6324
(lp6325
S'\nATF1 binds to ATF2, JUN and CREB1 in both fractions.'
p6326
as(S'CDC5L'
p6327
S'HOXA9'
p6328
S'increases'
p6329
tp6330
(lp6331
s(S'CDX2'
p6332
S'HOXA9'
p6333
S'increases'
p6334
tp6335
(lp6336
s(S'HMGA1'
p6337
S'POU2F1'
p6338
S'increases'
p6339
tp6340
(lp6341
s(S'Coumestrol'
p6342
S'KRAS MRNA'
p6343
S'decreases'
p6344
tp6345
(lp6346
s(S'LEF1'
p6347
S'FOXO3'
p6348
S'increases'
p6349
tp6350
(lp6351
s(S'CYP26A1'
p6352
S'MEIS1'
p6353
S'increases'
p6354
tp6355
(lp6356
s(S'GTF2A2'
p6357
S'MEIS1'
p6358
S'increases'
p6359
tp6360
(lp6361
s(S'REPIN1'
p6362
S'CBFA2T3'
p6363
S'increases'
p6364
tp6365
(lp6366
s(S'hsa-miR-143-3p'
p6367
S'HRAS'
p6368
S'decreases'
p6369
tp6370
(lp6371
s(S'[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID'
p6372
S'KRAS'
p6373
S'increases_activity'
p6374
tp6375
(lp6376
s(S'TFDP1'
p6377
S'ONECUT1'
p6378
S'increases'
p6379
tp6380
(lp6381
s(S'YY1'
p6382
S'CYP26A1'
p6383
S'increases'
p6384
tp6385
(lp6386
s(S'PITX2'
p6387
S'RUNX1'
p6388
S'increases'
p6389
tp6390
(lp6391
s(S'STAT5A'
p6392
S'NRAS'
p6393
S'increases'
p6394
tp6395
(lp6396
s(S'Valproic Acid'
p6397
S'HRAS MRNA'
p6398
S'increases'
p6399
tp6400
(lp6401
s(S'Malathion'
p6402
S'HRAS PROTEIN'
p6403
S'increases'
p6404
tp6405
(lp6406
s(S'TFAP4'
p6407
S'CBFA2T3'
p6408
S'increases'
p6409
tp6410
(lp6411
s(S'TFAP4'
p6412
S'EN1'
p6413
S'increases'
p6414
tp6415
(lp6416
s(S'POU3F2'
p6417
S'CYP26A1'
p6418
S'increases'
p6419
tp6420
(lp6421
s(S'PAX3'
p6422
S'FOXD3'
p6423
S'increases'
p6424
tp6425
(lp6426
s(S'FOXA2'
p6427
S'RUNX2'
p6428
S'increases'
p6429
tp6430
(lp6431
s(S'MAX'
p6432
S'BACH1'
p6433
S'increases'
p6434
tp6435
(lp6436
s(S'PDX1'
p6437
S'CYP26A1'
p6438
S'increases'
p6439
tp6440
(lp6441
s(S'EPO/EPOR (dimer)/JAK2'
p6442
S'SHC/GRB2/SOS1'
p6443
S'increases_activity'
p6444
tp6445
(lp6446
s(S'E2F1'
p6447
S'MEIS1'
p6448
S'increases'
p6449
tp6450
(lp6451
s(S'FOXF2'
p6452
S'MEIS1'
p6453
S'increases'
p6454
tp6455
(lp6456
s(S'SPZ1'
p6457
S'FOXJ2'
p6458
S'increases'
p6459
tp6460
(lp6461
s(S'SRY'
p6462
S'NRAS'
p6463
S'increases'
p6464
tp6465
(lp6466
s(S'REPIN1'
p6467
S'CYP26A1'
p6468
S'increases'
p6469
tp6470
(lp6471
s(S'VEGFR3/VEGFC-D'
p6472
S'PKC'
p6473
S'increases_activity'
p6474
tp6475
(lp6476
s(S'MEIS1'
p6477
S'EN1'
p6478
S'increases'
p6479
tp6480
(lp6481
s(S'FOXJ1'
p6482
S'FOXD3'
p6483
S'increases'
p6484
tp6485
(lp6486
s(S'SPZ1'
p6487
S'FOXO4'
p6488
S'increases'
p6489
tp6490
(lp6491
s(S'RHOA/GTP'
p6492
S'ROCK1-ROCK2'
p6493
S'increases_activity'
p6494
tp6495
(lp6496
s(S'HMGA1'
p6497
S'ONECUT1'
p6498
S'increases'
p6499
tp6500
(lp6501
s(S'uPA/uPAR/alphav/beta3 Integrin/Vitronectin'
p6502
S'SRC'
p6503
S'adds_modification'
p6504
tp6505
(lp6506
s(S'ETS1'
p6507
S'CYP26A1'
p6508
S'increases'
p6509
tp6510
(lp6511
s(S'ESRRA'
p6512
S'TLX2'
p6513
S'increases'
p6514
tp6515
(lp6516
s(S'ROCK2'
p6517
S'RHO FAMILY GTPASE-ACTIVE'
p6518
S'binds'
p6519
tp6520
(lp6521
s(S'ATF4'
p6522
S'CYP26A1'
p6523
S'increases'
p6524
tp6525
(lp6526
s(S'OR5I1'
p6527
S'CYP26A1'
p6528
S'increases'
p6529
tp6530
(lp6531
s(S'PITX2'
p6532
S'GATA1'
p6533
S'increases'
p6534
tp6535
(lp6536
s(S'AHR'
p6537
S'ONECUT1'
p6538
S'increases'
p6539
tp6540
(lp6541
s(S'PTF1A'
p6542
S'MECOM'
p6543
S'increases'
p6544
tp6545
(lp6546
s(S'arsenic trioxide'
p6547
S'HRAS MRNA'
p6548
S'increases'
p6549
tp6550
(lp6551
s(S'TCF3'
p6552
S'REPIN1'
p6553
S'increases'
p6554
tp6555
(lp6556
s(S'STAT6'
p6557
S'FOXO3'
p6558
S'increases'
p6559
tp6560
(lp6561
s(S'POU1F1'
p6562
S'POU2F1'
p6563
S'increases'
p6564
tp6565
(lp6566
s(S'RHOA/GTP'
p6567
S'ROCK'
p6568
S'increases_activity'
p6569
tp6570
(lp6571
s(S'PITPNA'
p6572
S'PI-4-5-P2'
p6573
S'translocates'
p6574
tp6575
(lp6576
s(S'MDM-2'
p6577
S'P14/19 ARF'
p6578
S'binds'
p6579
tp6580
(lp6581
s(S'TEAD1'
p6582
S'FOXO3'
p6583
S'increases'
p6584
tp6585
(lp6586
s(S'MYC'
p6587
S'MAX'
p6588
S'increases'
p6589
tp6590
(lp6591
s(S'GRB2:SOS1'
p6592
S'EGF:PHOSPHO-EGFR:PHOSPHO-SHC'
p6593
S'binds'
p6594
tp6595
(lp6596
s(S'NF1'
p6597
S'RUNX1'
p6598
S'increases'
p6599
tp6600
(lp6601
s(S'ZEB1'
p6602
S'GATA6'
p6603
S'increases'
p6604
tp6605
(lp6606
s(S'TBP'
p6607
S'EN1'
p6608
S'increases'
p6609
tp6610
(lp6611
s(S'FOXA1'
p6612
S'FOXD3'
p6613
S'increases'
p6614
tp6615
(lp6616
s(S'CART1'
p6617
S'EN1'
p6618
S'increases'
p6619
tp6620
(lp6621
s(S'MAX'
p6622
S'CEBPA'
p6623
S'increases'
p6624
tp6625
(lp6626
s(S'GATA6'
p6627
S'NRAS'
p6628
S'increases'
p6629
tp6630
(lp6631
s(S'PTF1A'
p6632
S'FOXO3'
p6633
S'increases'
p6634
tp6635
(lp6636
s(S'LEF1'
p6637
S'FOXA1'
p6638
S'increases'
p6639
tp6640
(lp6641
s(S'hsa-let-7g-5p'
p6642
S'KRAS'
p6643
S'decreases'
p6644
tp6645
(lp6646
s(S'ZBTB14'
p6647
S'CYP26A1'
p6648
S'increases'
p6649
tp6650
(lp6651
s(S'POU1F1'
p6652
S'FOXO4'
p6653
S'increases'
p6654
tp6655
(lp6656
s(S'PI3K'
p6657
S'PI-4-5-P2'
p6658
S'translocates'
p6659
tp6660
(lp6661
s(S'GABPB2'
p6662
S'NRAS'
p6663
S'increases'
p6664
tp6665
(lp6666
s(S'ELK1'
p6667
S'LEF1'
p6668
S'increases'
p6669
tp6670
(lp6671
s(S'Estrogens'
p6672
S'HRAS MRNA'
p6673
S'increases'
p6674
tp6675
(lp6676
s(S'CYP26A1'
p6677
S'CEBPA'
p6678
S'increases'
p6679
tp6680
(lp6681
s(S'SPI1'
p6682
S'POU2F1'
p6683
S'increases'
p6684
tp6685
(lp6686
s(S'PPARG'
p6687
S'CYP26A1'
p6688
S'increases'
p6689
tp6690
(lp6691
s(S'Asbestos, Serpentine'
p6692
S'HRAS PROTEIN'
p6693
S'increases'
p6694
tp6695
(lp6696
s(S'RET51/GFRALPHA1/GDNF/DOK1'
p6697
S'RASGAP'
p6698
S'binds'
p6699
tp6700
(lp6701
s(S'FOXO1'
p6702
S'GATA6'
p6703
S'increases'
p6704
tp6705
(lp6706
s(S'Cadmium'
p6707
S'KRAS PROTEIN'
p6708
S'increases'
p6709
tp6710
(lp6711
s(S'MAX'
p6712
S'EN1'
p6713
S'increases'
p6714
tp6715
(lp6716
s(S'TLX2'
p6717
S'NRAS'
p6718
S'increases'
p6719
tp6720
(lp6721
s(S'SREBF1'
p6722
S'CYP26A1'
p6723
S'increases'
p6724
tp6725
(lp6726
s(S'SMAD3'
p6727
S'MEIS1'
p6728
S'increases'
p6729
tp6730
(lp6731
s(S'Acetaminophen'
p6732
S'NRAS MRNA'
p6733
S'decreases'
p6734
tp6735
(lp6736
s(S'LEF1'
p6737
S'ETS1'
p6738
S'increases'
p6739
tp6740
(lp6741
s(S'SRF'
p6742
S'MEIS1'
p6743
S'increases'
p6744
tp6745
(lp6746
s(S'BRAF'
p6747
S'MKK3-MKK6'
p6748
S'increases_activity'
p6749
tp6750
(lp6751
s(S'HRAS/GTP'
p6752
S'RAF1'
p6753
S'adds_modification'
p6754
tp6755
(lp6756
s(S'MSX1'
p6757
S'CYP26A1'
p6758
S'increases'
p6759
tp6760
(lp6761
s(S'GATA4'
p6762
S'ETS1'
p6763
S'increases'
p6764
tp6765
(lp6766
s(S'E4F1'
p6767
S'FOXA1'
p6768
S'increases'
p6769
tp6770
(lp6771
s(S'FOXD1'
p6772
S'LEF1'
p6773
S'increases'
p6774
tp6775
(lp6776
s(S'CUX1'
p6777
S'MAX'
p6778
S'increases'
p6779
tp6780
(lp6781
s(S'CYP26A1'
p6782
S'CBFA2T3'
p6783
S'increases'
p6784
tp6785
(lp6786
s(S'CAM/CA2+'
p6787
S'KRAS ISOFORM 4B/GTP'
p6788
S'binds'
p6789
tp6790
(lp6791
s(S'MYOG'
p6792
S'STAT5A'
p6793
S'increases'
p6794
tp6795
(lp6796
s(S'MYOD1'
p6797
S'STAT5A'
p6798
S'increases'
p6799
tp6800
(lp6801
s(S'HNF1A'
p6802
S'POU3F2'
p6803
S'increases'
p6804
tp6805
(lp6806
s(S'EPH'
p6807
S'EPHR'
p6808
S'binds'
p6809
tp6810
(lp6811
S'Intensive research has focused on the molecular basis of SD structure and function and has resulted in the identification of a number of novel SD-associated proteins, including NEPHRIN, NEPH1, CD2-associated protein and PODOCIN ('
p6812
as(S'PDGF:PHOSPHO-PDGF RECEPTOR DIMER'
p6813
S'GRB2:SOS1'
p6814
S'binds'
p6815
tp6816
(lp6817
s(S'HRAS/GTP'
p6818
S'PI3K'
p6819
S'increases_activity'
p6820
tp6821
(lp6822
s(S'RUNX1'
p6823
S'TLX2'
p6824
S'increases'
p6825
tp6826
(lp6827
s(S'MYOG'
p6828
S'CYP26A1'
p6829
S'increases'
p6830
tp6831
(lp6832
s(S'PAX2'
p6833
S'EN1'
p6834
S'increases'
p6835
tp6836
(lp6837
s(S'TFCP2'
p6838
S'CYP26A1'
p6839
S'increases'
p6840
tp6841
(lp6842
s(S'hsa-miR-145-5p'
p6843
S'NRAS'
p6844
S'decreases'
p6845
tp6846
(lp6847
s(S'KAT2B'
p6848
S'GATA1'
p6849
S'increases'
p6850
tp6851
(lp6852
S'EVI1 interacts with a number of transcriptional and epigenetic regulators (CREBBP, CTBP, HDAC, KAT2B (P/CAF), SMAD3, GATA1, GATA2, DNMT3A, and DNMT3B), and mediates chromatin modifications and DNA hypermethylation.'
p6853
as(S'P-EGFR MUTANTS:P-Y349,350-SHC1'
p6854
S'GRB2:SOS1'
p6855
S'binds'
p6856
tp6857
(lp6858
s(S'E2F1'
p6859
S'MECOM'
p6860
S'increases'
p6861
tp6862
(lp6863
s(S'GNB1/GNG2'
p6864
S'SRC'
p6865
S'adds_modification'
p6866
tp6867
(lp6868
s(S'ZBTB14'
p6869
S'MAX'
p6870
S'increases'
p6871
tp6872
(lp6873
s(S'RALGDS'
p6874
S'P21 RAS:GTP'
p6875
S'binds'
p6876
tp6877
(lp6878
s(S'RHOA/GTP'
p6879
S'ROCK2'
p6880
S'increases_activity'
p6881
tp6882
(lp6883
s(S'NR1H3'
p6884
S'FOXD3'
p6885
S'increases'
p6886
tp6887
(lp6888
s(S'TFAP4'
p6889
S'GATA1'
p6890
S'increases'
p6891
tp6892
(lp6893
s(S'FOXA1'
p6894
S'GATA6'
p6895
S'increases'
p6896
tp6897
(lp6898
s(S'GRB2:SOS1'
p6899
S'P-SHC'
p6900
S'binds'
p6901
tp6902
(lp6903
s(S'E2F1'
p6904
S'FOXO3'
p6905
S'increases'
p6906
tp6907
(lp6908
s.